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Abstract 
Staphylococcus aureus mediated disruption of Blood-Brain Barrier Phenotype in                   
Human Brain Microvascular Endothelial cells 
Alisha McLoughlin 
Background: Staphylococcus aureus (SA) is a gram-positive, cocci-forming pathogen capable 
of causing serious-life-threatening illnesses (e.g. meningitis). In 2010, it was the number one 
cause of bacterial deaths in the USA. Moreover, SA is one of just a few bacteria that are able to 
gain access to the central nervous system (CNS) via the blood-brain barrier (BBB). The BBB 
comprises a monolayer of unique brain microvascular endothelial cells (BMvEC), which act as a 
seal to separate the CNS from the main circulatory system. BMvEC are equipped with specialised 
interendothelial tight and adherens junction protein complexes that regulate the paracellular 
traffic of fluids and solutes into the neural microenvironment. However, when this barrier is 
compromised by injury and/or infection it can result in BBB dysfunction. The main objective of 
this project was to investigate the effects of SA infection on the human blood-brain barrier (BBB) 
microvascular endothelium in-vitro with respect to: (i) interendothelial tight/adherens junction 
(TJ/AJ) protein expression; (ii) endothelial permeability and; (iii) to pro-inflammatory signalling. 
 
Methods: Primary-derived human brain microvascular endothelial cells (HBMvEC) were 
infected with either “formaldehyde-fixed” or “live” SA Newman wild-type (NWT) or mutant 
staphylococcal protein A (ΔSpA) strains. Infection dose- (multiplicity of infection/MOI) and 
time-dependency studies were routinely performed. The impact of infection was monitored on: 
(i) cell viability (by flow cytometry);  
(ii) bacterial adherence to HBMvEC; (iii) interendothelial junction protein expression (by 
Western blotting); (iv) HBMvEC monolayer paracellular permeability (by transendothelial 
permeability assay using FITC-dextran); (v) activation of NF-κB (by Western blotting for NF-κB 
phospho-p65); (vi) inflammatory cytokine and chemokine release (by ELISA and cytokine array 
panel); (vii) reactive oxygen species production (by flow cytometry) and; (viii) endothelial 
microparticle release post-infection (by flow cytometry). 
Main Results: Following 48 hrs infection using “fixed” NWT-SA bacterium (MOI 0-250), the 
expression of HBMvEC junctional proteins (VE-Cadherin, ZO-1 and claudin-5) were dose-
dependently downregulated, in parallel with increased monolayer permeability. Fixed NWT-SA 
infection significantly induced activation of NF-κB within just 1 hour of infection, whilst showing 
significant dose-dependent increases in release of IL-6, TNF-α and thrombomodulin. A cytokine 
array panel for fixed SA infections using MOI 0 and MOI 250 media samples showed six 
upregulated cytokines (RANTES, IP-10, G-CSF, GM-CSF, MCP-1 and IL-6). By contrast, 
minimal junctional protein decreases were recorded post-infection with “live” NWT-SA (MOI 0-
100, 3 hrs), in parallel with minimal barrier disruption, although NF-κB was activated in a time-
dependent manner. There was no difference in cytokine release using live SA media samples after 
3 and 12 hrs infection. Further infection studies using fixed NWT-SA showed dose-dependent 
increases in ROS generation and also release of annexin-V/VE-cadherin-positive endothelial 
microparticles. In a final series of experiments, the contribution of the virulence factor, SpA, to 
the effects of SA on HBMvEC barrier properties was investigated using the mutant bacterium 
(ΔSpA). The ΔSpA strain was attenuated in disrupting HBMvEC barrier properties as seen in the 
downregulation of adherens junction proteins (VE-cadherin), barrier permeabilization at low 
concentrations and in the activation of NF-κB in comparison to NWT-SA. 
Conclusion: Both SA strains (NWT-SA and ΔSpA) have shown decreased expression of 
interendothelial adherens/tight junction proteins, in parallel with elevated barrier permeabilization 
and pro-inflammatory index, albeit at different infection times and doses. Ultimately, the effects 
of SA infection result in BBB dysfunction and barrier compromisation indicative of a cerebral 
bacterial infection.   
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1.1 Vasculature Structure 
The entire vasculature network of humans is composed of three blood vessel structures, 
namely arteries, veins, and the much smaller capillaries, which as a collective provide 
nutrient and waste transport to and from surrounding cells, whilst also mediating gas 
exchange (Nemeno-Guanzon et al., 2012). Arteries are the main vessels that carry 
oxygenated blood away from the heart, whilst veins mediate blood flow back to the heart 
through the vena cava. Both arterial and venular walls consist of three cellular layers; (i) 
tunica interna/intima makes up the innermost monolayer of cells that interface directly 
with blood. These cells are non-fenestrated (not porous) endothelial cells; (ii) the tunica 
media, is an intermediate layer of vascular smooth muscle cells and pericytes that make 
up the bulk of the vessel wall thickness. This layer is much thicker in arteries than veins 
due to the higher workload of the arteries and; (iii) the tunica externa/ adventitia, a layer 
composed of structural proteins and collagen that combine to form the extracellular 
matrix (ECM).  
Capillaries are thin walled vessels that interlink with the main blood supply to distal sites 
of the human body. These vessels are primarily composed of endothelial cells, mimicking 
the tunica intima of the arteries and veins (Nemeno-Guanzon et al., 2012; (Townsley, 
2012) [Figure 1.1]. Capillaries can be classified into three structural categories: (i) 
continuous non-fenestrated capillaries found in the skin, brain and lungs; (ii) continuous 
fenestrated capillaries located in the intestinal villi and endocrine glands, and finally; (iii) 
discontinuous capillaries found in the liver (Daneman & Prat, 2015).  
 
Figure 1.1: Composition of arteries, veins and capillaries. Diagram outlining the 
different surface membranes of arteries, veins and capillaries (Kelvinsong, 2013). 
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1.2 Cerebral Vascular Network 
The human brain is known to contain up to 100 billion neurons and glial cells, along with 
astrocytes and pericytes, comprising approximately 80% of the brain’s volume. In 
addition, the extracellular space occupies up to 15-30%, whilst the cerebrovasculature 
accounts for just 3% of this total volume (Wong et al., 2013) [Figure 1.2]. The brain is 
fed oxygenated blood by four arteries, referred to as the internal carotid arteries and 
vertebral arteries. These arteries merge at the base of the brain in an area called the Circle 
of Willis. It is at this point that oxygenated blood is distributed into cerebral and pial 
arteries, which further penetrate into the cerebral capillaries via the parenchyma. These 
finely regulated capillaries make up what is known as the cerebral microvasculature, a 
600 km network of microvessels that provide the surface area to simultaneously facilitate 
effective oxygen and nutrient exchange for the brain, and also the removal of waste 
products via the jugular network (Wong et al., 2013). The cerebral microvasculature itself 
collectively constitutes the Blood-Brain Barrier (BBB), a monolayer of unique brain 
microvascular endothelial cells that form the surface area for solute/gaseous exchange 
along the capillary lumen effectively separating the central nervous system (CNS) from 
the main systemic circulatory system, ultimately controlling cerebral homeostasis. 
 
Figure 1.2: Cerebral microvasculature of the BBB (Zlokovic et al., 1998).  
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1.3 The Neurovascular Unit 
At its simplest level, the BBB functional unit is referred to as the Neurovascular Unit 
(NVU). The NVU is a collection of specialised cells that give rise to BBB capillaries and 
work to maintain cerebral homeostasis and BBB phenotype [Figure 1.3]. The different 
cell types are listed below: 
 
Figure 1.3: Neurovascular unit. The NVU is made up of specialised cells that regulate 
cerebral homeostasis, which include pericytes, microglia, astrocytes, neurons, basal 
lamina, and endothelial cells (Abbott, 2013). 
 
1.3.1 Microvascular endothelial cells 
Brain microvascular endothelial cells (BMvEC) are the key cells that form the interface 
of the BBB with any blood-borne molecules, thereby preventing unregulated access to 
the brain microenvironment (Wilhelm et al., 2011). These microvascular cells create the 
luminal portion of BBB capillaries. Because the BBB capillaries are just one cell thick, 
does not mean that they are weakened or at a disadvantage from other peripheral vessels. 
In fact, BMvEC are 39% less thick than muscle-derived endothelial cells (Daneman & 
Prat, 2015). Unlike large vessel endothelium, the BBB endothelium is relatively non-
fenestrated, meaning they form a very tight single monolayer with low levels of pinocytic 
activity and highly restrictive paracellular and transcellular transport mechanisms as seen 
with having a high transendothelial electrical resistance (TEER) (Lawther et al., 2011; 
Naik & Cucullo, 2012). This restrictive BBB enables the sophisticated regulation of 
solute entrance and exit across the BBB. This is achieved in-part with the aid of 
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interendothelial junctional proteins (i.e. forming the paracellular pathway), which 
maintain cerebral homeostasis and protect the brain from various toxins, pathogenic 
onslaughts, and cerebral injury and disease (Daneman & Prat, 2015). A greater overview 
of the paracellular pathway between brain endothelial cells constitutes a fuller 
understanding of tight junction (TJ) and adherens junctions (AJ) proteins. These will be 
discussed in section 1.4.1. Unlike other derived endothelial cells, BMvEC also contain a 
higher number of mitochondria in order to express sufficient adenosine triphosphate 
(ATP) to help regulate ion gradients used for BBB transport processes (Hawkins & Davis, 
2005). In a healthy CNS, BMvEC express very low numbers of immune receptors e.g. 
leukocyte adhesion molecules in comparison to other peripheral cells. This limits the 
interaction between both cell types; however, upon injury or disease, these receptors are 
quickly expressed (Daneman & Prat, 2015). 
 
1.3.2 Pericytes 
Pericytes, “peri” meaning surrounding, are so-called because of their location in brain 
microvessels in the perivascular space (ElAli et al., 2014). They were first described 140 
years ago by Charles Benjamin Rouget and were originally called the “Rouget cell” 
(Bonkowski et al., 2011). These cells are located in the basal lamina in close contact with 
the basolateral surface of BMvEC, with approximately one pericyte per 5-6 BMvEC 
(Cardoso et al., 2010). Pericytes have long projecting arms covering 33% of all cerebral 
capillaries (Carvey et al., 2009; Hurtado-Alvarado et al., 2014; ElAli et al., 2014). 
Increasing evidence shows they play a structural and functional role in stabilising and 
supporting the brain capillaries (Ballabh et al., 2004). Not only are pericytes known to 
provide stability to the BBB but they have also been shown to be involved in BBB 
transport mechanisms, communicating with tight junctions to initiate barrier morphology 
changes. Hypoxia, brain injury, or viral/bacterial infection have each been shown 
independently of one another to induce pericyte translocation away from the BBB; an 
effect that coincided with increased BBB permeability and capillary diameter (Cardoso 
et al., 2010; Bonkowski et al., 2011; Hurtado-Alvarado et al., 2014). Furthermore, it has 
been recently shown that pericytes may play a greater role in cerebral immunity by 
expressing many macrophage markers (e.g. CD4, a glycoprotein commonly found on 
immune cells to attract macrophages) and major histocompatibility complexes I and II 
(MHC I and MHC II) (Hurtado-Alvarado et al., 2014). In-vitro studies using mouse 
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primary brain capillary pericytes showed that these cells also express a number of 
cytokine and chemokine markers such as interleukins (IL-9, -10, -12, -13 and -17), TNF-
α and IFN-γ, as well as expressing inducible nitric oxide synthase (iNOS) (ElAli et al., 
2014). 
 
1.3.3 Microglial cells 
Microglia cells are found in the perivascular space of the brain cavity monitoring for any 
changes of the BBB as a result of infection and/or disease. They account for 5-20% of all 
glial cells in an adult human brain with their main role to ensure that the homeostatic 
environment of the neural parenchyma is maintained (Lourbopoulos et al., 2015). These 
“surveying” cells were once thought to be dormant due to their “ramified” morphology 
when in a resting state. However, when in contact with an invading pathogen, microglial 
cells become “activated” by assuming a more amoeboid morphology. In doing so, the 
cells become macrophage-like, performing phagocytosis and removing cellular debris in 
order to re-establish the homeostatic cerebral environment (Cardoso et al., 2010; 
Kettenmann et al., 2011; Hefendehl et al., 2014). 
In this activated state, subpopulations of microglia have been shown to be major players 
in the production of IFN-β. IFN-β is a treatment option used for multiple sclerosis (MS) 
sufferers and patients with autoimmune encephalomyelitis (EAE). Using a mouse model 
of EAE, it was observed that microglia localised to the damaged regions of the CNS and 
activated phagocytosis-associated genes, clearing myelin debris (Kocur et al., 2015). 
Microglia cells are also capable of secreting a variety of cytokines (Lourbopoulos et al., 
2015). Microglials have a long half-life due to the restrictive nature of the BBB. 
Moreover, they are 20-30 fold slower at replenishing their stocks when compared to 
circulating monocytes, meaning the cells are subjected to age-related changes that may 
impact on their ability to rectify any changes in homeostatic conditions (Lourbopoulos et 
al., 2015). The manner in which microglia operate to maintain a healthy brain has been 
investigated in great detail and two signalling pathways have emerged. The first involves 
the activation of toll-like receptors (TLRs) and the second activation by nucleotide-
binding oligomerization domain-2 (NOD-2) receptors on microglia, stimulating the 
release of pro-inflammatory molecules that may result in neuronal damage. TLRs will be 
disscussed in more detail in section 1.6.3.3.1. The latter method is less destructive and 
involves palmitoylethanolamide to activate microglia, thereby upregulating phagocytosis 
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and pathogen elimination without activating pro-inflammatory cytokines (Nau et al., 
2014; Ferreira & Bernardino, 2015). 
 
1.3.4 Astrocytes 
Perivascular astrocytes act as a liaison for “endothelial-neuronal coupling”, playing a key 
role in BBB function and maintenance, providing assistance with neuronal signalling and 
cellular connections to the BMvEC (Esen et al., 2003). Astrocytes are star-shaped cells 
located in the perivascular space where they mediate signals from the capillary to the 
brain neuron and vice versa. Their long projecting astrocytic end-feet cover 90% of 
BMvEC capillaries which are known to regulate water levels via aquaporin-4 (AQP4), 
and also ion concentrations, while its synaptic connections with neurons regulates 
neurotransmitter signalling (Sofroniew & Vinters, 2010; Wong et al., 2013; ElAli et al., 
2014). Astrocytes are also known for their alignment along the interfaces between the 
CNS and non-neural cells such as endothelial cells, pericytes, and meningeal surfaces. In 
a healthy CNS environment, the astrocytic location prevents leukocyte engagement with 
the CNS. However, when the CNS is damaged, astrocytes form scars comprising new 
proliferating astrocytes, which were once thought to hamper CNS recovery. However, 
this is no longer believed to be the case, as it was observed that astrocytes unable to form 
scars were seen to cause further inflammation and damage (Sofroniew, 2015). More 
recently, it has been found that astrocytes can control blood flow through the production 
of arachidonic acid when calcium levels reach a certain threshold, triggering 
vasoconstriction, or alternately, vasodilation through the production of prostaglandin E2 
(Cardoso et al., 2010; Stanimirovic & Friedman, 2012; Obermeier et al., 2013). 
Astrocytes have also been shown to play a role in the innate and adaptive immune 
response, expressing MHC Class II molecules when stimulated with IFN-γ in-vitro (Esen 
et al., 2003). They can also display pro-inflammatory and anti-inflammatory functions 
too when stimulated with various signalling outputs. Astrogliosis is the term used to 
describe astrocytic behaviour upon CNS onslaught. This can be either beneficial or 
damaging to the BBB. The advantages of astrogliosis include the encouragement of 
wound healing and closure, BBB repair and limited CNS inflammation, whilst the 
disadvantages include prolonged inflammation and interference with synapse and axonal 
growth (Sofroniew, 2015). These macroglial cells have been shown to play an important 
role in directing brain endothelial cells to adopt BBB characteristics (Keller, 2013). At 
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present, it is still unclear how the brain endothelium and astrocyte end-feet interact and 
communicate with each other but some advances have been made. For instance, the bone 
morphogenetic protein receptor type 1 (BMPR1A) has been shown to be important to the 
recruitment of astrocytic end-feet around the BBB, whilst pericyte-astrocyte signalling 
helps regulate astrocyte end-feet polarisation (Keller, 2013). There are two genetic 
diseases which are known to affect astrocyte function and cause BBB dysfunction and 
impairment. The first, known as Alexander disease, is a neurodegenerative disease caused 
by mutations in the GFAP gene responsible for the production of glial fibrillary acidic 
protein (GFAP), leading to astrocyte death. The second, referred to as megalencephalic 
leukoencephalopathy with subcortical cysts (MLC), is a rare leucodystrophy caused by 
two mutations in either MLC1 or GLIALCAM genes. MLC1 plays a role in regulating 
water transport in astrocytes as well as other transport mechanisms (Keller, 2013).  
 
1.3.5 Neurons 
Another key function of the BBB is its ability to maintain an ionic environment that 
enables neuronal function and activity. It was previously believed that when 
concentration levels of oxygen and glucose fell below a certain threshold, or when CO2 
levels increased, this would trigger neuronal signalling to increase blood flow. However, 
this concept has since been challenged with the discovery of “neurotransmitter-mediated 
signalling”. Neurotransmitter signalling from neurons is passed to capillaries through 
astrocytes forming what is known as the gliovascular unit (G-Unit). This has the potential 
to induce vasodilation or vasoconstriction through glutamate-mediated signalling, where 
neurons can either signal directly to blood vessels, or indirectly by activating astrocytes 
to release nitric oxide (NO) or arachidonic acid (Banerjee & Bhat, 2007; Sofroniew & 
Vinters, 2010; Cardoso et al., 2010). When neurons are deprived of oxygen and glucose, 
they either become severely injured or die; in order to prevent this, the brain has evolved 
to develop a “neurovascular coupling” mechanism whereby there is increased blood flow 
to the area of the brain with active neurons. Neuronal damage is linked to many if not all 
brain diseases e.g. Alzheimer's disease, Parkinson’s disease and motor neuron disease 
(MND).  
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1.3.6 Basement membrane 
The basement membrane, also referred to as the basal lamina acts as the structural scaffold 
of the BBB, securing the BMvEC and pericytes in place, whilst also acting as an 
attachment site for the other constituents of the NVU within the perivascular space. The 
basement membrane comprises three classes of ECM proteins: (i) structural proteins such 
as elastin; (ii) specialized proteins including fibronectin and; (iii) proteoglycans (Cardoso 
et al., 2010). The BMvEC is surrounded by two basement membranes: (i) inner vascular 
basement membrane (endothelial side) is secreted by endothelial cells and pericytes and; 
(ii) the outer parenchymal basement membrane (also referred to as vascular glia limitans 
perivascularis) is secreted by astrocytic processes (Keller, 2013; Daneman & Prat, 2015). 
Matrix metalloproteinases (MMPs) (e.g. MMP 2/9) are produced by a variety of cells 
under different pathophysiological circumstances in the CNS. MMPs are capable of 
digesting the basement membrane of the NVU causing barrier dysfunction. It has been 
shown using mouse models lacking key basement membrane components that animals 
may suffer from haemorrhages as a result of weak vessels. Similarly in human genetic 
studies it has been shown that defective genes encoding an element of collagen may also 
result in haemorrhagic strokes (Keller, 2013).  
 
1.4 Blood-Brain Barrier Structure 
As discussed in the previous section, the neurovascular unit consists of numerous cell 
types, all working together in a cohesive unit to maintain brain homeostasis, yet it is the 
brain microvascular endothelial cells (BMvEC) within the NVU that form the backbone 
of the BBB, essentially forming the capillary wall. This helps to maintain a homeostatic 
environment for the brain to work efficiently. Ehrlich first promoted the concept of a BBB 
in 1885 when he injected a dye intravenously into mice. He saw that the brain was the 
only region not to be stained. Later studies confirmed that the BMvEC differ significantly 
to peripheral endothelial cells as they are not fenestrated (not porous), meaning they form 
a single monolayer that is 50-100 times tighter than other peripheral vessels (Lawther et 
al., 2011). However, what makes these cells ideal for selective permeability are the highly 
expressed tight junction (TJ) and adherens junction (AJ) proteins located within the 
interendothelial space [Figure 1.4]. TJ proteins (e.g. claudins and occludin) are located 
on the interendothelial membrane surface between adjacent cells, regulating the 
paracellular diffusion of water and solutes. Extracellular TJ protein loops bind to 
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homologous partners on the opposite BMvEC, essentially sealing the paracellular space. 
Within the cell cytosol, adaptor proteins such as zonula occludens-1 (ZO-1) serve to tether 
the membrane–bound proteins to the actin cytoskeleton. AJ proteins (e.g. VE-cadherin) 
are located in a discrete complex basolaterally to the tight junction protein complex 
(Ballabh et al., 2004; Hawkins & Davis, 2005; Cardoso et al., 2010). Importantly there is 
considerable “cross-talk” between TJ and AJ proteins in order to regulate the BBB, as 
previously observed by Walsh et al. (2011) who showed that VE-cadherin regulates TJ 
organisation and barrier function in response to shear stress (Walsh et al., 2011). These 
junctional complexes endow the BBB with the ability to regulate paracellular transport. 
 
Figure 1.4: BBB and paracellular space between BMvEC. The BBB is composed of 
TJ and AJ proteins located in the paracellular space between BMvEC e.g. claudin-5, 
occludin, ZO-1 and AJ VE-cadherin. EC: Endothelial cells. (Förster, 2008). 
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1.4.1 Interendothelial junction proteins  
As previously mentioned, BMvEC are equipped with TJ and AJ protein complexes 
ensuring the brain retains its selective-pressure of allowing only the required solutes into 
the brain. Tight junction proteins are described as having “gate” and “fence” functions. 
The “gate” function refers to the regulation of molecules and ions through the paracellular 
route, while the “fence” function refers to the limited movement of solutes from the apical 
to the basolateral side of the cell, thus helping to maintain cell polarity (Tietz & 
Engelhardt, 2015). Until now, TJ were always thought of as being exclusively located 
between adjacent endothelial cells. However, the discovery of tricellular TJ proteins 
located on the corners of three endothelial or epithelial cells somewhat changes the 
previous analogy of TJ conformation. Tricellular TJ proteins have been located in the 
BMvEC of the BBB (Tietz & Engelhardt, 2015). Adherens junctions (AJ) proteins are 
equally important as the TJ proteins for BBB formation. Proper junctional protein 
upregulation and localization plays an important role in maintaining the integrity of the 
BBB, which is why when one or more become affected, either by pro-inflammatory injury 
or by pathogenic infection, this can result in serious consequences to BBB integrity. The 
key TJ and AJ proteins are summarised below.  
 
1.4.1.1 Claudins  
There are 24 claudin proteins (~20-27 kDa) within the tight junction (TJ) family described 
to date, with claudin-5 being a specialised TJ protein of the BBB. Claudin-1,-3,-5 and -
12 have also been associated with TJ formation (Ballabh et al., 2004; Chen et al., 2006; 
Wong et al., 2013). Claudin proteins contribute to tight junction formation by creating 
two extracellular linkages to an adjacent claudin-5 on the opposite BMvEC with the 
second extracellular loop shown to provide TJ support and integrity through homo- and 
hetero-dimerization, subsequently restricting the size of the paracellular space (Cardoso 
et al., 2010; Luissint et al., 2012). Intracellularly, the carboxyl-terminal end of the 
claudin-5 protein combines with ZO-1 (cytoplasmic TJ protein), cross-linking it with 
actin filaments within the microvascular endothelial cell (Ballabh et al., 2004). Knockout 
(KO) mice studies for claudin-5 revealed that this protein regulates the permeability of 
small molecules less than 800 Da, whereas claudin-12 regulates the larger molecules 
greater than 800 Da (Chen et al., 2006; Jiao et al., 2011). Phosphorylation events can 
occur at various residues on claudin-5, and depending on the phosphorylated site, can 
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result in increases or decreases in TJ confirmation and function. For instance, 
phosphorylation of Thr207 on claudin-5 caused an increase in barrier function in brain 
BMvEC; however, when the same residue was phosphorylated in lung endothelial cells 
it caused the barrier to loosen resulting in the influx of small molecules (Gonçalves et al., 
2013). Matrix metalloproteinases (MMPs) are known to target TJ proteins for proteolytic 
degradation as a means for cellular renewal. This process however, can be exacerbated 
through cell injury and excessive inflammatory stimulus as seen for claudin-5 and 
occludin following the onset of stroke (Jia et al., 2014). However, it has also been seen 
that when MMPs are inhibited this too leads to BBB disruption. Nevertheless, it would 
seem there is a fine balance required to maintain BBB function and stability (Gonçalves 
et al., 2013; Jia et al., 2014). It was also noted that when BMvEC were tested against high 
levels of glucose and neurotoxicants (malathion and lead acetate), this resulted in 
increased barrier permeability in parallel with reduced claudin-5 expression, clearly 
suggesting claudin-5 is a key mediator of barrier integrity. As BMvEC are a component 
of the NVU, other NVU cell types such as pericytes also stimulate TJ proteins. Pericytes 
release neurotrophic factors that may directly increase the expression of claudin-5, 
resulting in increased barrier function (Jia et al., 2014). Because claudin-5 plays an 
important role in barrier permeability, it is essential that it retain its healthy confirmation. 
However, when targeted by MMPs or damaged through injury, downregulation of 
claudin-5 has been implicated in many BBB diseases such as multiple sclerosis and 
Alzheimer’s disease (Hair et al., 2008) 
 
1.4.1.2 Occludin 
Occludins were one of the first transmembrane TJ proteins discovered (Furuse et al., 
1993). They are 60-65 kDa in size and play an essential role in regulating the paracellular 
diffusion of solutes across the BBB in conjunction with claudin-5. Like claudin-5, 
occludin is cross-linked to the actin filaments within the cytoplasm via ZO-1, whilst also 
containing two extracellular loops that interconnect with adjacent occludin strands. If the 
second or both extracellular loops are absent, it results in occludin residing in the cytosolic 
space and not anchored to the TJ region, illustrating their importance for occludin 
tethering across the paracellular surface (Chen et al., 2006; Luissint et al., 2012). 
Occludin and claudin-5 do not have any sequence homology despite having a similar 
structural organisation within the paracellular space (Ballabh et al., 2004; Chen et al., 
2006). In-vivo studies using occludin KO mice experienced postnatal growth problems, 
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as well as inflammation and calcification deposits on the brain, but surprisingly, the TJ 
architecture was still maintained as it is thought that claudin-3, ZO-1, ZO-2, and VE-
cadherin compensate for this loss. This would suggest that occludin is a potentially 
dispensable TJ protein and is more likely responsible for “stabilising” TJ architecture 
(Zlokovic, 2008; Cummins, 2012; Luissint et al., 2012). Occludin can be downregulated 
through proteolysis or by the use of permeabilizing molecules such as VEGF, and 
phospholipase D2 (PLD2), both of which cause an increase in barrier permeability, once 
again illustrating that occludin may play a role in barrier stability (Cummins, 2012). As 
mentioned previously, MMPs are able to target TJ proteins for degradation. The same is 
true for occludin, acting as a substrate for MMP targeting by MMP-2/9. The endothelial 
layer can produce MMPs; however, the other cells of the NVU such as astrocytes, and 
pericytes, as well as circulating cells, are also producers of MMPs (Cummins, 2012). 
Several studies have been conducted in relation to MMP proteolysis, for instance an in-
vivo study using a rat model for cerebral ischemic injury showed MMP-2 was required to 
cleave occludin from the cell membrane, while MMP-9 caused further occludin 
breakdown and barrier disruption 24 hrs post-ischemic injury (Cummins, 2012). 
 
1.4.1.3 Junctional adhesion molecule-1 
Junctional adhesion molecule-1 (JAM-1) is also an integral membrane protein like 
occludin and claudin, but is one of the lesser known TJ proteins of the BBB (Luissint et 
al., 2012). It belongs to the IgG family, establishing the early attachment of adjacent cells. 
JAM is made up of a single membrane-spanning chain with a large extracellular portion 
that adheres to another JAM chain on the opposite BMvEC. Other isoforms of JAM such 
as JAM-2 and -3 are also found in endothelial cells (but not in epithelial cells) (Hawkins 
& Davis, 2005). Like the other TJ proteins, JAM-1 regulates paracellular transport of 
molecules; however, when under inflammatory conditions, JAM-1 acts like a leukocyte 
adhesion molecule interacting with a leukocyte function associated antigen-1 (LFA-1). 
LFA-1 is affiliated with cell migration and the recruitment of leukocyte attachment to the 
apical surface of cells. Research by Stamatovic et al. (2012) has shown that JAM-1 along 
with other leukocyte attachment markers gather together in a ring structure on the apical 
surface forming a transmigration “tunnel” for paracellular and transcellular leukocyte 
traversal or “diapedesis” across the endothelium, as seen in brain endothelial cells 
(Stamatovic et al., 2012). 
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1.4.1.4 Zonula-occludens 
Zonula-occludens (ZO) proteins belong to a family of membrane-associated guanylate 
kinases (MAGUK) whose role is to facilitate cytoskeletal tethering of TJ proteins. There 
are three ZO proteins found in the TJ region; ZO-1 (220 kDa), ZO-2 (160 kDa) and ZO-
3 (130 kDa), with ZO-2 and ZO-3 interconnecting with ZO-1 through heterodimerization 
(Luissint et al., 2012). ZO-1 is a phosphoprotein in which the carboxyl-terminal end 
adheres to actin filaments bridging the gap between the cytoskeleton and the TJ. As a 
result, ZO-1 has been shown to anchor TJ-associated claudin-5, occludin and JAM to the 
cytoskeleton (Bauer et al., 2010; Luissint et al., 2012). All three ZO proteins form a 
complex with α-catenin and actin filaments, initiating a rigid scaffold between the TJ and 
cytoskeleton. As well as providing a structural role to the TJ, ZO proteins have also been 
implicated in signalling and transcriptional activities. Loss of ZO-1 results in increased 
BBB permeability as a result of poor TJ recruitment of claudin-5 and occludin to the TJ 
region, as seen in-vitro with Eph4 cells, whilst in-vivo studies showed that ZO-1 KO mice 
embryos were fatal at mid-gestation as well as being implicated in diseases such as 
diabetic retinopathy (Bauer et al., 2010). Recent work has shown that two of the most 
commonly expressed pro-inflammatory mediators of the innate immune response, TNF-
α and IL-6, cause a dose-dependent decrease in ZO-1 at the mRNA and protein level, as 
seen using primary-derived human brain microvascular endothelial cells (HBMvEC) 
(Rochfort & Cummins, 2015). ZO-1 immunoreactivity was also redistributed away from 
the cell-cell border post-cytokine treatment, thereby illustrating the profound effect of 
these inflammatory proteins on junctional stability (Rochfort & Cummins, 2015). 
 
1.4.1.5 Cadherins 
Cadherins are important proteins that form adherens junctions (AJ) between adjacent 
endothelial cells, intermingling with the TJ complexes to offer greater stability and 
support to the BMvEC monolayer. Vascular endothelial cadherin (VE-cadherin), 
previously known as cadherin-5, is the only cadherin located at the paracellular surface 
of two adjacent BMvEC (Vestweber, 2008; Walsh et al., 2011). VE-cadherin is a 
transmembrane protein consisting of five extracellular transmembrane regions. The 
cytoplasmic tail interlinks with α- and β-catenin, structural proteins found in the BMvEC 
cytoplasm (Sidibé & Imhof, 2014). Both catenins are further linked to actin filaments, 
which in-turn can augment morphological barrier changes (Vestweber, 2008). 
Furthermore, in-vivo and in-vitro work has shown that VE-cadherin is pivotal for 
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endothelial integrity in quiescent vessels, whilst also playing a major role in structurally 
managing new vessels (Zlokovic, 2008). Research has shown that TJ proteins require the 
presence of AJ proteins in order to establish a working barrier (Tietz & Engelhardt, 2015).  
In-vivo studies looking at phenotypic changes in KO mice models for claudin-5 and VE-
cadherin noted very different results. Firstly, the claudin-5 KO mice grew normally but 
died shortly after birth due to the formation of a defective BBB, while VE-cadherin KO 
mice died during pregnancy as a result of multiple deformities (Gavard, 2009). The 
relationship between claudin-5 and VE-cadherin was further highlighted with the ability 
of VE-cadherin to bind to repressive transcriptional factors, thereby disabling them from 
binding to the claudin-5 promoter allowing the continued expression of the TJ protein 
(Taddei et al., 2008). As VE-cadherin is located within the paracellular space it also 
possesses “gate-like” properties similar to TJ proteins that regulate macromolecule influx 
to the basolateral side of the cell (Dejana et al., 2008; Gavard, 2009). New research has 
shown that phosphorylation of VE-cadherin at two tyrosine residues potentiates vascular 
permeability in-vivo. For instance, tyrosine phosphorylation of VE-cadherin by VEGF 
results in VE-cadherin disruption, internalisation and ultimately degradation of the AJ 
protein. (Sidibé & Imhof, 2014; Tietz & Engelhardt, 2015; Rochfort et al., 2015).  
 
1.5 BBB Transport Mechanisms 
Since the early studies by Ehrlich on what became known as the BBB, it has become 
apparent that the brain is an organ with highly restricted access pathways. The 
microvasculature of the BBB forms the largest interface for molecular exchange between 
the blood and the CNS due to having the shortest distance to travel to the neurons (Abbott, 
2013). Even today, great efforts have been made to develop therapeutics to cross the BBB, 
with many studies ending unsuccessfully. Moreover, it also follows that several 
cerebrovascular and neurodegenerative diseases manifest BBB dysfunction, leading to 
unwanted traffic into the CNS. In the following section, some regulated pathways for 
BBB entry are discussed. Specifically, there are four key transport routes applicable to 
the BBB, namely: (i) paracellular diffusion; (ii) passive diffusion; (iii) facilitated 
diffusions via carrier-mediated receptors and; (iv) transcytosis [Figure 1.5].  
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Figure 1.5: Transport mechanisms of the blood-brain barrier. Paracellular and 
transcellular routes are the main pathways used to gain access across the BBB via passive, 
cell-mediated and cell receptor pathways (Abbott et al., 2006). 
 
1.5.1 Paracellular diffusion 
The paracellular space between brain capillary endothelial cells comprises what we now 
know are TJ and AJ protein complexes, which give the brain endothelium its restrictive 
paracellular permeability. This is in contrast to non-brain endothelial beds, whereby 
paracellular transport is a more common route of solute transmission (Wolburg & 
Lippoldt, 2002). Despite this, water-soluble agents are able to gain entry via the 
paracellular route of the BMvEC. Diseases such as stroke, MS and brain tumours can 
result in paracellular TJ dissolution, thereby compromising the integrity of the barrier and 
resulting in BBB dysfunction (Luissint et al., 2012) [Figure 1.5A]. 
 
1.5.2 Passive diffusion 
Small gaseous or inorganic molecules such as oxygen, carbon dioxide and water are free 
to pass through the lipid membranes of the BBB by concentration gradient. In addition, a 
compound that has five or less hydrogen bonds, is facilitated across the membrane 
(Lawther et al., 2011). This process is known as passive diffusion (Abbott et al., 2006; 
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Lawther et al., 2011) [Figure 1.5B]. In order to passively diffuse across the BBB, the 
molecule must be hydrophilic in order to travel in water and lipophilic in order to pass 
through the lipid membrane of the BBB. Such molecules are also required to have a 
molecular weight less than 500 Da and have five or less hydrogen bonds. In such cases, 
passive diffusion is a very selective process with 98% of all small molecules failing to 
cross the barrier (Wong et al., 2013). 
 
1.5.3 Facilitated diffusions 
Not all molecules are able to gain entry via the aforementioned route. Therefore, the 
apical surface of the BMvEC is equipped with several transport systems to overcome this. 
It so happens that many of the key nutrient providers of the BBB and CNS are small 
hydrophilic, polar molecules that are unable to penetrate the BMvEC via passive 
diffusion. As a result, these essential molecules are aided across the BBB by carrier-
facilitated diffusion, whereby the molecules interact with surface protein carriers that 
slowly permeate through the BMvEC to the basolateral side (Wong et al., 2013). Such 
molecules that use this route are glucose, amino acids and small peptides. This form of 
transport is energy-independent (Lawther et al., 2011) [Figure 1.5C]. As the brain is 
reliant on certain key nutrients such as glucose, the BBB possesses a glucose-transporter 
1 (GLUT-1) carrier facilitating its transport across the membrane (Abbott et al., 2006; 
Lawther et al., 2011).  
 
1.5.4 Transcytosis 
The final means of BBB transport is transcytosis, also referred to as endocytosis [Figure 
1.5 D-E]. This form of transport involves two mechanisms: (i) receptor-mediated 
transcytosis (RMT) and; (ii) absorptive-mediated transcytosis (AMT). These mechanisms 
enable large hydrophilic macromolecules such as peptides and proteins to access the CNS 
via clathrin-coated vesicles and caveolae (Abbott et al., 2006; Hervé et al., 2008). The 
RMT route is a more specific pathway than the AMT as it requires the macromolecules 
to bind to a receptor on the BMvEC surface, whereby it becomes engulfed within the 
vesicle or caveolae for transport across the BMvEC being released by exocytosis on the 
basolateral side. RMT has been shown to facilitate access of insulin, IgG and TNF-α into 
the CNS (Wong et al., 2013; Abbott, 2013). The luminal surface of cerebral endothelial 
cells has an overall negative charge due to sialo-glycoconjugates and heparan sulphate 
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proteoglycans, which together form the glycocalyx (Hervé et al., 2008; Abbott, 2013). 
This overall negative charge facilitates AMT and is regarded as being a non-specific 
process (Hervé et al., 2008). It uses the negatively- charged clathrin-coated pits found on 
the apical surface of the endothelial cell, repelling anionic proteins whilst attracting 
cationic ones, thereby enabling the transfer of such proteins to the basolateral side of the 
brain microvasculature (Hervé et al., 2008). Both histones and albumin use AMT for 
transport across the BBB (Abbott, 2013; Wong et al., 2013). 
The BBB has to be selective in choosing what is able to gain access to the CNS, but there 
are certain instances where this diffusion barrier can be breached. In such instances, the 
“enzymatic barrier” of the BMvEC comes into effect, comprising intracellular and 
extracellular enzymes that are able to degrade any unwanted molecules that may have 
attached to the surface of the BMvEC, or have managed to gain access to the BMvEC 
(Abbott, 2013). Nucleotidases and peptidase ecto-enzymes are capable of removing 
unwanted peptides from the BMvEC. They are able to do this by having their active site 
located on the external plasma membrane (Goding, 2000; Abbott et al., 2006). The 
presence of intracellular enzymes such as cytochrome P450 and monoamine oxidase can 
also deactivate toxic and harmful compounds within the BMvEC vicinity (Abbott et al., 
2006). The presence of efflux pumps also aids in ejecting unwanted molecules back into 
the circulatory system (Wong et al., 2013).  
 
1.6 Staphylococcus aureus 
The main goal of this research project was to gain a better understanding of 
Staphylococcus aureus (SA) infection within the cerebrovasculature, which can 
ultimately lead to BBB dysfunction. This was approached by infecting human primary-
derived BBB microvascular endothelial cells with SA and examining the changes that 
occurred. As a result, it is of key importance to completely understand SA infection 
strategies. It has been shown that SA is constantly evolving in order to overcome 
antibacterial treatments, as seen with penicillin-like antibiotics. This is extremely 
worrying with SA having now gained extra virulence factors to enable it to become 
established within the community and outside of the hospital environment, where it was 
once contained. This section aims to highlight SA biology and focuses on many of the 
virulence factors at its disposal. The manner by which SA potentially engages with the 
epithelium and endothelium layers is also discussed in section 1.7 and 1.8.   
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1.6.1 Staphylococcus aureus composition 
Staphylococcus aureus (SA) is a gram-positive commensal pathogen responsible for 
many infections that occur in both humans and animals. The name originates from its 
colour and shape with the word “aureus” meaning gold, while “cocci” refers to its circular 
shape when grown on agar. SA normally reside in pairs or in larger clusters, which 
resemble grape-like clusters when stained with crystal violet for peptidoglycan gram-
staining. Up to 50% of the bacterial cell wall is composed of peptidoglycan, which is 
integral for SA survival when experiencing high temperatures and challenging osmotic 
conditions (Harris et al., 2002). SA is also non-motile and non-spore forming, although 
they make up for this by being able to produce biofilms, a protective extracellular matrix 
that acts like a strong glue holding the bacteria in a fixed position, whilst also rendering 
it temporarily inactive (Harris et al., 2002). As well as having a strong cell wall composed 
of peptidoglycan, SA also contain an outer membrane called a capsule, which endows SA 
with another layer of protection. This capsule is also regarded as one of many virulence 
factors which SA possess (Harris et al., 2002). SA virulence factors will be described in 
section 1.6.3.3.3. 
In humans, SA is found in the mucosal surfaces such as the nasal cavity and 
gastrointestinal tract (GI), whilst also being found in the underarm and groin (Sheen et 
al., 2010). In the USA SA was the number one killer with respect to bacterial infections 
in 2010, illustrating its widespread prevalence and virulence. For instance, SA 
bacteraemia (SAB) accounts for 20-50 cases/100,000 population per year, with 10-30% 
of these cases resulting in mortality. In its entirety, this amounts to greater mortality rates 
than AIDS, tuberculosis and viral hepatitis combined (van Hal et al., 2012). 
Approximately 20-30% of the population are persistent carriers of nasal SA, while 30-
50% are said to be intermittent carriers (Frank et al., 2010; Ryu et al., 2014). It is 
interesting to note that some carriers of this pathogen do not experience any problematic 
symptoms associated with it. However, in susceptible individuals it can cause mild to 
severe infections such as systemic infection post-surgery, skin and soft tissue infections 
(SSTI), sepsis and also cerebral meningitis (Wertheim et al., 2005; Foster, 2005; 
O’Seaghdha et al., 2006). An outline of illnesses associated with SA is illustrated in 
Figure 1.6. Out of the 15 illnesses listed, endocarditis of the heart has become the most 
deadly, whereby SA adheres to the lining of the heart muscle resulting in vegetative 
deposits forming on the endocardium ultimately leading to heart failure and/or stroke.  
30 
 
 
Figure 1.6: Staphylococcal infections. Outline of human conditions associated with the 
contraction of Staphylococcus aureus infections (Wertheim et al., 2005).  
 
 
Two strains of SA were used for in-vitro infections; (i) NCTC 8178 Newman wild-type 
(NWT) and; (ii) staphylococcal protein A deficient (ΔSpA) SA strains. The NWT strain 
was isolated from a male patient infected with tubercular osteomyelitis in 1952 (Duthie 
& Lorenz, 1952). Since then, SA Newman has been used in a variety of experimental 
studies involving human illnesses and in animal models. Because technology has 
advanced, the NWT strain has been fully sequenced allowing for the identification of 
sequence homology or likeness between other staphylococcal, and indeed other bacterial 
strains. A study by Baba et al. (2008) completed the genetic sequence of NWT-SA in 
2008. They identified 20% variability0 between SA genomic sequences and found 30 
genes were required for SA pathogenesis. Their findings also showed that the Newman 
strain contained four integrated prophages, which were seen to play an important role in 
pathogenesis when removed in mutant studies. During the study, it was noted that other 
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staphylococcal strains carried their virulence genes in mobile pathogenicity islands 
whereas in the Newman strain, these were found within prophages (Baba et al., 2008). 
 
The reasoning behind using NWT-SA is because it is a well-studied bacterium and it is 
cooperative in mutagenesis studies such as the development of mutant staphylococcal 
protein A (ΔSpA) (Section 2.2.5.2).  
 
1.6.2 Role in disease 
The prevalence of SA has increased significantly in the last few years due to its 
adaptability and genomic plasticity to survive antibiotic treatment through the uptake of 
genes from other closely related species via horizontal gene transfer, and through 
bacteriophage infection (Sivaraman et al., 2009; Viegas et al., 2011). SA is an adaptable 
pathogen that is able to survive in the mucosal areas of the human body, namely the nasal 
cavity, as well as surviving on the skin. Because of this, SA gains access to its host 
through mucosal/skin wounds such as puncturing of the dermal layer by intravenous 
drips, infection post-surgery, insertion of surgical implants colonised with SA biofilms, 
under-going any dialysis regimes or even ingestion of contaminated food (Kobayashi & 
Deleo, 2013). Once SA has gained access to the circulatory system there is a possibility 
of it breaching the CNS, ultimately leading to cerebral meningitis, of which it is 
responsible for causing 10% of cases, most commonly in neonates and young children, 
whilst some rare cases have been recorded in adults (Teh & Slavin, 2012). Methicillin-
resistant SA (MRSA) is one of the deadlier strains of SA capable of causing cerebral 
meningitis (Chavakis et al., 2005). MRSA is commonly found in hospitals in 
immunocompromised patients known as healthcare-associated MRSA (HA-MRSA). 
However, community-associated MRSA (CA-MRSA) is the new term coined to describe 
people infected with MRSA outside of a hospital environment, illustrating that SA has 
overcome the ideal environment of a hospital setting and re-modelled itself to survive in 
a more competitive environment. Due to the successful nature of CA-MRSA, 
hematogenous meningitis has developed, which has been shown to effect elderly patients 
suffering from other underlying conditions (e.g. cardiovascular disease). However, in 
recent times, this form of meningitis has been found in young people with no underlying 
conditions, which suggests the bacteria is still evolving in order to colonize both healthy 
and immunocompromised individuals (Aguilar et al., 2010). The successful nature of CA-
MRSA is partially attributed to the cytolytic toxin called Panton-Valentine Leukocidin 
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(PVL), which is found in some, but not all, CA-MRSA cases (Shore et al., 2014). PVL is 
a bi-component pore-forming toxin that forms β-barrel pores on the leukocyte 
cytoplasmic membrane causing cell lysis and apoptosis (Foster, 2005; Shore et al., 2014). 
As PVL is a bi-component leukotoxin it is made up of two subunits, which align together 
and form either hexameric or heptameric oligomers that have a strong attraction to 
phagocytic leukoctyes such as polymorphonuclear (PMN) leukocytes, monocytes and 
neutrophils (Foster, 2005; Diep et al., 2010; Powers & Bubeck Wardenburg, 2014). This 
toxin is associated with causing necrotizing infections such as pneumonia; however, the 
main mechanism by which it causes cell injury is still unknown. It has been suggested 
that the toxin may interact directly or indirectly with leukocytes, as in-vitro studies have 
shown that PVL activation of PMNs leads to proinflammatory and reactive oxygen 
species production (Diep et al., 2010). The pvl gene products (lukF-PV and lukS-PV) 
which are encoded by specific bacteriophages are found in a large proportion of CA-
MRSA strains in which the pvl gene is now considered a suitably stable biomarker for the 
identification of CA-MRSA strains (Lo & Wang, 2011; Shore et al., 2014). CA-MRSA 
transmission occurs from person-to-person and is said to result from direct skin contact 
(Brown et al., 2014). This is not uncommon as one fifth of the population are permanent 
nasal carriers of SA, living in synergy with other pathogens that are able to colonise this 
tissue-specific site e.g. Staphylococcus epidermidis and Streptococcus pneumonia 
(Brown et al., 2014). MRSA gained its methicillin resistance by acquiring the mecA gene, 
a penicillin-binding protein that is located on a SCCmec DNA element (Fan et al., 2009). 
The differences between HA-MRSA and CA-MRSA is dependent on this SCCmec 
element; for instance HA-MRSA is associated with a large SCCmec element types 1-3, 
while a small SCCmec is common for CA-MRSA disease types 4-8, which allows it to 
compete with MSSA in the community, instead of being outnumbered and out-grown by 
MSSA (Fan et al., 2009). A paper by Shore et al. (2014) authored in conjunction with the 
Irish National MRSA Reference Laboratory (NMRSARL), recorded a 44-fold increase in 
CA-MRSA strains in Ireland, over a 9-year period (2002-2011). They also recorded a 6-
fold increase in the number of MRSA samples resistant to a variety of antibiotics (Shore 
et al., 2014). 
 
1.6.3 SA survival strategy 
SA possess an array of defensive mechanisms that enable its survival within the host. 
These include the production of toxins, invasins and various adhesins to help colonise the 
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host. Essentially, it has three important stages to overcome in order establish host 
infection. The three stages include: (i) entry/adhesion; (ii) internalisation and; (iii) 
immune evasion. Each of these stages will be discussed next. 
 
1.6.3.1 Entry/adhesion 
As mentioned previously, SA is found in 30% of the population, located within the 
mucosal regions of the human body and on the skin surface. As a result, the main 
defensive barrier between SA colonisation is the skin (epidermis), which comprises 
proliferating basal and superbasal keratinocytes (Ryu et al., 2014). Also found within the 
dermal layer are dendritic cells, macrophages, plasma cells and natural killer (NK) cells, 
which aid in immune defence mechanisms for the dermal layer. The skin naturally has a 
low temperature and pH due to filaggrin breakdown, an epidermal structural component 
degraded to urocanic acid and pyrrolidone carboxylic acid. Both acidic products have 
shown inhibition of two SA adherens, ClfB and FnBP-A (Ryu et al., 2014). 
When sites colonised with SA experience injury or abrasions, it allows the bacteria to 
gain access into the host dermal layer resulting in SSTI or abscesses. However, when an 
individual sustains an open wound following an injury, operation or catheter site, this 
gives SA free access into the blood stream (Kobayashi & Deleo, 2013). SA bacteraemia 
has the potential of developing secondary SA infections such as infective endocarditis of 
the heart, osteomyelitis of bone tissue and septic arthritis (Edwards & Massey, 2011). In 
order to establish these secondary infections, SA has to adhere to the host cell lining, 
which can be epithelial, endothelial, capillary-based or tissue-specific (Oviedo-Boyso et 
al., 2008). It has previously been shown that SA preferentially binds to venular sites 
following pre-treatment with TNF. This suggests that the venular endothelium is a prime 
target site for SA attachment (Chavakis et al., 2005). Of the many SA virulence proteins, 
a subset are referred to as cell wall-anchored (CWA) proteins, which play a significant 
role in host cell binding (Foster et al., 2014). For instance a sub-type of CWA proteins 
are microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs), which are a group of proteins that encode the majority of SA virulence 
factors that help SA modulate its adhesion to host epithelial and endothelial cell surfaces 
(Henderson et al., 2011; Foster et al., 2014). A classical MSCRAMM structure contains; 
(i) an N-terminal signalling region that regulates protein secretion across the bacterial 
membrane; (ii) IgG binding domains; (iii) variable repeat regions; (iv) a membrane-
spanning C-terminal region, containing an LPXTG site (Leu-Pro-X-Thr-Gly); (v) a 
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hydrophobic domain and; (vi) a charged tail, which covalently anchors proteins to 
peptidoglycan within the cell wall [Figure 1.7] (Roche et al., 2003; Mulcahy et al., 2012; 
Sørum et al., 2013).  
 
 
Figure 1.7: MSCRAMM motif. A classical MSCRAMM motif contains an N-terminal 
sequence, followed by five IgG domains, variable repeat sequence and finally a C-
terminal sequence. 
 
The sortase enzyme is a membrane bound transpeptidase that is able to cleave the amide 
bond between threonine and glycine of the LPXTG motif. The liberated threonine forms 
a cross bridge with peptidoglycan, hence becoming a cell wall-associated protein [Figure 
1.8] (Roche et al., 2003; Hendrickx et al., 2011). SA strains lacking the sortase gene 
(srtA) were unable to cleave the LPXTG motif, hence MSCRAMM proteins were not 
anchored to the cell wall but instead remained intact to the cell membrane. The mutant 
sortase SA strains were also attenuated in SA infection models (Roche et al., 2003). Wall 
teichoic acid (WTA), staphylococcal protein A (SpA) and clumping factors (ClfA and B) 
are key proteins that contain this MSCRAMM motif and will be discussed next (Kubica, 
et al., 2008; Liu, 2009; Krishna & Miller, 2012a).   
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Figure 1.8: LPXTG cleavage by sortase A. The LPXTG motif found in the C-terminal 
region of an MSCRAMM structure is cleaved by the Sortase A enzyme. This allows 
threonine to covalently link to the nascent pentaglycine cross bridge within peptidoglycan 
and as a result, become a cell wall anchored protein. 
1.6.3.1.1 Wall teichoic acids 
Approximately 40% of SA cell wall mass is made up of teichoic acid (TA) (Harris et al., 
2002). There are two different forms of TA, cell wall teichoic acid (WTA) and cell 
membrane teichoic acid (also known as lipoteichoic acid, LTA), found covalently linked 
to peptidoglycan on the bacterial surface or found within the lipid membrane of SA 
(Harris et al., 2002) [Figure 1.9]. It has been shown that WTA is not important for SA 
viability in-vitro but seemingly plays an important role in colonisation and infection in-
vivo. LTA are made of glycerol phosphates that traverse across the peptidoglycan-coated 
cell wall. They are anchored to the SA cytoplasmic membrane by a cytoplasmic 
glycolipid-binding protein called diglucosyl-diacylglycerol (DG1cDAG). It has been 
shown in-vitro that the deletion of Ypfp, the enzyme required for DG1cDAG synthesis 
led to an 87% decrease in SA-associated LTA invasion of human brain microvascular 
endothelial cells (HBMvEC) and human umbilical vein endothelial cells (HUVEC). This 
has also been shown in-vivo using a mouse infection model (Sheen et al., 2010). LTA are 
also found in Streptococcus and Bacillus strains.  
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Figure 1.9: Wall teichoic acid and lipoteichoic acid surface proteins. Staphylococcus 
aureus cell surface composed of adhesion molecules called wall teichoic acid (WTA) and 
lipoteichoic acid (LTA) (Cabeen & Jacobs-Wagner, 2005). 
 
1.6.3.1.2 Staphylococcal protein A 
Staphylococcal protein A (SpA) is a 40-60 kDa protein mainly found on the surface of 
SA making it an ideal marker for strain typing to distinguish SA from other 
staphylococcal strains (Soong et al., 2011; Foster et al., 2014). This protein can also be 
released in an extracellular form from the cell surface (Yung et al., 2011). Full length 
SpA comprises an MSCRAMM structure with an N-terminal signal sequence followed 
by five Ig-binding domains named E, D, A, B, C. This is followed by a variable repeat 
region, which is prone to frameshift mutations and concludes with a C-terminal domain 
[Figure 1.7] (Sørum et al., 2013). This protein plays a major role in initiating bacterial 
adhesion to the host cells, binding to the Fc regions of IgG preventing phagocytosis by 
immunoglobulins as they coat SA in an irregular way, rendering it unrecognisable to 
neutrophils for degradation (Gómez et al., 2006). It can also bind to the Fab region of 
VH3 immunoglobulins, which causes B-lymphocytes to undergo apoptosis (Sørum et al., 
2013). Von Willebrand Factor (vWF), TNFR1 and EGF receptor (EGFR) are also known 
receptor binding sites of SpA (Soong et al., 2011; Widaa et al., 2012; Kobayashi & Deleo, 
2013).  
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1.6.3.1.3 Clumping factors 
The well-defined mechanism of SA adhesion to host cells is regarded as a key step for 
bacterial survival. The “clumping factors”, namely clumping factor A (ClfA) and 
clumping factor B (ClfB) are important proteins in this regard. ClfA is part of the 
MSCRAMM family that binds to fibrinogen on host cells, which is key for establishing 
early infection (Nizet, 2007; Scully et al., 2014) [Figure 1.11]. Macrophages infected with 
a SA expressing ClfA strain were attenuated in their ability to phagocytose the bacteria 
when compared to a ClfA mutant strain. This suggests ClfA display on the surface of SA 
impedes the host immune response to actively clear infections (Palmqvist et al., 2004). 
ClfA also possesses the capabilities of disrupting the complement pathway through the 
degradation of C3b, a complement control protein that coats bacterial cells marking them 
for degradation. However, this does not take place as C3b is cleaved to inactive C3b 
(iC3b) by the complement regulatory protein factor I, which ClfA is able to bind to 
(Serruto et al., 2010). The cleavage of C3b has a knock-on effect, thereby preventing the 
alternative complement pathway, whilst also preventing neutrophil phagocytosis (Hair et 
al., 2008; Foster et al., 2014). SA has a tendency to bind to sites of vascular injury 
resulting in the aggregation of platelets. SpA and ClfA are both platelet-binding proteins 
that enable bacterial adherence and a possible means to pass through the damaged 
membrane (Siboo et al., 2001). 
 
1.6.3.2 Internalisation 
When SA has made a contact point with a host cell (i.e. phagocytic cell and/or endothelial 
cell), the next step involves SA manipulating its way using its virulence factors to become 
internalised. There are several possible mechanisms as to how this can occur: (i) 
transcytosis; (ii) paracytosis; (iii) phagocytic transport; (iv) thrombus formation and; (iv) 
macroaperture formation. Each will be discussed in the following sections. 
  
38 
 
 
Figure 1.10: Bacterial invasion of host cells. The mechanisms used by bacteria to invade 
host cells: (A) transcytosis, utilising host cell receptors to access cell membrane; (B) 
paracytosis, travelling in the spaces between cells to access the basolateral side; (C) 
phagocytic transport, using phagocytic immune cells as vesicles to remain undetected and 
pass freely through the cell membrane; (D) thrombus formation, attaching to injured or 
activated endothelium and enabling pathogen binding resulting in further injury to the 
membrane and enabling pathogen access into blood stream and; (E) macroaperture 
formation, by causing actin cytoskeleton realignment resulting in the formation of a pore, 
which runs from the apical to the basolateral side of the cell (Edwards & Massey, 2011). 
 
1.6.3.2.1 Transcytosis 
Transcytosis is the term used to describe the process of transporting a microbe across an 
endothelial cell. Within blood vessels, the endothelium is the main cellular layer in direct 
contact with blood flow. Therefore, if SA is present in circulation, it has to try to engage 
with the endothelial cell barrier. The main SA marker in this pathway is fibronectin 
binding protein (FnBP), which is vital for endothelial adherence and invasion as seen in-
vivo (Schro et al., 2006; Edwards & Massey, 2011; Herman-Bausier et al., 2015) and in 
vitro studies (Massey et al., 2001) [Figure 1.10A]. There are two main FnBPs, FnBP-A 
and FnBP-B, each with the ability to bind to fibrinogen and fibronectin-binding sites on 
endothelial cells. FnBPs bind to fibronectin and utilise it as a bridging molecule between 
SA and the α5β1 integrin found on endothelial cells (Claro et al., 2011). Upon α5β1 
integrin recognition of fibronectin facilitates its internalisation along with SA into the cell 
(Foster, 2005). This interaction also results in endothelial activation and actin 
cytoskeleton rearrangement, which induces a pro-inflammatory and pro-coagulant 
response (Schröder et al., 2006; Bingham et al., 2008). SA FnBP-A has a high affinity 
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for endothelial cell receptors, which means the bacteria only needs to express a small 
number of FnBPs, resulting in SA successfully masking itself from the host immune 
response (Edwards & Massey, 2011).  
 
1.6.3.2.2 Paracytosis 
Paracytosis is the method pathogens use to travel between adjacent endothelial cells (i.e. 
the paracellular pathway) to gain entry into the basal lamina and host tissue [Figure 
1.10B]. It is able to do this through actin-cytoskeletal realignment by stimulating 
surrounding cells to produce TNF-α, VEGF and NO, which prepare cells for leukocyte 
infiltration. This causes junctional conformational changes enabling SA to burrow its way 
between the endothelial cells as seen using in-vitro studies involving HBMvEC and 
BAEC (Sheen et al., 2010; Oviedo-Boyso et al., 2011; Edwards & Massey, 2011).  
 
1.6.3.2.3 Phagocytic transport 
Phagocytic transport or the “Trojan Horse” approach is used by pathogens to prevent 
activating a full-blown immune response. They do this by hiding within the confines of a 
phagocytic cell before hijacking it completely for opportunistic gain [Figure 1.10C]. SA 
is able to survive within macrophages after engulfment, by surviving within a vacuole. 
The two cells appear to work in synergy, with the macrophage maintaining its ability to 
continue phagocytic activities. However, after a number of days, the intracellular SA 
within the vacuole free themselves and lyse the macrophage to allow bacterial release 
into circulation (Edwards & Massey, 2011). 
 
1.6.3.2.4 Thrombus formation 
A thrombus (blood clot) can develop on the endothelium as a result of SA infection. In 
addition to SA FnBP-A binding to the endothelium via α5β1, it alerts the surrounding 
cells to an immediate infection (Gómez et al., 2006). To counteract this, the endothelial 
cells engage in pro-inflammatory and pro-coagulation responses through the upregulation 
of intercellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 
(VCAM-1) and IL-8, all of which are neutrophil chemoattractants for transendothelial 
migration, whilst the pro-coagulation response increases tissue factor (TF) expression on 
the endothelium surface (Tajima et al., 2007). The presence of TF is the first step required 
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for thrombus formation. The development of the thrombus is further enhanced by 
activated platelets with the help of SA surface proteins ClfA, SpA and FnBPs, which are 
known to adhere to and activate platelets [Figure 1.10D] (Bingham et al., 2008). As the 
thrombus grows in size, some sections may break away resulting in emboli. Emboli have 
the ability to spread the infection to distant tissue sites in the host and develop further 
abscesses and thrombi (Edwards & Massey, 2011). The endothelial surface harbouring 
the thrombus becomes weakened as a result of SA toxin and protease production, which 
in turn allows SA a direct route into the cells where it can further establish a more 
threatening infection. 
 
1.6.3.2.5 Macroaperture formation 
Another known mechanism for SA to gain entry into endothelial cells is through the 
development of a macroaperture tunnel (Lemichez et al., 2010). This is essentially a 
tunnel that runs from the apical to the basolateral cell surface [Figure 1.10E]. The pores 
are said to develop as a result of the SA endotoxin epidermal-cell differentiation inhibitors 
(EDINs), which target the Rho GTPases that regulate the host actin-cytoskeleton. Rho-
GDP proteins are initially found in the cytoplasm bound to Rho-GDP dissociation 
inhibitors (Rho-GDIs). When Rho-GDI is released from Rho-GDP, it is free to travel to 
the plasma membrane where it can become activated to Rho-GTP through guanine-
nucleotide exchange factors (GEF) initiating a cascade of actin-cytoskeleton realignment. 
Rho-GTP inactivation is initiated by GTPase-activating proteins (GAP) through the 
hydrolysis of GTP back to GDP (Huveneers & Danen, 2009; Sit & Manser, 2011). The 
EDIN endotoxin inactivates Rho GTPase by catalysing its ADP-ribosylation (Lemichez 
et al., 2010). The macroaperture tunnel is only present for a few minutes but long enough 
for SA to traverse across to the other side of the cell. Because of the quick opening and 
closing of the tunnels, the adherens junctions of endothelial cells remain unaffected 
(Lemichez et al., 2010). There are three SA EDINs called EDIN-A, EDIN-B and EDIN–
C. Using a mouse model infected with an SA strain containing EDIN-B encouraged SA 
extravasation and metastatic infection (Boyer et al., 2006; Huveneers & Danen, 2009; 
Edwards & Massey, 2011; Sit & Manser, 2011).   
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1.6.3.3 Immune evasion 
Once SA has gained entry into the host, the pathogen has to contend with the host’s 
internal immune response. In order to appreciate the effectiveness of the host immune 
response and the ability of SA to withstand and evade it, a fuller understanding is 
warranted.  
 
1.6.3.3.1 Host immune response 
Not all pathogens found in the bloodstream are able to establish immediate host cell 
binding. Many are prevented and cleared from the blood stream with the help of the host 
immune response, namely the innate phagocytic cells, macrophages, neutrophils and 
dendritic cells, which are the first responders to any infectious agent (Fournier & Philpott, 
2005). The adaptive immune response is activated when presented with antigenic proteins 
on the surface of B and T lymphocytes. However, the turnaround time for the adaptive 
immune response to become fully activated can take several days; therefore, the innate 
immune cells of the host need to be able to withstand the pathogen until the adaptive 
response is primed. For the innate response to achieve this, it has to regulate the 
production of pro-inflammatory cytokines and chemokines and initiate macrophage 
activation (Fournier & Philpott, 2005). Upon entry into the bloodstream, pattern 
recognition receptors (PRRs), which include toll-like receptors (TLRs) recognise 
pathogen-associated molecular patterns (PAMPs) associated with SA, triggering the 
immediate activation of the pro-inflammatory immune response.  
 
A1. TLRs 
TLRs are type-1 transmembrane glycoproteins containing a Toll IL-1 receptor (TIR) 
domain. They are found in a variety of cell types such as dendritic cells, macrophages, 
natural killer cells, T and B-lymphocytes, neuronal cells, astrocytes, microglia, and 
epithelial and endothelial cells. TLRs can also be found in the plasma membrane, within 
endosomes, lysosomes and endolysosomes targeting extracellular and intracellular 
pathogens (Stenzel et al., 2008; Pietrocola et al., 2011). Most mammals are known to 
have 10-15 types of TLRs (Pietrocola et al., 2011). Currently, there are 10 human TLRs 
identified with each isoform recognising different pathogenic PAMPs e.g. TLR2 
recognises peptidoglycan and lipoteichoic acid of SA, while TLR4 identifies 
lipopolysaccharide (LPS) and hyaluronic acid (Fukata et al., 2009; Pietrocola et al., 
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2011). TLR-1, -2, -4, -5, and -6 are expressed on cell surfaces, while TLR -3, -7, -8, and 
-9 are found in the intracellular compartments of the endosomes and endoplasmic 
reticulum (Pietrocola et al., 2011; Foley et al., 2015). For SA recognition, the key TLRs 
are TLR2 and TLR4 found on the cell surface, while TLR7 and/or TLR9 identify SA 
nucleic acids within the endosomal compartments. Individuals with TLR2 
polymorphisms e.g. R753G showed increased signs of susceptibility to Mycobacterium 
tuberculosis and gram-positive bacterial infections, whilst individuals with TLR4 
polymorphisms D229G or T399I are hyporesponsive to LPS of gram-negative bacteria 
(Askarian et al., 2014). TLR signalling in humans involves five adapter proteins; (i) 
myeloid differentiation factor 88 (MyD88); (ii) MyD88 adaptor-like (MAL) protein; (iii) 
TIR-domain-containing adaptor protein inducing IFN-β (TRIF); (iv) TRIF-related 
adaptor molecule (TRAM) and; (v) sterile-α and armadillo-motif-containing protein 
(SARM). MAL, TRIF and TRAM are also referred to as TIR domain-containing adaptor 
protein (TIRAP) (Foley et al., 2015). The listed adapter proteins activate either nuclear 
factor-κB (NF-κB) or interferon (IFN)-regulatory factor (IRF) family members (Foley et 
al., 2015). TLR2 is a key mitigating factor in SA recognition, activating both NF-κB and 
mitogen-activated protein kinase (MAPK) signalling pathways; this will be discussed in 
more detail in the next section.  
 
A1.1. TLR2 
TLR2 is a versatile PRR with the ability to recognise many different pathogenic PAMPs, 
including lipopeptides from gram-positive bacteria and lipoarabinomannan from 
mycobacteria (Pietrocola et al., 2011). The reasoning behind its ability to recognise many 
pathogenic strains is down to its heterodimerization with TLR1 or TLR6 (Yimin et al., 
2013). TLR2-TLR6 heterodimerization is able to assist class II scavenger receptor 
(CD36) found on the cell surface with recognising PAMPs, whilst also augmenting 
phagocytosis and cytokine release as a result of SA invasion (Pietrocola et al., 2011). 
TLR2 is expressed by macrophages, neutrophils, dendritic cells, astrocytes and 
endothelial cells (Fournier & Philpott, 2005). It has been shown that TLR2 is upregulated 
in microglia and astrocytes in response to SA. As a result, there are many possible ligands 
for TLR2 to bind on the bacterial protein-coated surface. Some ligands include: (i) 
lipoproteins; (ii) peptidoglycan (PGN); (iii) LTA and; (iv) Panton-Valentine leukocidin 
(PVL). TLR2-deficient mice infected with SA resulted in an excessive pro-inflammatory 
cytokine release of TNF-α and IL-6, which led to increased mortality rates when 
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compared to WT treated mice. It was suggested that the excessive cytokine imbalance 
was due to the reduced release of IL-10 from the deficient mice (Stenzel et al., 2008; 
Yimin et al., 2013). 
Most commonly, when a TLR is engaged with its ligand it can activate two signalling 
pathways: (i) the MyD88-dependent pathway, which activates NF-κB to augment 
chemokine and cytokine secretion, induce inflammation and promote leukocyte 
recruitment to site of infection (TLR2 uses this pathway) and/or; (ii) the MyD88-
independent pathway, also referred to as the TRIF-dependent pathway, whereby type 1 
interferons are upregulated (Fukata et al., 2009; Pietrocola et al., 2011).  
 
A1.2. TLR2 signalling pathway 
The MyD88-dependent pathway is used by TLR2 [Figure 1.11]. The initiation of this 
pathway involves a ligand binding to the TLR2 receptor on the cell. This engagement 
establishes the recruitment of several proteins, the Toll-interleukin 1 receptor (TIR) 
domain of the adapter protein (TIRAP), which acts as an anchor between TLR and 
MyD88. With MyD88 in place, it enables the recruitment of an IL-1 receptor-associated 
kinase (IRAK), namely IRAK -4, -1, and -2 in that sequence. The IRAK component 
engages with TNF receptor-associated factor 6 (TRAF6), forming a complex with E2 
ubiquitin-conjugating enzyme. This complex causes TRAF6 to become polyubiquinated, 
which in turn activates transforming growth factor-β-activated kinase 1 (TAK1) and 
TGF-β-activated kinase 2 binding protein (TAB2). Both TAK1 and TAB2 activate IκB 
Kinase (IKK) complex comprising of IKK-α, IKK-β and IKK-γ (also called NF-κB 
essential modulator, NEMO). This causes NF-κB inhibitory protein (IκB) to be 
phosphorylated resulting in ubiquitin-proteasome degradation. As IκB is no longer 
adjoined to NF-κB (p50/p65 subunits), it is free to traverse to the nucleus to activate 
inflammatory mediators such as cytokine and chemokine proteins e.g. TNF-α (Fournier 
& Philpott, 2005; Oliveira-Nascimento et al., 2012). TAK1 also activates mitogen-
activated protein (MAP) kinase (MAPK) pathway via MAP kinase kinase-6 (MKK)-6, 
which in turn activates p38 and C-Jun NH2-terminal kinases (JNK), leading to activator 
factor-1 (AP-1) mediated transcription of inflammatory genes (Zarubin & Han, 2005; 
Oliveira-Nascimento et al., 2012). 
As mentioned earlier, TLRs contain a TIR-domain, which is required for the recruitment 
of TIR-containing adaptor proteins such as MyD88. However, database searches have 
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shown that SA contains a gene expressing a homologue of the human TIR-domain 
MSSA476, referred to as staphylococcal TIR-domain protein (TirS). TirS has the ability 
to interfere with TLR2 signalling via MyD88 and TIRAP as well as the MAPK signalling 
pathways, resulting in decreased cytokine expression of MCP-1 and G-CSF, as seen using 
HEK293 and HaCaT cell lines (Askarian et al., 2014). 
 
 
Figure 1.11: TLR2 signalling pathway. The MyD88-dependent pathway is used by 
TLR2 to activate pro-inflammatory genes through NF-κB activation. (TLR, Toll-like 
receptor; MyD88, myeloid differentiation factor 88; TIRAP, Toll/IL-1 receptor (TIR) domain-
containing adaptor protein; IRAK, IL-1 receptor-associated kinase; TRAF6, TNF receptor-
associated factor 6; TAB2, transforming growth factor-β-activated kinase 2 binding protein; 
TAK1, transforming growth factor-β-activated kinase; NEMO, NF-κB essential modulator; IKK, 
IκB Kinase; IκB, inhibitor of NF-κB; MKK6, mitogen-activated protein (MAP) kinase kinase-6; 
P38, p38 mitogen-activated protein kinases; JNK, C-Jun NH2-terminal kinases; AP-1, activator 
factor-1) (Oliveira-Nascimento et al., 2012).  
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A2. TNFR1 
Tumour necrosis factor alpha-receptor 1 (TNFR1) is the receptor for the pro-
inflammatory cytokine TNF-α. Another known receptor is TNFR2. The two receptors 
differ in that TNFR1 is widely expressed by nearly all cells of the human body. As of yet, 
no cell type has been found that does not express TNFR1. However, TNFR2 is selectively 
expressed on endothelial cells and immune cells (Moelants et al., 2013). TNFR1 
signalling by TNF-α can result in two possible outcomes: (i) the activation of NF-κB and; 
(ii) the initiation of cellular apoptosis through the recruitment of death domains (Naudé 
et al., 2011). The TNFR1 signalling cascade is activated by both soluble (17 kDa) and 
transmembrane (26 kDa) TNF-α (Moelants et al., 2013). Prior to activation, the 
unstimulated TNFR1 receptor is occupied by a cytoplasmic protein called silencer of 
death domain (SODD). SODD binds to the death domains (DD) on TNFR1 via its own 
(DD) within the cytosol, thereby preventing TNFR1 signalling (Bradley, 2008; Moelants 
et al., 2013). It has been proven that staphylococcal protein A (SpA) of SA is able to bind 
to TNFR1 of primary airway epithelial cells (Gómez et al., 2006), osteoblasts (Widaa et 
al., 2012; Claro et al., 2013) and epithelial cells (Foster et al., 2014). As mentioned in 
section 1.6.3.1.2, SpA is one of the many CWA virulence factors of SA coating the 
exterior surface of the bacterium. When purified SpA was added to monocytes and 
fibroblasts it resulted in the release of several pro-inflammatory cytokines and 
chemokines, IL-1β, IL-4, IL-6, IL-8 and IFN-γ, whilst TNF-α was poorly expressed 
(Fournier & Philpott, 2005). It has also been shown that mice infected with a SA strain 
deficient in SpA had higher survival rates than the WT strain (Fournier & Philpott, 2005). 
The importance of TNFR1 receptor was shown when mice that were lacking TNFR1 did 
not contract SA pneumonia, while a SA mutant with defective SpA did not induce the 
infection in the WT mouse. Therefore, this would suggest that both SpA and TNFR1 are 
required to induce a robust SA infection (Gómez et al., 2006). Interestingly, when SpA 
binds to the TNFR1 receptor it mimics the response of TNF-α, which would otherwise 
not be expected. This interaction results in the induction of IL-8 and the recruitment of 
polymorphonuclear cells (PMN) with the help of NF-κB activation (Fournier & Philpott, 
2005). SpA also causes TNFR1 ectodomain shedding through activation of the TNF-α 
converting enzyme (TACE). The cleaved ectodomain is capable of binding to free TNF-
α in circulation. Therefore, it can be suggested that SA plays a direct role in inhibiting the 
pro-inflammatory response via the TNFR1 signalling pathway (Gómez et al., 2006). 
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A2.1. TNFR1 signalling pathway 
When a ligand binds to the TNFR1, it recruits an adapter protein called TNF-receptor-
associated protein with a death domain (TRADD) and RIP [Figure 1.12]. Through this 
initial binding, TRADD also recruits a protein called TRAF2 along with cellular inhibitor 
of apoptosis proteins 1 and 2 (cIAP1/2). Both cIAP1/2 label TRAF2-RIP with 
polyubiquitin chains, subsequently forming a linear ubiquitin chain assembly complex 
(LUBAC). TAK–TAB complex (mentioned previously for TLR2 signalling) engages 
with a receptor-interacting protein (RIP), which activates TAK, which targets IKK-
γ/NEMO of the IKK complex marking it for degradation, enabling IκB to be 
phosphorylated and subsequently allowing NFκB (p50/p65) to travel to the nucleus to 
activate pro-inflammatory genes (Wajant & Scheurich, 2011; Ingaramo, 2013). The 
TNFR1 signalling pathway is not only associated with the activation of the inflammatory 
response but is also associated with the apoptotic signalling cascade. The RIP protein can 
also associate with FAS-associated death domain protein (FADD), which recruits the 
activation of caspase 8, activating a series of downstream caspases, that culminate in 
apoptosis (Ofengeim & Yuan, 2013).  
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Figure 1.12: TNFR1 signalling pathway. TNFR1 follows the classical pathway of 
activating NF-κB, which requires a death domain called TRADD and RIP, both needed 
for the recruitment of TRAF2. (TNF-α, tumour necrosis factor alpha; TNFR1, tumour necrosis 
factor alpha-receptor 1; TRADD, TNF-receptor-associated protein with a death domain; RIP1, 
receptor-interacting protein; TRAF2, TNF receptor-associated factor 2 IκB, inhibitor of NF-κB) 
(Stokes et al., 2015).
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A lot of emphasis and importance has been shown in the activation of NF-κB, which is a 
key modulating factor of cytokine and chemokine release. Figure 1.13 illustrates the 
commonality of the TLR2 and TNFR1 signalling pathways for NF-κB activation.  
 
 
Figure 1.13: Overview of TLR2 and TNFR1 signalling pathways. Each pathway 
follows the classical pathway of NF-κB activation through the degradation of IκB 
enabling NF-κB to transcribe the appropriate inflammatory genes in the nucleus (Fournier 
& Philpott, 2005). 
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1.6.3.3.2 Pro-inflammatory response 
B1. NF-κB 
NF-κB is a key transcriptional activator of inflammatory molecules as seen previously in 
TLR2 and TNFR1 signalling pathways. This multifaceted signalling protein also plays a 
role in cell immunity, proliferation, differentiation and cell survival. However, much 
interest is focused on the role of NF-κB in the augmentation of inflammatory responses 
upon pathogen recognition e.g. Porphyromonas gingivalis, Streptococcus pyrogenes and 
Mycobacterium bovis bacillus Calmette-Guerin (BCG) including SA (Ning et al., 2010). 
SA surface protein SpA binds to the TNFR1 receptor on host cells, inducing NF-κB 
activation via the MyD88-dependent pathway. It would appear that NF-κB activation is 
reliant on SA attachment to the host cell, as seen using osteoblasts in-vitro (Ning et al., 
2010). This same study observed SA activation of NF-κB post-infection, which 
seemingly upregulates IL-6 secretion into the media (Ning et al., 2010).  
NF-κB is a dimeric protein part of the Rel family consisting of five members: p65 (RelA), 
RelB, c-Rel, p105/p50 and p100/p52, which have the ability of forming homo- and 
hetero-dimers (Kempe et al., 2005; Oeckinghaus & Ghosh, 2009). Inactive NF-κB is 
found in the cytoplasm bound to IκB, which prevents NF-κB from reaching the nucleus. 
Once fully activated, NF-κB has the ability to enter the nucleus and engage in gene 
expression (Lawrence, 2009). Rel protein members can form up to 15 different dimers, 
although not all have been elucidated to date. There are two known pathways that activate 
NF-κB: (i) the canonical or classical pathway used by TLRs and TNFR1 (described 
previously), which relies on the degradation of IκB for p50/Rel A activation and; (ii) the 
non-canonical or alternative pathway used by a subgroup of TNF ligands, namely CD40 
ligands and lymphotoxin-β, which relies on the processing of p100 subunit to p52 [Figure 
1.14] (Sun, 2011).   
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Canonical Pathway           Non-Canonical Pathway 
 
Figure 1.14: NF-κB signalling pathways. Activation of NF-κB through the classical and 
alternative pathways (Gerondakis et al., 2014). 
 
Once the prescribed genes have been transcribed, the activated NF-κB can be inhibited in 
a number of ways: (i) the reproduction of IκB, which is in fact produced by NF-κB. A 
sub-unit of IκB called IκBα can remove the bound NF-κB from the DNA and return it in 
its inactivated state back to the cytoplasm; (ii) post-translational modification events of 
NF-κB sub-units such as acetylation of p65 and; (iii) oxidation/alkylation of the cysteine 
amino acid found in the DNA binding region of NF-κB (Oeckinghaus & Ghosh, 2009). 
The initiation of the pro-inflammatory response of endothelial cells upon pathogen 
infection can stimulate the production and release of cytokines and chemokines, 
51 
 
endothelial microparticles and reactive oxygen species (ROS). These agents are discussed 
in the next section. 
 
B2. Cytokines and chemokines 
Upon pathogen recognition, pro-inflammatory and immunomodulating cytokines are 
produced by lymphocytes, neutrophils, macrophages, platelets, epithelial and endothelial 
cells (Fournier & Philpott, 2005). Cytokines play a significant role in limiting the extent 
of infection. A mouse model deficient in producing cytokines had detrimental effects for 
their survival. However, the overexpression of cytokines can also have a damaging 
outcome such as the development of multiple organ failure and death (Fournier & 
Philpott, 2005). Cytokines can be divided into six different categories: (i) interleukins e.g. 
IL-6 and IL-10; (ii) cytotoxic cytokines e.g. TNF-α and TNF-β; (iii) colony-stimulating 
factors e.g. granulate colony-stimulating factor (GCS-F); (iv) interferons e.g. IFN-γ; (v) 
growth factors e.g. platelet-derived growth factor and; (vi) chemokines e.g. IL-8 and 
MCP-1 (Fournier & Philpott, 2005; McNicholas et al., 2014). It is interesting to note that 
systemic cytokine responses are detectable 50-75 hrs after the initial infection with gram-
positive bacteria, whilst detection is evident 1-5 hrs after gram-negative infection 
(Fournier & Philpott, 2005). 
A variety of cytokine and chemokine proteins are produced upon the recognition of SA 
peptidoglycan and lipoteichoic acid (LTA). The key cytokines include TNF-α, IL-1β and 
IL-6, which are regarded as pro-inflammatory cytokines, while the chemokine IL-8 is a 
potent inducer of neutrophil recruitment to the site of infection. Monocyte 
chemoattractant protein-1 (MCP-1), as its names suggests, is a recruiting agent of 
monocytes (Fournier & Philpott, 2005; McNicholas et al., 2014). In-vitro studies using 
HUVEC infected with live and UV-killed SA showed significant increases in IL-6 and 
IL-1β when either live or UV-fixed strains of SA were employed. However, the induction 
of both cytokines was slower with UV-killed bacteria suggesting bacterial replication 
and/or the production of bacterial virulence factors may play a role in initiating the 
cytokine response (Yao et al., 1995). It is also worth noting that TNF-α has the ability to 
activate the endothelium by stimulating the adhesion molecules. This in turn allows SA 
to have a greater binding affinity to the newly activated endothelial layer (Oviedo-Boyso 
et al., 2008).   
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B3. Reactive oxygen species 
Reactive oxygen species (ROS) comprise reactive molecules and free radicals that are 
generated from molecular oxygen. The majority of ROS molecules are generated as by-
products of the mitochondrial electron transport chain during aerobic respiration resulting 
in the generation of adenosine triphosphate (ATP). While some are also generated by 
oxidoreductase enzymes (Held, 2014). ROS are formed when an atomic oxygen 
undergoes reduction by the addition of electrons, resulting in the formation of molecular 
species that include: superoxide, hydrogen peroxide, nitric oxide (NO), hydroxyl radicals 
and hydroxyl ions (Kalyanaraman 2013; Bonini & Malik 2014; Held, 2014). It is 
important that there is an appropriate balance between ROS production and removal as 
oxidative stress can build up if the levels are not balanced. In order to limit the extent of 
ROS damage, cells are equipped with several enzymes to deal with this problem such as 
catalases, peroxiredoxins and superoxide dismutases (SODs). SODs can convert two 
superoxides to hydrogen peroxide and oxygen, where the enzyme catalase can further 
convert hydrogen peroxide to water and oxygen, making the once potentially harmful 
superoxides into safe waste products (Fang, 2011; Kalyanaraman, 2013; Held, 2014).  
ROS production is a very important feature in host immunity, especially in phagocytic 
cells for bactericidal activity. The NADPH oxidase (NOX) enzyme is the main enzyme 
responsible for ROS activation in neutrophils, monocytes, eosinophils and endothelial 
cells. Upon bacterial engulfment by phagocytic cells, NOX is recruited to the wall of the 
vacuole harbouring the engulfed bacteria, where it is able to produce superoxide and 
hydrogen peroxide – referred to as a “respiratory burst” due to the large consumption of 
oxygen by these cells (van Sorge et al., 2013). The superoxide alone is weakly 
microbicidal but the oxidants it generates are highly microbicidal and include, 
hypochlorous acid, hydroxyl radical, chloramines and singlet oxygen (Rigby & DeLeo., 
2012; Kalyanaraman, 2013). The hydrogen peroxide produced can form a hydroxyl 
radical when in contact with free iron, forming a strong antimicrobial agent 
(Kalyanaraman, 2013). When inflammatory mediators activate leukocytes, NO and 
inducible nitric oxide synthase (iNOS) are generated, which are able to inhibit several 
bacterial species. These components also engage with other ROS molecules to generate 
further antibacterial mediators to combat the spread of the bacteria (van Sorge et al., 
2013). 
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B4. Microparticles 
Much work and research has been focused on the production of microvesicles by 
endothelial cells as potential biomarkers to detect cell injury and CVD risk (Koga et al., 
2005). Microvesicles can be sub-categorised as being microparticles (MPs), exosomes or 
apoptotic bodies. MPs have been shown to play a key role in intercellular exchange 
between cells. The MP population is heterogeneous because all eukaryotic cells are able 
to produce them, including platelets, endothelial cells and erythrocytes, including cells of 
the CNS, neurons, astrocytes and microglia (Schindler et al., 2014; Berezin et al., 2015). 
Therefore, MPs will derive from different cell plasma membrane compositions as a result 
of their parental cell type. MPs are normally 100-1000 nm in size enabling them to 
perform as vectors carrying a variety of molecules such as cytokines, enzymes, 
transcription factors, signalling proteins, mRNA and microRNA to nearby or distant cell 
sites (Leroyer et al., 2010; Mause & Weber, 2010). Exosomes are smaller in diameter in 
comparison to MPs, ranging from 40-100 nm, arising from the endoplasmic reticulum 
(Mause & Weber, 2010). Apoptotic bodies are the largest microvesicles identified, up to 
4000 nm in size. They are released from apoptotic cells, comprising DNA-rich remnants 
of the dying cell as well as microRNA and chromatin (Mause & Weber, 2010; Berezin et 
al., 2015). At present, there is much interest in MPs as they have been shown to play a 
role in cell activation, remodelling, and function. Some studies have shown endothelial 
MPs (EMPs) to assist in cell protection and repair, whilst also demonstrating anti-
coagulant and anti-inflammatory properties (Martin et al., 2014). There are two possible 
mechanisms identified for MP intercellular signalling: (i) MPs may interact with other 
cell receptors as a result of their surface membrane containing matching protein 
molecules and; (ii) MPs may alter cell signalling by delivering their contents to the target 
cells. The introduction of this new material to the target cells may induce cellular 
activation changes, cell modification and altered cell function (Mause & Weber, 2010). 
Platelets constitute the most abundant source of MPs, accounting for 70-90% of all MPs 
found in circulation (Mause & Weber, 2010). Severe cases of SA infections, such as 
septicaemia and peritonitis, can lead to blood clotting (Nettey et al., 2013). This is the 
result of tissue factor (TF), a transmembrane pro-coagulant glycoprotein and a known 
initiator of coagulation. TF is found on a variety of cell types, namely smooth muscle 
cells, fibroblasts, monocytes, platelets and endothelial cells, whilst also being secreted 
into circulation on MPs (Lopes-Bezerra & Filler, 2003). However, it is important to note 
that TF is only expressed on endothelial cells when they are stimulated to do so (Mattsson, 
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2002; Lopes-Bezerra & Filler, 2003). Studies have shown there is a constant release of 
MPs into circulation in healthy individuals; however, upon pathogenic invasion or injury, 
MP release is elevated (DeWalt et al., 2013). A study using a pulmonary cell line found 
increased secretion of TF-positive EMPs upon SA infection and that the severity of the 
infection was dependent on the level of TF-positive EMPs circulating in blood (DeWalt 
et al., 2013). Endothelial-derived microparticles (EMPs) are generating a lot of interest 
as a possible method of cell-to-cell signalling, possessing beneficial qualities by 
contributing to cell survival, repair, and also counteracting pro-coagulation processes. 
EMPs are typically regarded as key biological markers of endothelial injury and disease, 
released from apoptotic or activated cells upon exposure to inflammatory conditions. 
With respect to the latter, there is greater interest in EMPs as modulators of cardiovascular 
disease by contributing to plaque formation on aortic endothelial cells as a result of 
activating cells and promoting leukocyte recruitment (Berezin et al., 2015). The activated 
endothelium enables pathogens to bind and develop a thrombus as discussed previously. 
The composition of EMPs is dictated by the state of the cell they are produced from, as 
activated endothelial cells produce EMPs that are phenotypically different to EMPs 
produced by apoptotic endothelial cells (Schindler et al., 2014). If released from apoptotic 
endothelial cells, the surface of the EMP is coated with an excessive amount of 
phospholipid indicative of apoptotic cells. However, if produced by healthy/activated 
endothelial cells, they possess a low amount of phospholipid but contain a large amount 
of signalling proteins and peptides instead [Figure 1.15] (Berezin et al., 2015). Both MS 
and cerebral malaria patients have increased EMP in their CSF and plasma, implicating 
their involvement in disease pathogenesis. Brain microvascular endothelial cell (BMvEC) 
dysfunction associated with MS patients is attributed to EMP expressing BBB damaging 
markers, such as CD51 and platelet-endothelial cell adhesion molecule-1 (PECAM-1) 
(Schindler et al., 2014). Cerebral malaria caused by the Plasmodium falciparum parasite 
activates EMP through pro-inflammatory stimulation via TNF-α (Schindler et al., 2014). 
There is also the possibility of using MPs as therapeutic molecules, as they are able to 
store a variety of molecules such as cytokines, MMPs, growth factors, mRNA, signalling 
proteins and proteolytic enzymes. However, the contents of MPs depend on the status of 
the parental cell. Early studies have shown that platelet-derived MPs containing growth 
factors were able to stimulate neurogenesis when added to neural stem cells post-brain 
injury (Schindler et al., 2014). EMP production by HBMvEC in response to SA infection 
will be discussed later.  
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Figure 1.15: Endothelial microparticles. Graphic representation of various endothelial 
surface markers found on EMP (Dignat-George & Boulanger, 2011). 
 
1.6.3.3.3 Immune evasion  
SA encodes a large variety of specialised virulence factors that include the secretion of 
toxic compounds e.g. α-hemolysin (Hla), while also expressing key surface proteins that 
augment adhesion to host cells e.g. ClfA, FnBPs and Eap, all of which facilitate pathogen 
survival within of the host (including its colonisation) (Krishna & Miller, 2012b). The 
majority of SA virulence factors are under the control of three global regulators, agr, sarA 
and sae (Nizet, 2007; Kubica et al., 2008). The accessory gene regulator (agr) is 
monitored by quorum sensing and has been shown to upregulate many exoproteins such 
as the extracellular protein Hla, a pore-forming cytotoxin (PFT) expressed by SA, whilst 
decreasing CWA protein expression (Fournier & Philpott, 2005). Its role is to create 
heptameric pores between the lipid bilayer of the host cells resulting in pneumonia, 
dermal infections and Toxic Shock Syndrome (TSS). The staphylococcal accessory 
regulator (sarA) is an important transcriptional regulator activating the cytolytic α-toxin 
and FnBPs for bacterial adhesion to host cells (Haslinger-Löffler et al., 2005; Nizet, 2007; 
Liu, 2009). The final global regulator identified is SA accessory element (sae), which 
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plays a role in the production of virulence factors at the transcriptional level (Harris et al., 
2002). 
In order for SA to colonise and establish infection in humans, it has to overcome the 
innate and adaptive immune responses. The innate immune response, which includes 
phagocytic cells (neutrophils and dendritic cells) and complement proteins, are first 
activated upon bacterial infection, whilst the adaptive immune response is a more 
specialised response comprising B and T lymphocytes, producing antibodies and killing 
pathogens effectively (Janeway et al., 2001a).  
However, SA is equipped with many well-defined proteins and enzymes that are able to 
over-come and prevent the innate and adaptive immune response. SA immunoinhibitory 
molecules are either secreted (enzymes and toxins) into circulation, cell wall-associated, 
or are membrane-bound proteins present on the bacterial surface promoting adhesion to 
cells [Figure 1.16] (Foster, 2005).  
 
Figure 1.16: Staphylococcus aureus virulence mechanisms. Image highlighting the key 
virulence strategies SA has in place to overcome the immune response and colonise host 
tissues (Nizet. 2007).  
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1.7 Staphylococcus aureus and the epithelium 
SA is a diverse pathogen capable of colonising various organs in humans such as the lung 
epithelium causing debilitating diseases like necrotizing pneumonia and repeated 
colonisation to cystic fibrosis (CF) sufferers (Goerke & Wolz, 2010; Soong et al., 2011). 
The abundantly produced SpA has been shown to play a substantial role in initiating 
access to the host epithelial lung matrix, where it has been shown to activate numerous 
signalling pathways, including the TNF-α signalling pathway via SpA binding to TNFR1 
and EGFR (Soong et al., 2011). Mice lacking TNFR1 showed no symptoms of 
bacteraemia after intranasal inoculation in comparison to the wild-type (WT) mice, 
suggesting activation of TNFR1 may be a key invasive step required for SA penetration 
(Soong et al., 2011). Activation of the TNF-α pathway also enlists the activation of Rho 
GTPases, which cause actin filaments to contract resulting in gap formations in the 
epithelium monolayer, thereby compromising epithelial barrier function (Soong et al., 
2011). The lung epithelium also contains junctional protein complexes similar to those of 
the BBB e.g. occludin and E-cadherin. However, these junctional proteins are also 
targeted by SA through the activation of TLR-2, which in turn activates ERK MAPKs 
(Soong et al., 2011). Activation of the ERK MAPK pathway induces proteases called m-
calpains that cleave occludin and E-cadherin in the paracellular space allowing both SA 
and polymorphonuclear (PMN) leukocytes to traverse the airway epithelium (Soong et 
al., 2011). The PMN try to alleviate the bacterial symptoms in the lung epithelium; 
however, SA possess a cytotoxin called Panton-Valentine Leukocidin (PVL), a pore-
forming toxin that targets PMN to induce cell death and subsequently cause further tissue 
necrosis as a result of PMN degranulation (Diep et al., 2010).  
SA also has the ability to colonise the nasal epithelium of humans with some individuals 
becoming persistent carriers of a single SA strain for a long period of time, whilst 
intermittent carriers possess different SA strains for short periods of time (Corrigan et al., 
2009). The key challenge for SA to colonise the moist squamous epithelium of the 
anterior nares is that it has to compete with other nasal colonisers in order to become 
established. The key surface proteins investigated for nasal SA are clumping factor B 
(ClfB) and iron-regulated surface determinant protein A (IsdA), which have been shown 
to play a role in-vitro and in-vivo in a rat model (Corrigan et al., 2009; Mulcahy et al., 
2012). ClfB binds to a component of the epithelial cell envelope called loricin, which has 
been shown to be a key interaction for SA colonisation as seen in a mutant loricin mouse 
model. In order to further prove this theory, a Lactococcus lactis strain containing a 
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plasmid expressing ClfB was also shown to promote SA in the nasal cavity of mice 
(Mulcahy et al., 2012). 
In addition to an ability to bind to the epithelium both in-vivo and in-vitro, SA also has 
the ability to bind to and invade the endothelium (including the BBB), which will be 
discussed next. 
 
1.8 Staphylococcus aureus and the endothelium 
The BBB is a prime target site for bacterial infections as a means to gain access to the 
CNS resulting in meningitis and the formation of brain abscesses. As discussed, SA has 
numerous protein markers and virulence factors that enable the bacterium to penetrate 
this barrier. To the best of one’s knowledge, a paper by Sheen et al. (2010) is the most 
recent paper to publish the interaction of SA with the BBB endothelium (Sheen et al., 
2010). 
Using “immortalised” human brain microvascular endothelial cells (HBMvEC), Sheen 
and his group found intracellular traces of SA inside endocytic vacuoles after 1 hour 
infection, while also finding traces of SA in close range of the cell surface, suggesting 
that within this time SA was able to adhere to and invade the microvascular endothelium 
[Figure 1.17A]. They later found that SA was able to modify the endothelial cytoskeleton 
in order to penetrate the BBB, in a similar manner to SA invading the lung epithelium, 
with an invasion rate of 34%, comparable to another BBB invader - Group B 
Streptococcus (GBS) at 30% (Sheen et al., 2010). Using an actin inhibitor called 
cytochalasin D further demonstrated decreased levels of SA invasion, suggesting 
cytoskeleton realignment is a possible invasive condition of SA as seen in-vitro using 
HBMvEC.  
As discussed previously, SA contains LTA, a cell wall attachment protein that has been 
implicated in SA anchoring to the BBB. Consequently, Sheen and his co-workers 
investigated this theory on HBMvEC by using WT and a mutant strain of SA (ΔypfP) that 
contains defective LTA. Results showed similar levels of bacterial adherence, but 
decreased levels of SA invasion to WT. In-vivo work with mice using the same WT and 
mutant strain showed fewer bacteria in the mutant treated mice in contrast to the WT. 
Upon further investigation, SA was shown to persist in the brain despite being cleared 
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from the circulatory system, demonstrating its potential to withstand the host immune 
response (Sheen et al., 2010). 
 
Figure 1.17: Staphylococcus aureus infection of HBMvEC. (A) HBMvEC infected 
with SA after 1 hr infection with multiplicity of infection (MOI) 10. Harvested brain 
tissue from mice infected with (B) WT SA, exhibiting meningeal thicking; (C) mutant 
ypfp SA resulting in defective LTA exhibits normal brain features. Harvested brain tissue 
from mice infected for 96 hrs with SA showcased (D) meningeal thickening and 
hemorrhage; (E) formation of abscess and (F) close up view of abscess at 40x with black 
arrow pointing to SA present within it (Sheen et al., 2010). 
 
Other SA surface proteins have been studied which include the fibronectin binding 
proteins A and B (FnBPA and FnBPB). Like the other SA virulence factors such as WTA 
and SpA, FnBPs belong to the fibronectin-binding MSCRAMM family. Fibronectin is a 
glycoprotein found on the surface of endothelial and epithelial cells interlinking the ECM 
to the cytoskeleton (Henderson et al., 2011). Fibronectin is also found on other host cell 
types such as osteoblasts and keratinocytes (Herman-Bausier et al., 2015). FnBPs are not 
capable of facilitating SA invasion of host cells but instead require an endothelial integrin 
called α5β1 as a bridging molecule. This interaction induces integrin clustering, ultimately 
resulting in actin cytoskeletal remodelling (Schröder et al., 2006). Most, if not all, strains 
of SA have FnBPs on their surface, although the Newman WT (NWT) strain has defective 
fnbpA and fnbpB genes, resulting in faulty FnBPs. Consequently, Newman FnBPs cannot 
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bind to fibronectin. However, it was noted that SA Newman was in fact able to adhere 
and invade endothelial cells as a result of the extracellular adherence protein (Eap), which 
is also able to bind to fibronectin and fibrinogen (Henderson et al., 2011). Eap is a 
member of the secretable expanded repertoire adhesive molecules (SERAM). It differs 
from FnBPs in that it is made up of a single MAP domain composed of an α-helix and a 
small β-sheet (Henderson et al., 2011). Eap, peptidoglycan and WTA triggers immune 
cells to produce cytokines and chemokines (e.g. TNF-α). TNF-α secretion has 
subsequently been shown to enhance SA adhesion to endothelial cells through SpA by 
interacting with an endothelial surface protein called gC1qR/p33. When this receptor was 
blocked in a mouse model using anti- gC1qR/p33 monoclonal antibodies, it showed 
decreased levels of SA adhesion to endothelial cells pre-treated with TNF-α in contrast 
to WT suggesting this receptor is a key attachment site for SA (Edwards et al., 2012). 
 
1.9 Other bacterial pathogens that impact the BBB 
As previously indicated, SA is one of the lesser-known bacteria that cause bacterial 
meningitis. However, its prevalence is steadily increasing due to its successful 
haematogenous spread as a secondary infection. SA binding mechanisms to epithelial 
cells have been well established, but little light has been shed on adherence to endothelial 
cells and especially to the BMvEC of the BBB. With the aid of other bacterial infection 
studies targeting endothelial cells, it may help in delineating a possible adherence 
mechanism that may be applicable to this project.  
 
1.9.1 Neisseria meningitides  
Neisseria meningitides (NM) is a gram-negative commensal bacterium, carried by 8-25% 
of the population and is responsible for causing respiratory tract infections, meningitis 
and sepsis (Stephens, 2009). The survival of this pathogen is solely reliant on colonising 
its only host – humans. Like SA, the bacterium inhabits the mucus membranes of the 
human body namely the nasopharynx, buccal mucus, rectum, urethra, urogenital track 
and dental plaque. Recent research has determined its long survival as a result of biofilm 
formation within these mucus sites (Stephens, 2009). NM is able adhere to and grow on 
endothelial cells by forming micro-colonies on the apical surface, which are able to 
withstand high shear stress rates (Mairey et al., 2006). NM has been shown to gain access 
61 
 
to HBMvEC in-vitro through vacuole internalisation, while it has also been suggested 
that it is capable of delocalising the junctional proteins of HBMvEC in-vitro resulting in 
paracellular transport across the membrane with no evidence of transcytosis (Coureuil et 
al., 2010). It is able to do this by forming a “cortical plaque”, which can modify the host 
cell homeostasis resulting in barrier breakdown (Stephens, 2009; Coureuil et al., 2010). 
SA may potentially operate in a similar manner. 
 
1.9.2 Streptococcus pneumoniae 
Streptococcus pneumoniae (SP) is another invader of the BBB. Like SA, it is also a gram-
positive bacterium responsible for causing pneumonia, meningitis, middle ear infection 
and sinusitis. It is a potentially lethal pathogen, having a 100% mortality rate for untreated 
patients (Barichello et al., 2012a). Similarly to NM, SP colonises the nasopharynx and 
this found in 40% of infants and 15% of adults, where it produces mucus-degrading 
enzymes called exoglycosidases (e.g. neuraminidase) as well as an endotoxin called 
pneumolysin, which enables enhanced bacterial adhesion to the host by lowering the 
beating of the epithelial ciliary in the nares (Barichello et al., 2012b). SP has been shown 
to cross the BBB both transcellularly and paracellularly (Mook-Kanamori et al., 2011). 
Its intracellular mechanism involves SP phosphorylcholine binding to the vascular 
endothelial platelet-activating factor (PAF) receptor found on cerebral endothelial cells, 
enabling the bacterium to be transcytosed across the endothelium (Mook-Kanamori et al., 
2011). Another possible method is the adhesion of pneumococcal surface protein C 
(PspC) binding to the laminin receptor on BMvEC. Laminin appears to be a binding site 
for meningitis-causing pathogens to cerebral endothelial cells, aiding SP and NM 
adhesion to the brain microvascular endothelium (Mook-Kanamori et al., 2011). SP is 
also capable of binding to other BBB cell surface proteins such as fibronectin, vitronectin 
and collagen located in the ECM, whilst also being capable of disrupting the TJ and AJ 
of BMvEC in-vitro enabling paracellular transport (Mook-Kanamori et al., 2011). This 
was also confirmed using a rodent in-vivo model (Quagliarello et al., 1986).  
Unfortunately, 30% of patients treated for SP infection are susceptible to sensory 
complications such as deafness and blindness, with some individuals also experiencing 
memory loss (Barichello et al., 2012b). During infection, the bacterium stimulates 
neuronal cells to undergo apoptosis via the caspase-dependent and/or independent route, 
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ultimately resulting in further brain trauma and injury. Again, SA may operate in a similar 
manner to this. 
 
1.9.3 Streptococcus agalactiae 
Streptococcus agalactiae also referred to as Group B Streptococcus (GBS) is a gram-
positive bacterium known to cause cerebral meningitis in neonates, with approximately 
3-25% dying even with the administration of proper treatment (Kim et al., 2015a). Post-
infection, approximately 25-50% children are left with severe complications such as 
cerebral palsy, blindness and deafness, or suffer from seizures (Doran et al., 2005). Out 
of the nine strains of GBS identified, all are known to cause meningitis with serotype III 
proving to be most detrimental (i.e. 80-85% of cases proving positive for this strain). 
When GBS was tested in-vitro, using immortalised BMvEC, it was able to adhere and 
invade the cells, whilst also surviving intracellularly. GBS was seen to invade the cells 
using three different methods. The first method showed GBS exploiting the BMvECs’ 
own transport pathways to access the cell (discussed in Section 1.5). The second method 
showed GBS causing BMvEC cytoskeleton realignment, while the third method showed 
GBS entering the cell through endocytic engulfment (Doran et al., 2005). Recent work 
using immortalised human BMvEC infected with a clinical virulent strain of GBS 
(serotype III) showed an upregulation of a global transcriptional repressor of tight 
junction proteins called Snail1 (SNAI1). The induction of Snail1 was also seen in S. 
pneumoniae and Bacillus anthracis, but interestingly not seen in non-pathogenic strains 
of SA. Post-infection with GBS, immortalised HBMvEC showed significant decreases in 
TJ and AJ proteins, namely ZO-1, occludin, claudin-5 and VE-cadherin, both seen in-
vivo and in-vitro studies (Kim et al., 2015a).  
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1.10 Project overview 
As it stands, SA is not regarded as one of the leading bacteria to cause bacterial meningitis 
(of which BBB disruption is a major feature); however, it is one of the top 10 causes for 
infection-related deaths worldwide (van Sorge & Doran, 2012). The more commonly 
known perpetrators are Streptococcus pneumoniae, Neisseria meningitidis and Group B 
Streptococcus (GBS) (Bottomley et al., 2012). However, SA does account for 10% 
bacterial meningitis cases with a mortality rate of 36% (Teh & Slavin, 2012). Its incidence 
is predominantly seen in neonates and young children and more recently, MRSA-
dependent meningitis has been seen in HIV-patients (Sayana & Khanlou, 2008; 
Bottomley et al., 2012). There are two possible mechanisms to contract SA meningitis: 
(1) by post-operative procedures including head traumas or; (2) hematogenous meningitis 
(spontaneous) where the disease arises as a secondary infection originally sourced outside 
of the CNS (Sayana & Khanlou, 2008; Teh & Slavin, 2012). Hematogenous 
staphylococcal meningitis is regarded as a community-associated disease, which could 
ultimately lead to BBB dysfunction through several mechanisms: (i) through the 
production of toxins e.g. (PFT); (ii) upregulation of inflammatory mediators e.g. 
cytokines and chemokines and; (iii) use of adhesion proteins on the outer bacterial surface 
that can alter endothelial cell signalling, resulting in interendothelial junctional protein 
disassembly and BBB permeabilization. This project sets out to develop and characterize 
an in-vitro model of HBMvEC barrier function in response to SA infection, thus 
facilitating a more comprehensive understanding of bacterially-mediated BBB infection. 
1.10.1 Hypothesis 
 SA infection causes BBB dysfunction through the dysregulation of interendothelial 
junctional proteins, leading to increased paracellular permeability. 
1.10.2 Objectives 
1. To develop and characterise an in-vitro HBMvEC/SA model using “fixed SA”. 
2. To develop and characterise an in-vitro HBMvEC/SA model using “live SA”. 
3. To monitor the effects of infection on HBMvEC viability and barrier function 
indices. 
4. To examine the role of pro-inflammatory signalling in SA-induced dysregulation 
of HBMvEC barrier function.  
5. To employ SA mutants to probe the mechanism of SA-mediated HBMvEC injury.   
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Chapter 2 
Material and Methods 
  
65 
 
2.1 Materials 
Abcam, (Cambridge, UK):  
Mouse anti-VE-cadherin monoclonal IgG2a antibody. 
 
Ambion, (California, USA): 
Trizol. 
 
Becton Dickinson Biosciences, (Oxford, UK): 
FACS Flow sheath fluid, FACS Rinse solution, FITC/annexin V, Phycoerythrin (PE)-
Mouse anti-human CD144 and round-bottomed FACS tubes. 
 
Cell Signalling Technology, (Massachusetts, USA): 
Anti-mouse and anti-rabbit IgG HRP-linked secondary antisera and rabbit anti-phospho-
NF-κB p65 (Ser536) IgG. 
 
Cell Systems Inc., (Washington, USA): 
Attachment factor and Human Brain Microvascular Endothelial Cells (HBMvEC), lot 
number of new stock 376.01.01.0103).  
 
Cruinn Ltd., (Dublin, Ireland):  
StarLab TipOne® 100-1000 μl XL and 1-200 μl graduated filter tips. 
 
DAKO, (California, USA): 
Fluorescent mounting media. 
 
Fisher Scientific Ireland Ltd., (Dublin, Ireland):  
Isopropanol, L-shaped spreaders, trizma base and weigh boats. 
 
Ibidi, (Martinsried, Germany): 
Fluorescent mounting medium. 
 
Invitrogen, (Groningen, Netherlands):  
Anti-claudin-5 monoclonal mouse IgG, anti-occludin monoclonal mouse IgG, anti-ZO-1 
monoclonal mouse IgG, Countess™ cell counter chips and propidium iodide (PI).  
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Labtech, (East Sussex, UK):  
ADAM™ counter kit. 
 
Lennox, (Dublin, Ireland) 
Industrial methylated spirits (IMS). 
 
Lonza, (Basel, Switzerland) 
Mycozap™ antibiotics. 
 
Millipore, (Cork, Ireland):  
0.4 μm transwell inserts, EndoGRO™ MV complete media, human recombinant 
fibroblast growth factor, immobilon-P transfer PVDF membranes for Western blot (0.45 
μm), Luminata Forte™ Western HRP substrate and recombinant tumour necrosis factor-
α (TNF-α).  
 
Molecular Probes, (California, USA): 
Alexa fluor 546 goat anti-mouse IgG, flow cytometery dead cell apoptosis kit with 
annexin V, Alexa Flour 488 and propidium iodide (PI) and rhodamine phalloidin.  
 
PromoCell, (Heidelberg, Germany):  
Cryo-SFM. 
 
Research and Development Systems (R & D), (Abingdon, UK): 
ELISA kits for TNF-α and thrombomodulin and human cytokine array panel A (Proteome 
Profiler TM). 
 
Roche Diagnostics, (West Sussex, UK):  
Complete EDTA-free protease inhibitor cocktail tablets and PVDF Western blot 
membrane.  
 
Sarstedt, (Wexford, Ireland):  
0.2 μm and 0.45 μm, FiltropurS syringe filters, 0.2, 0.5, and 1.5 ml PCR micro tube, 10 
ml blow-out pipette, 100 mm tissue culture dishes, 15 and 50 ml centrifuge tubes, 2 ml, 
5 ml, 10 ml serological pipettes, 2 μl 10 μl, 200 μl, and 1000 μl pipette tips, 6-well, 24-
well, and 96-well tissue culture plates, cell scrapers (25 cm), cell scrapers and cryovials.  
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Sigma-Aldrich Chemical Co., (Wicklow, Ireland):  
2-mercaptoethanol, 3,3',5,5'-tetramethylbenzidine liquid substrate, brain heart infusion 
(BHI) broth, BHI agar, 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI), 
acrylamide/bis-acrylamide 30% solution, bovine serum albumin (BSA), ammonium 
chloride, ammonium persulfate, brilliant blue R bromophenol blue, chloroform, 
Dihydroethidium (DHE), DMEM-high glucose media, DNase1 amplification kit, 
Dulbecco’s phosphate buffered saline (PBS), EDTA, FITC-dextran, gelatin from cold 
water fish skin, glycerol, glycine, HEPES, hydrochloric acid, hydrogen peroxide solution, 
latex beads, polystyrene 0.1 μm, magnesium sulphate, methanol, anti-protein A mouse 
monoclonal IgG, paraformaldehyde, PBS tablets, penicillin-streptomycin (100X), 
ponceau S solution, saponin, SDS, sodium azide, sodium carbonate, sodium chloride, 
sodium deoxycholate, sodium fluoride, sodium orthovanadate, sodium phosphate, SYBR 
Green II, TEMED, Triton™X-100, trizma base, trypsin-EDTA solution (10x) and 
Tween®-20. 
 
Thermo Scientific, (Leicestershire, UK):  
BCA protein assay kit, PageRuler Plus prestained protein ladder, Restore™ Western blot 
stripping reagent, and Spectra Multicolour High Range protein ladder.  
 
VWR International Ltd., (Dublin, Ireland) 
Cover slips 24 x 24 mm and microscopy slides. 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Culturing HBMvEC 
HBMvEC were stored in cryogenic vials in a liquid nitrogen cryo-freezer unit (Taylor-
Wharton). HBMvEC require EndoGroTM basal growth media supplemented with 
EndoGro-LS supplement (0.2%), epidermal growth factor (recombinant human) (5 
ng/ml), ascorbic acid (50 µg/ml), L-glutamine (10 mM), hydrocortisone hemisuccinate 
(1.0 µg/ml), heparin sulphate (0.75 U/ml) and FBS (2%) prepared in a Holten laminar air 
flow cabinet (Thermo Electron Corporation) and stored at 4ºC. A thin layer of gelatin 
(attachment factor) was added to each cell culture plate prior to HBMvEC addition except 
when conducting bacterial infection studies with HBMvEC. HBMvEC were grown on 
100 mm cell culture dishes in a humidified incubator at 5% CO2/95% air at 37ºC in a 
steri-cycle CO2 incubator HEPA class 100 (Thermo Electron Corporation). 
 
2.2.1.2 Experimental model HBMvEC: SA co-culture 
Cultured HBMvEC were infected with either formaldehyde-fixed or live Newman WT or 
mutant SpA SA strains with varying bacterial dose (multiplicity of infection up to MOI 
0-250) and infection times (up to 48 hrs), in order to assess tight/adherens junction 
disruption characteristics and inflammatory signalling in HBMvEC. For live SA 
infections, the lower bacterial MOI range (0-100) and shorter infection time (0-12 hrs) 
were specifically employed due to bacterial growth issues.  
 
2.2.1.3 Trypsinisation of HBMvEC 
HBMvEC are an adherent cell line, growing as a monolayer in culture. Cells were washed 
with phosphate buffered saline (PBS) to remove trypsin inhibitors present in serum and 
non-adhered cells. When fully confluent, cells were trypsinised using 1x trypsin/EDTA. 
Fresh pre-warmed media was used to neutralise the trypsin activity before the cell 
suspension was centrifuged for 5 mins at 100 × g. The supernatant was removed and the 
cell pellets re-suspended in fresh media before being added to new cell culture dishes 
containing additional fresh media.  
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2.2.1.4 Cell counting 
Two methods were used to count cells, manually using a haemocytometer and 
electronically using the Advanced Detection and Measurement (ADAM) counter and the 
Countess® Automated Cell Counter. 
A haemocytometer involves counting cells on a gridded slide allowing for an approximate 
calculation of how many cells are found in 1 ml of solution. The haemocytometer was 
viewed using a Nikon Eclipse TS100 phase-contrast microscope. Advanced Detection 
and Measurement (ADAM) counter involved mixing the cell suspension with two ADAM 
reagents called N and T, which stain the cells accordingly depending on their viability 
status. The cell suspensions were loaded onto an ADAM chip, which was then read by 
the ADAM reader. The Countess™ Automated Cell Counter works in a similar manner 
to the haemocytometer and ADAM reader as cells were stained with tryphan blue, prior 
to insertion into the CountessTM reader. 
 
2.2.1.5 Long-term cell storage 
HBMvEC were trypsinised, counted, and the cell pellet resuspended in Cryo-SFM 
freezing media. The solution was transferred to a cryovial and stored in a Mr. Freeze® 
storage unit containing isopropanol, which was then left at -80°C overnight. The 
isopropanol freezes the cells at a rate of -1°C/min. The vials were then transferred to a 
liquid nitrogen container. To reconstitute the cells from liquid nitrogen storage, the vial 
was quickly thawed in a water bath at 37°C and added to a 100 mm cell culture plate 
coated with attachment factor, containing fresh media and left overnight in a 37°C 
incubator.  
 
2.2.2 Cell treatments 
2.2.2.1 Shearing cells 
Endothelial cells were grown to confluency in 6-well plates for shearing by orbital 
rotation. Using the equation taken from Hendrickson et al. (1999) the speed required to 
set the rotator was calculated to achieve shear flow that mimics the physiologic 
haemodynamic environment of endothelial capillaries (Hendrickson et al., 1999).   
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When the cells were 80-95% confluent, PBS wash steps removed non-adhered or 
detached cells. Fresh media was added to each well and the plates fixed to a Stuart 
scientific mini orbital shaker set at 230 rpm (10 dynes/cm2). The rotator was placed in an 
incubator at 37ºC for 24 hrs. Images of sheared cells were taken with a Leica inverted 
microscope. 
 
2.2.3 Protein extraction and quantification 
2.2.3.1 Generating HBMvEC total protein lysate 
Cells in culture were lysed using a 1x RIPA lysis buffer to extract cellular protein as 
published by Harhaj et al. (2006). The recipe for 1x RIPA is shown in Table 2.1. Cells 
were kept on ice for the duration of the experiment in order to preserve the extracted 
protein. Cells were washed thrice with 1x non-sterile PBS to rid the plate of floating or 
non-adhered cells. For a 100 mm cell culture dish, 80 µl of RIPA was added. With a cell 
scraper, the contents of the well were added to a 1.5 ml centrifuge tube. The samples were 
rotated for 1 hr at 4°C to further facilitate protein solubilisation. The cell suspension was 
centrifuged at 9830 × g at 4°C for 20 mins and the supernatant (protein lysate) added to 
a fresh tube and stored at -80°C. The concentration of the total cell protein lysate was 
determined by a BCA assay. 
 
1x RIPA Volume (µl) 
Protease inhibitor (25x) 20 
1.28x RIPA 390 
0.5 M Sodium Fluoride 10 
0.5 M EDTA pH 8.0 5 
0.1 M Sodium Phosphate 50 
10 mM Sodium Orthovanadate 50 
Table 2.1: Contents of 1x RIPA lysis buffer.  
Shear Stress = 𝛼 𝜌𝑛(2𝜋𝑓)3 
α = radius of rotation (cm) 
ρ = density of liquid (g/L) 
n = 7.5 x 10
-3
 (dynes/cm
2
 at 37
o
C) 
f = rotation per second 
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2.2.3.2 Bicinchoninic acid assay  
The bicinchoninic acid assay was used to calculate the protein concentrations of unknown 
samples relative to a set of BSA standards, as published by Smith et al. (1985). The 
standards were made using 2 mg/ml BSA stock as shown in Table 2.2. A 1:5 dilution of 
the protein lysates was loaded in triplicate to a 96-well plate, including 1x RIPA lysis 
buffer acting as a negative-control for the assay. The BCA working reagent was added to 
the plate, covered in tinfoil, and left at 37°C for 30 mins. The absorbance was read at 562 
nm on an ELx800 microplate reader (Biotek) and the concentration of the protein samples 
calculated. 
 
Table 2.2: BSA standards for protein assay (0-2 mg/ml). 
 
 
2.2.3.4 Western blotting 
This experiment follows the same protocol as Laemmli, (1970) who ran total protein 
lysates on SDS-PAGE gels made using either 7.5% or 12% resolving gels with 5% 
stacking gels (Guinan et al., 2013). Protein samples were prepared and loaded equally 
with 4x sample solubilisation buffer (SSB) containing glycerol. Samples were run at 80 
V until they reached the base of the gel [Figure 2.1A]. The gel was then transferred onto 
PVDF overnight at 4°C at 50 V [Figure 2.1B]. The membrane was Ponceau stained to 
confirm protein transfer. The membrane was then blocked with 5% BSA TBS-Tween and 
then incubated with primary antibody overnight at 4°C with a gentle rocking motion. The 
membrane was washed with TBS-Tween and subsequently incubated with the 
corresponding secondary antibody for 2-3 hrs. The membrane was finally re-washed and 
probed with a Luminata Western HRP kit for visualisation of protein bands. Protein bands 
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of interest were quantified by densitometry analysis with the samples normalised to an 
endogenous control protein (β-actin). Antisera details are given in Table 2.3. 
 
 
 
Figure 2.1: Western blot running and transfer procedures. (A) Graphic representation 
of running total protein samples on SDS-PAGE gels on a Mini-PROTEAN Tetra Cell 
Trans-Blot® Module and; (B) transfer onto PVDF using the same system (Bensaccount, 
2009).  
PVDF
A
B
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    Primary Secondary 
TJ/AJ kDa Species Dilution Species Dilution 
VE-Cadherin 130-140 
Mouse Monoclonal 
IgG 
1:500 
Anti-mouse 
HRP-conjugated 
IgG 
1:500 
ZO-1 210-225 
Mouse Monoclonal 
IgG 
1:1000 
Anti-mouse 
HRP-conjugated 
IgG 
1:3000 
Claudin-5 23 
Mouse Monoclonal 
IgG 
1:1000 
Anti-mouse 
HRP-conjugated 
IgG 
1:1500 
Occludin 68 
Mouse Monoclonal 
IgG 
1:1000 
Anti-mouse 
HRP-conjugated 
IgG 
1:1000 
Phospho-NF-
κB p65  
(Ser536) 
65 
Rabbit Monoclonal 
IgG 
1:1000 
Anti-rabbit  
HRP-conjugated 
IgG 
1:1000 
vWF 300 
Rabbit polyclonal 
IgG 
1:1000 
Anti-rabbit  
HRP-conjugated 
IgG 
1:2000 
β-actin 42 
Mouse Monoclonal 
IgG 
1:10,000 
Anti-mouse 
HRP-conjugated 
IgG 
1:20,000 
Table 2.3: Primary and secondary antibodies for Western blot analysis. 
 
 
2.2.3.5 Enzyme linked immunosorbent assay  
An enzyme linked immunosorbent assay (ELISA) was used to detect and quantitate 
HBMvEC cytokine levels post-infection with SA. Cell culture media was harvested post-
infection and centrifuged at 100 × g for 6 mins to remove cell debris. The supernatant 
was further centrifuged at 3220 × g for 10 mins to remove SA still present in the harvested 
media. The final supernatant was stored at -80°C. ELISA kits for IL-6, TNF-α and 
thrombomodulin (TM) were used. Capture antibody was added to a F96 maxisorp Nunc-
Immuno 96-well plates and left to adhere overnight at 4°C for IL-6 or room temperature 
(RT) for TM and TNF-α assays. The plate was washed with wash buffer prior to being 
blocked with reagent diluent. Following this, protein standards and undiluted media 
samples are added to the ELISA plate [Figure 2.2 Step 1]. The plate was then re-washed 
followed by the addition of detection antibody [Figure 2.2 Step 2]. The plate was re-
washed and streptavidin-horseradish peroxidase (HRP) was added to each sample well 
[Figure 2.2 Step 3]. TMB substrate was added followed by the stop solution, which results 
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in a yellow colour [Figure 2.2 Step 4]. The plate is read using a dual wavelength of 450 
nm and 562 nm. 
 
 
Figure 2.2: Sandwich ELISA procedure. Illustration of sandwich ELISA procedure 
outlining each of the key steps; (1) capture antibody; (2) detection antibody; (3) 
streptavidin-HRP; (4) substrate colour change (R&D Systems). 
 
2.2.4 Physiological assays 
2.2.4.1 Trans-endothelial permeability assay  
This assay is a modified version of Rochfort et al. (2014). Static and sheared HBMvEC 
were trypsinised and 4x105 cells/ml seeded onto a 0.4 µm transwell inserts with a 24 mm 
filter diameter to a final volume of 2 mls with media. Fresh media was added also to the 
subluminal compartment of the well. The cells were left to adhere for 24-48 hrs at 37ºC. 
A fluorophore (250 μg/ml FITC-labelled dextran, 40 kDa) was added to the upper luminal 
compartment of the insert [Figure 2.3]. The experiment takes place over 3 hrs with 
samples taken from the subluminal compartment every 30 mins and added in triplicate to 
a white 96-well plate for examination by fluorimetry using a TECAN Safire 2 
75 
 
fluorospectrometer or a Wallac 1420 VICTOR2™ plate reader set at 490 nm for 
excitation and 520 nm for emission. The presence of the fluorophore in the subluminal 
space was calculated as % Trans Endothelial Exchange (TEE) FD40 Dextran.  
 
 
Figure 2.3: Transwell insert. Endothelial cells form a monolayer on the transwell insert. 
FITC-dextran (40 kDa) is added to the apical compartment and over time will permeate 
through the paracellular spaces between endothelial cells and the transwell insert into the 
basolateral chamber. 
 
2.2.4.2 Fluorescence activated cell sorting 
Flow cytometry or fluorescence activated cell sorting (FACS) is a process used to 
characterize the properties of fluorescently labelled cells. It gives information about cell 
size, granularity, and the phenotypic expression of protein markers on or in a particular 
cell, as well as the proliferative, apoptotic and necrotic state of cells in response to 
different experimental treatments.  
 
2.2.4.2.1 Cell viability 
An Alexa Fluor 488 annexin V/Dead cell apoptosis kit was used to monitor HBMvEC 
viability post-infection with SA. The two main stains used in this kit are annexin V and 
PI. Annexin V is a human anticoagulant phospholipid-binding protein. It has a high 
binding affinity for phosphatidylserine (PS), a component of the cell membrane. Annexin 
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V is labelled with Alexa fluor 488, a dye that can adhere to PS exposed on the outer 
membrane of early apoptotic cells but not healthy cells [Figure 2.4]. PI as mentioned 
previously is a red nucleic acid binding fluorescent dye that only stains necrotic and late 
apoptotic cells. Overall, by using both stains, apoptotic cells emit green fluorescence, 
necrotic cells emit a red/green fluorescence, and live healthy cells exhibit little or no 
fluorescent properties. All flow cytometry experiments were done using the FACSAria 
(BD Biosciences, UK) and results analysed using FlowJo software.  
 
  
Figure 2.4: Apoptosis assay with annexinV/FITC and propidium iodide. Graphic 
representation of how annexin V and PI interact with cell membranes (Dojindo.com). 
 
2.2.4.2.2 Reactive oxygen species  
Dihydroethidium (DHE) is an intracellular superoxide indicator. It stains the cytoplasm 
of living cells blue; however, when oxidised by a superoxide (i.e. ROS) it generates 
ethidium, which has the ability to intercalate with DNA staining it red (Peshavariya et al., 
2007) [Figure 2.5]. For this assay, both uninfected and infected HBMvEC were treated 
with 3 μM of DHE for 30 mins prior to completion of the infection incubation period. 
The media was aspirated from the wells while the cells were trypsinised and washed with 
pre-warmed PBS. Both the media, wash solution and trypsinised cells were all pooled 
together and centrifuged. The cell pellets were resuspended in 250 μl of FACS buffer. 
The samples were kept on ice and in the dark before being analysed by flow cytometry.  
Annexin V/Alexa Flour 488 
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Figure 2.5: Dihydroethidium principle. DHE is converted to ethidium when a 
superoxide (i.e. ROS) is present (Chu et al., 2014). 
 
2.2.4.2.3 Endothelial microparticle release 
Flow cytometry was also used to analyse endothelial microparticles (EMP) released into 
the cell culture media during the SA infection process. For the isolation of EMP present 
in HBMvEC-conditioned media, the methods of Lacroix et al. (2007 and 2012) were 
employed with minor modifications. Following experiments, conditioned media was 
harvested and centrifuged at 3220 × g for 10 mins to facilitate removal of bacteria and 
cellular debris. The media was then centrifuged at 15,000 × g for 90 mins, after which the 
supernatant was set aside and the pellet resuspended in PBS. The washed pellet was 
subjected to a second centrifugation at 15,000 × g for 90 mins to yield a final EMP pellet. 
The EMP pellet was resuspended in 100 μl of FACS buffer (2% foetal calf serum, 0.1% 
(w/v) sodium azide, 98% PBS) including 20 μl of phycoerythrin (PE) mouse anti-human 
CD144 (VE-cadherin). The EMP samples were left to incubate for 30 mins at 4°C prior 
to the addition of 5 μl FITC/annexin V, which was also left to incubate for 30 mins at 
4°C. The samples were centrifuged and resuspended in FACS buffer to a final volume of 
250 μl before running on the FACSAria flow cytometer. The machine was pre-calibrated 
using standard 0.1 mm polystyrene-latex beads, whilst also using a suspension of EMPs 
isolated from control HBMvEC for further optimisation.  
 
2.2.4.3 Cytokine array 
A Human Cytokine Array Panel A (R&D Systems, Abingdon, UK), containing four pre-
coated nitrocellulose membranes with 36 duplicated cytokine and chemokine markers 
was employed to identify a variety of inflammatory cytokines that may be secreted in 
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response to SA infection of HBMvEC. Media was harvested from HBMvEC infected 
with fixed and live SA. The pre-coated nitrocellulose blots were blocked for 1 hr using 
array buffer 4. During this time, 1 ml of the harvested media sample was added to 500 μl 
of Array buffer 4, including 15 μl of detection antibody, and incubated at room 
temperature for 1 hr. The blocking buffer was aspirated from the nitrocellulose blots and 
the solution containing the sample, array buffer 4 and detection antibody was added to 
the membranes to incubate at 4°C on a rocking platform overnight. The membranes were 
then washed thrice with 1x wash buffer for 10 mins before the addition of 1:2000 HRP 
solution for 30 mins at room temperature. The blots were re-washed and blotted dry 
before examination with chemiluminescent reagents 1 and 2 for imaging in the G-Box. 
Densitometry analysis was used to evaluate cytokine expression release. Three pairs of 
reference markers spotted on the nitrocellulose blots confirm assay validity. The data 
were presented as percentage (%) area in terms of pixilation.  
 
2.2.4.4 Immunofluorescent microscopy 
In order to visualise the subcellular localization of HBMvEC interendothelial junctional 
proteins, immunofluorescent microscopy was carried out according to Rochfort et al. 
(2015). Post-infection with SA, HBMvEC were washed thrice with PBS before fixation 
for 10 mins at 4°C using 3.7% paraformaldehyde (containing 0.1M sodium hydroxide, 
pH-adjusted 7.2). Upon aspiration, 50 mM ammonium chloride was added to the cells for 
10 mins at room temperature. The cells were then blocked for 30 mins using a permablock 
reagent (0.1% saponin, 0.02% sodium azide, 0.25% fish gelatin and PBS). Once blocked, 
primary antibody solutions prepared in permablock were added to the cells and incubated 
overnight at 4°C. Following a series of wash steps, secondary antibodies prepared in 
permablock were added to the cells and left to incubate at room temperature for 2 hrs. A 
DAPI stain was used to stain cell nuclei and rhodamine phalloidin was used for 
filamentous-actin staining. The cells were then washed twice with permablock solution 
before adding 2 drops of DAKO fluorescent mounting medium along with a coverslip. 
Samples were stored in the dark and viewed on a Nikon Eclipse Ti microscope (Nikon).  
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1° AB Dilution Incubation 2° AB Dilution Incubation 
ZO-1 
(Invitrogen) 
1:50 Overnight 4°C 
Alexa Fluor 546  
Goat-anti-Mouse 
1:500 2 hrs 
- - - Rhodamine Phalloidin 1:50 30 mins 
- - - DAPI 1:2000 3 mins 
Table 2.4: Primary and secondary antibodies for immunocytochemistry. 
 
2.2.5 Bacterial preparation 
2.2.5.1 Bacterial preparation and storage 
All bacterial preparations and live experimental studies were conducted in the 
Department of Molecular and Cellular Therapeutics (MCT) in RCSI, Dublin.  
 
2.2.5.2 Staphylococcal strains 
Two staphylococcal strains were used for the purpose of this research project; Newman 
NCTC 8178 wild-type SA strain and a Newman mutant staphylococcal protein A 
(∆spa∷Kar strain). Vials were stored at -80°C in brain heart infusion (BHI) broth 
containing 12% glycerol. The bacterial cells were defrosted at room temperature, added 
to 50 ml centrifuge tubes containing 15 mls of BHI broth, and incubated overnight at 
37°C. After ~17 hrs incubation (stationary phase), the tubes were centrifuged at 3220 × g 
for 10 mins [Figure 2.6]. The supernatant was discarded and the pellet re-suspended in 5 
mls sterile PBS and re-spun. Both live and fixed bacteria were used in our HBMvEC co-
culture studies. When live bacteria were required, the pellet was re-suspended in 1 ml 
PBS, whereas 4.8% formaldehyde was used for all fixation studies. The bacteria were 
incubated for 15 mins on an agitator and washed thrice with PBS before being centrifuged 
at 3220 × g for 10 mins between washes. After the final PBS wash, the bacterial pellets 
were re-suspended in 1 ml PBS. The bacterial suspension was adjusted to an optical 
density (OD) of 1 set at 600 nm using a spectrophotometer (Pharmacia) –this is equivalent 
to 1x108 CFU/ml, as proven by using spread BHI agar plates [Figure 2.7]. 
 
Allele replacement site-directed mutagenesis was performed in order to explore the effect 
of a known gene e.g. knocking out staphylococcal protein A (SpA) in SA. Protein A-
deficient SA was generated using a SA 8325-4 strain (generating 8325-4 spa∷KanR, 
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KanR: kanamycin resistance) (Patel et al., 1987). The DNA of a SA strain called 8325-4 
was constructed in a replacement vector called λL47.1, which was used to subclone and 
carry out restriction mapping experiments. The spa gene fragment (EcoRI) generated 
from this method was cloned using a cloning vector (pACYC184), prior to insertion into 
a temperature-sensitive E. coli plasmid (pSPA721). This vector was further cleaved with 
restriction enzymes called PstI, BclI and EcoRI. The generated fragments were run on 
agarose gels, which enabled the electroelution of fragments PstI-BclI and BclI-EcoRI. 
Both fragments were ligated with another cloning vector (pUC18), which was then 
transformed into E.coli. The appropriate colonies (∆spa, pEBP962) containing both 
fragments were screened by plating the bacteria on L agar plates. The incorporation of a 
DNA fragment that confers ethidium bromide resistance (BglII) was introduced into 
pEBP962, generating pEBM1. Following a series of replica plating, the appropriate ∆SpA 
recombinants (∆spa∷∆EtbrR) were selected and inserted into a SA shuttle plasmid 
(pEBM15) containing the DNA from pEBM1 and an additional SA plasmid (pE194) that 
confers erythromycin resistance. The generated recombinants from pEBM15 were 
transformed into SA RN4220 protoplasts. The plasmid was then transduced along with 
another plasmid (pEC1) that confers chloramphenicol resistance into SA 8325-4 strain. 
Colonies generated were purified following rounds of saturation to ensure the bacteria no 
longer contained the SA shuttle plasmid (Patel et al., 1987; Ní Eidhin et al., 1998; O’Brien 
et al., 2002; Higgins et al., 2006). This inactivation process for SpA was utilised by 
Higgins et al. (2006) to generate a Newman strain lacking spa. This was achieved by 
phage 85 transduction from the 8325-4 spa∷KanR SA strain and to which was used for 
this project (Higgins et al., 2006). 
 
2.2.5.3 Preparation of bacterial stocks 
Bacteria were grown overnight as described in section 2.2.5.2. After centrifugation, the 
supernatant was removed and the bacterial pellet re-suspended in 10 ml BHI broth 
supplemented with 12% glycerol. Glycerol enables the long-term storage of bacteria 
preventing the formation of ice crystals, which can damage the frozen sample. The 
bacterial suspension was placed in 1 ml aliquots and frozen at -80°C for future use. 
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Figure 2.6: Staphylococcus aureus growth curve. The growth rate of SA occurs in 6 
phases; (1) lag phase; (2) acceleration phase; (3) growth phase (exponential); (4) decline 
phase; (5) stationary phase; (6) death phase (Cunningham 2001-2010). 
 
 
2.2.5.4 Spread plates 
In order to confirm an OD1 at 600 nm for SA, BHI agar spread plates were made to 
calculate CFU/ml. Serial dilutions were made of the OD1 stock to 10-8, spreading 100 µl 
of each dilution onto BHI agar plates using a plate spreader. Plates were incubated in a 
non-CO2 incubator at 37°C [Figure 2.9]. Colony counts were calculated after 24 hrs taking 
into consideration the dilution factor for an overall summation of CFU/ml.  
 
 
Figure 2.7: Serial dilution of Staphylococcus aureus. Serial dilutions of SA grown on 
BHI agar for 24 hrs. 
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2.2.5.5 Multiplicity of infection 
Multiplicity of infection (MOI) refers to the ratio of bacteria to mammalian cells e.g. MOI 
100 states that for every mammalian cell present, it will be infected with 100 bacteria. 
This was the dose-infection method employed to infect HBMvEC with either fixed or live 
SA. MOI is calculated using the formula: MOI = CFU required / number of cells.  
 
2.2.5.6 Treatment with pre-conditioned media 
SA is an opportunistic pathogen equipped with many virulence factors, which can be 
released by the bacteria when stimulated to do so. In order to look more closely at the 
consequences of SA virulence factor release, HBMvEC media was incubated with live 
SA for 12 hrs. The media was centrifuged at 3220 × g to remove bacteria prior to adding 
to confluent (uninfected) HBMvEC. The pre-conditioned media was left on the cells for 
36 hrs in order to monitor any changes in cell physiology and barrier integrity. 
2.2.5.7 SA BMvEC adhesion assay 
A bacterial adhesion assay measures the number of adhered bacteria to a set number of 
mammalian cells. Static and sheared HBMvEC were trypsinised and a cell suspension of 
2x105 cell/ml prepared. Using this cell suspension, 100 µl was added in triplicate to a 
clear 96-well plate. The cells were allowed to adhere for 2-3 hrs in an incubator at 37°C.  
The plate was washed with PBS and blocked using 1% BSA for 1 hr to prevent non-
specific binding of the bacteria to the unoccupied regions of the well. The cells were re-
washed with PBS. Live SA was then prepared as described previously, but for the purpose 
of the adhesion assay it was stained with 1x SYBR Green II. The fluorescently stained 
bacterium, adjusted to an OD of 1, was added to the HBMvEC in the 96-well plate, while 
tris-buffered saline (TBS) was added as a negative control. The plate was incubated for 1 
hr to allow bacterial attachment to the HBMvEC. The plate was read twice using a 
fluorescence plate reader set at 485/535 nm for excitation and emission respectively. The 
first reading generates a total cell count, counting adhered and non-adhered bacteria. The 
second reading measures only adhered bacteria, as the plate is washed 3 times with TBS 
removing the non-adhered SA. Data was calculated as bound bacteria per well per 
condition/treatment (e.g. static versus sheared HBMvEC or fixed versus live SA). 
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2.2.5.8 Dot blot 
In order to identify SA from other staphylococcal strains, tests are carried out for the 
presence of SpA, which is found on the surface of SA only, thereby distinguishing it from 
other Staphylococci. To ensure the strain being used was in fact SpA-positive Newman, 
a SpA dot blot was performed. A dot blot is another form of Western blot technique, 
where instead of running samples on an SDS-PAGE gel, the samples were “dotted” onto 
a nitrocellulose membrane and allowed to dry out completely. In this regard, diluted 
samples of Newman wild-type SA (NWT-SA) were added to nitrocellulose and left to 
dry completely. The membrane was blocked with 5% milk powder containing TBS-T for 
20 mins before adding primary antibody for 1 hr under constant rotation at RT. The 
membrane was washed and probed with a secondary horse anti-mouse IgG antibody for 
1 hr at RT. The blot was subsequently re-washed to remove non-bound antibody and then 
placed into a development cassette along with an enhanced chemiluminescence (ECL) 
reagent. The cassette was closed, incubating the blot for 3-5 mins. After incubation, the 
blot was exposed to an X-ray film for 20 seconds before adding to developer and fixer 
solutions for 30-second washes. The x-ray film was then washed with water and left to 
dry. 
 kDa Primary Antibody Secondary Antibody 
Protein A 50 
1:1000 Monoclonal chicken IgY  
anti-SpA raised in mouse 
1:2000 Horse anti-
mouse IgG 
Table 2.5: Protein A antibodies used for dot plot analysis. 
 
2.2.6 Statistical analysis 
Results are expressed as mean ± S.E.M. Experimental points were performed in triplicate 
with a minimum of three independent experiments (N= 3). Statistical comparisons 
between control and experimental groups was by ANOVA in conjunction with a 
Dunnett’s post-hoc test for multiple comparisons (*). A Student’s t-test was also 
employed for pairwise comparisons (δ). A value of p≤0.05 was considered significant.  
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Chapter 3  
Infection Model Characterization 
HBMvEC/ S. aureus  
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3.1 Introduction 
The blood-brain barrier (BBB) is the central regulator of the NVU, being the main 
interface that regulates the entry of nutrients and removal of waste molecules from the 
CNS. However, this barrier is frequently exposed to many viral and bacterial challenges, 
which in some cases can greatly reduce BBB functionality leading to major cerebral 
dysfunction. The initial objective was to model the impact of Staphylococcus aureus (SA) 
infection on the BBB in-vitro with a key emphasis on how cellular health and junctional 
integrity are affected. In order to pursue this, primary-derived human brain microvascular 
endothelial cells (HBMvEC) were used. Initial characterisation of these commercially 
acquired BBB cells confirmed the presence of endothelial-specific von Willebrand factor 
(vWF), a glycoprotein involved in vascular homeostasis. Moreover, both static and 
sheared HBMvEC were used for these experiments. In this respect, HBMvEC 
characteristically exhibited a “cobblestone” morphology under static conditions and an 
“elongated” morphology under sheared conditions. In subsequent studies, both static and 
sheared HBMvEC were routinely infected with SA using multiplicity of infection (MOI) 
as the unit of infectious co-culture. This MOI parameter enabled a reproducible infection 
range to injure HBMvEC. Firstly, it was of key importance to assess cell viability post-
infection with SA. Using flow cytometry analysis with an apoptosis assay kit, quantifiably 
measured and determined the level of cell viability of HBMvEC post-infection with fixed 
SA. Bacterial adherence assays were then used to investigate if SA had a particular 
preference of binding to endothelial cells under different physiological conditions (i.e. 
static versus shear). In this chapter, the impact of SA infection on HBMvEC morphology 
as well as junctional protein expression using Western blots and immunofluorescent 
staining was monitored. To investigate if SA was responsible for causing barrier 
permeabilization, a transendothelial permeability assay was also carried out on HBMvEC 
infected with fixed or live SA. Importantly, all investigations were conducted to compare 
the impact of HBMvEC characteristics of “fixed” versus “live” SA preparations, 
assessing the suitability of either preparation for in-vitro BBB/bacteria co-culture 
modelling. 
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3.1.1 Human Brain Microvascular Endothelial Cells 
3.1.1.1 Basic cell characterisation 
HBMvEC are an adherent cell line when grown in culture, growing in a “cobblestone” 
manner. However, when exposed for 24 hrs at 10 dynes/cm2 of applied shear, the cells 
elongate and morphologically align tightly together in the direction of flow, mimicking 
endothelial cells in-vivo [Figure 3.1A]. A common endothelial marker for HBMvEC is 
von Willebrand factor (vWF), a glycoprotein involved in vascular homeostasis [Figure 
3.1B]. 
 
 
 
Figure 3.1: Characterisation of primary-derived HBMvEC. Both static and sheared 
HBMvEC were routinely used for experimental procedures. (A) HBMvEC have a 
“cobblestone” morphology when static; when sheared the cells tighten and elongate 
aligning in the direction of flow. Images taken at 10x; (B) HBMvEC are positive for vWF 
(300 kDa), a key protein involved in haemostasis. Images are representative.  
A
B
HBMvEC- Static
(0 dynes/cm2)
HBMvEC- Shear
(10 dynes/cm2)
vWF
300 kDa marker
Ladder Lysate
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3.1.2 HBMvEC: SA infection - initial studies 
3.1.2.1 SA multiplicity of infection (MOI) range  
In order to determine a working range of “formaldehyde-fixed” and “live” SA infection 
with HBMvEC, batches of each strain (formaldehyde-fixed and live SA) were prepared 
and incubated with HBMvEC according to MOI concentrations, with subsequent 
monitoring of cell morphology and viability. The reasoning behind using formaldehyde-
fixed SA was due to the fact that live SA can produce toxins and rapidly utilise the 
nutrients within the media, thereby rendering it unsuitable to sustain HBMvEC growth 
beyond a few hrs. Formaldehyde-fixed and live Newman wild-type (NWT) SA strain (1 
ml of OD1= 1x108 CFU) was added to 2 mls of Roswell Park Memorial Institute (RPMI) 
media and left at 37°C for 2 hrs. A noticeable colour change was evident from the live 
SA infected well to the uninfected and fixed SA infected wells. RPMI media contains a 
phenol indicator, which turns yellow when the media becomes acidic, suggesting that live 
SA is utilising the media’s nutrients and releasing waste products, in contrast to the fixed 
SA strain [Figure 3.2A]. By “fixing” SA, it preserves the bacterial structure and external 
protein complement, whilst rendering the bacterium metabolically inactive, which helps 
to monitor endothelial-bacterial interactions without the rapidly limiting factors of 
nutrient deprivation and media spoilage. 
The main aim was to identify effective experimental bacterial doses that would not induce 
substantive compromise to cell viability. Fixed bacterial stocks were prepared and 
adjusted to OD600nm = 1.0, prior to storage at -20/-80°C. It was rapidly determined that 
the stored bacterial stocks did not perform as well as freshly prepared stocks (data not 
shown). As such, only freshly prepared stocks were used for experimental studies before 
being routinely disposed of.  
 
The strain of SA used for this research was Newman wild-type (NWT). All SA strains 
contain staphylococcal protein A (SpA), which aids in distinguishing SA from other 
staphylococcal strains. SpA is one of many virulence factors belonging to SA. For routine 
quality control purposes, a dot blot using protein A-specific antibodies was used to prove 
that the NWT-SA strain used in these infection studies contains this surface protein. OD1 
concentrations of live SA were spotted on a nitrocellulose blot before incubation with 
primary and secondary anti-sera for protein A detection using HRP substrate. A positive 
result is indicated when a black dot develops after chemiluminescent exposures [Figure 
3.2B].   
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In order to quantify the concentration of SA, BHI agar spread plates were streaked with 
serial dilutions of NWT-SA (OD600nm = 1.0). Initially, SA was grown overnight in BHI 
broth for approximately 17 hrs (stationary phase). The cells were centrifuged and adjusted 
to an OD600nm of 1 using a spectrophotometer. This OD 1 suspension was further diluted 
and 100 μl spread evenly on BHI agar until fully dried before being inverted and stored 
overnight at 37°C. The colony counts confirmed that an OD600nm = 1.0 equates to 1x108 
CFU/ml [Figure 3.2C]. 
Multiplicity of infection (MOI) was the infectious unit of measure used for this project. 
This unit refers to the ratio of bacterial cells to endothelial cells, for instance, a MOI 100 
would be to infect one endothelial cell with 100 bacterial cells. MOI 100 is calculated by 
multiplying the HBMvEC count with the required MOI value. Therefore, with 1x105 
HBMvEC, a concentration of 1x107 CFU of bacteria would need to be added to achieve 
a MOI 100 [Appendix A1]. 
 
 
Figure 3.2: Staphylococcus aureus control studies. (A) Media utilisation by SA in 
phenol-containing media; (B) Dot blot for SpA using NWT-SA, Lactococcus lactis WT 
(-SpA) and Lactococcus lactis (+SpA); (C) SA spread plates to calculate CFU/ml in an 
OD600nm =1.  
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3.1.2.2 Effects of SA infection on HBMvEC morphology 
For fixed SA studies, MOI concentrations of 0, 100, and 250 were routinely used for 24 
and 48 hrs infections. It was noted that different HBMvEC stocks (as provided by the 
manufacturer ACBRI 376) exhibited different degrees of sensitivity (as monitored by 
observation of gross cellular morphology) to infection with fixed SA. Both batches of 
cells were taken from the same donor tissue, but have different lot numbers. The old stock 
of HBMvEC exhibited substantive tolerance to fixed SA at MOI 250 for up to 48 hrs, 
whilst another more recently purchased stock exhibited obvious signs of cellular stress at 
this SA dose after just 24 hrs [Figure 3.3 & 3.4]. This points to batch-to-batch variation 
in the sensitivity of purchased HBMvEC to treatment with fixed SA, underpinning the 
importance of selecting suitable SA MOI dose and treatment time for a given HBMvEC 
batch. The earlier HBMvEC stock was used for the majority of experiments in this thesis. 
 
For live SA infection, much lower MOI concentrations and infection times were 
employed in comparison to fixed studies as indicated above. Initially, cells were infected 
for 2, 3, 4, 6, 8, and 24 hrs where it was noted after long-term infections (greater than 4 
hrs), that the HBMvEC monolayer was severely damaged. However, after 3 hrs infection 
with live SA the media showed early signs of succumbing to the bacterial load, although 
the HBMvEC remained intact. As a result of this preliminary experiments, it was 
determined that live infection studies with HBMvEC would be conducted for 3 hrs 
maximum using MOI concentrations of 0-100 [Figure 3.5]  
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Figure 3.3: HBMvEC infected with fixed SA (24 hrs). Confluent HBMvEC from two 
different stocks were infected with 4.8% formaldehyde-fixed SA (MOI 0-250, 24 hrs). 
Images (10x) are representative. 
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Figure 3.4: HBMvEC infected with fixed SA (48 hrs). Confluent HBMvEC from two 
different stocks were infected with 4.8% formaldehyde-fixed SA (MOI 0-250, 48 hrs). 
Images (10x) are representative. 
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Figure 3.5: HBMvEC infected with live SA. Confluent HBMvEC infected with live SA 
(MOI 0-100, 3 hrs). Images (10x) are representative. 
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3.1.2.3 Effects of SA on HBMvEC apoptosis/viability 
HBMvEC (old stock) were infected with fixed SA for 48 hrs. Cell counts were conducted 
before re-suspending the cell pellets in a cocktail mixture containing propidium iodide 
(PI), and Alexa Fluor 488 conjugated with annexin V. PI binds to the nucleic acid of 
apoptotic cells and annexin V binds to phosphatidylserine (PS), the latter relocating to the 
outer membrane of early-apoptotic cells. After 48 hrs infection, the majority of cells for 
all three MOI concentrations were found in the “live” quadrant. The complied results 
from triplicate experiments resulted in 93% viability for MOI 0, 88% for MOI 100 and 
84% for MOI 250, whilst necrosis levels were negligible, reading at 1% [Figure 3.6].  
  
Figure 3.6: Flow cytometry analysis of HBMvEC viability following infection with 
fixed SA. HBMvEC were infected with fixed SA (MOI 0-250) for 48 hrs. Percentage 
viability of cells post-infection stained with annexin V-FITC and PI is shown. 
Representative raw FACS scans of MOI 0, MOI 100 and MOI 250 (N=3). (*P< 0.05 
versus MOI 0). [* denotes ANOVA with post-hoc test. This statistical test was carried out for all 
subsequent figures in this chapter].  
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3.1.3 Staphylococcus aureus adherence properties 
3.1.3.1 SA adherence to static and sheared HBMvEC 
SA bacterial adherence is regulated by several virulence factors found on the outer leaflet 
of SA e.g. staphylococcal protein A (SpA). The growth cycle of SA and the accessory 
gene regulator (agr) have been shown to have a significant influence on SA adhesive 
properties (Pöhlmann-Dietze et al., 2000). It has been well established that SA is able to 
bind to epithelial cells, but only limited research has been conducted with endothelial 
cells (Kumar et al., 2004; Corrigan et al., 2009; Foster et al., 2014). In order to look at 
SA adhesive properties with endothelial cells, an adhesion assay was performed. Firstly, 
HBMvEC were infected with a range of MOI concentrations to determine if SA could 
bind to the cells [Figure 3.7A]. The results from this showed that SA bound to HBMvEC 
in a dose-dependent manner with increasing bacterial adhesion as MOI concentrations 
increased peaking at MOI 500. Next, to monitor the effects of SA adherence under both 
static and sheared conditions, three different endothelial cell lines were employed: bovine 
aortic endothelial cells (BAEC), human aortic endothelial cells (HAEC), and HBMvEC. 
Cells were comparably infected with either fixed or live SA. The results showed SA 
adhered to all three endothelial cell lines in equal quantities regardless of their 
static/sheared state [Figure 3.7B].  
 
Figure 3.7: SA adhesion to endothelial cells. (A) Live SA adhesion to HBMvEC using 
MOI 0-500; (B) Static and sheared HAEC, HBMvEC and BAEC infected with SYBR 
stained fixed and live SA (MOI 100, 1 hr) (N=3). Bound bacteria measured using a 
fluorescent plate reader.  
Fixed SA Live SA
A
B
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3.1.4 Tight and adheren junction protein expression 
3.1.4.1 Impact of SA infection on HBMvEC TJ and AJ protein expression 
The junctional proteins of the BBB located at the endothelial cell-cell border play an 
important role in regulating the paracellular pathway of the BBB, as well as maintaining 
cerebral homeostasis for neuronal networking to perform optimally. When these 
junctional protein complexes are disassembled by injury or infection, the paracellular 
route is compromised and potentially offers an easy means for pathogens to penetrate the 
BBB without having to cross the BBB transcellularly. Total protein lysate samples were 
harvested post-infection with either fixed or live SA. Preliminary studies employed 
“fixed” SA infection with HBMvEC for up to 24 hrs using 0-1000 MOI (data not shown). 
Results showed that only at very high MOI concentrations of SA were TJ/AJ protein 
expression compromised- most noticeably for VE-cadherin and claudin-5. From this 
result, it was decided to increase the incubation time for a further 24 hrs to 48 hrs 
infection, and also to employ a lower dose range of MOI 0-250. Using this method, TJ/AJ 
protein expression decreased dose-dependently with MOI, as seen for VE-cadherin and 
ZO-1 (approximately 2-fold decreases) and claudin-5 (approximately 3-fold decreases) 
[Figure 3.8]. Immunocytochemical staining showed noticeable discontinuous localization 
of ZO-1 (green) at the periphery of HBMvEC following infection with MOI 100 NWT-
fixed SA when compared to MOI 0 (uninfected control). Similarly, the rhodamine 
phalloidin stain (red) for filamentous actin (F-actin) was used to give an indication of cell 
health and function. The uninfected samples displayed a solid cortical stain around the 
outer membrane, whilst a disrupted cortical stain was seen in the infected cells [Figure 
3.9]. 
In further experiments, the live SA: HBMvEC co-infection model was implemented. The 
junctional proteins tested showed minor expressional decreases at the higher MOI 
concentrations of 25-100 [Figure 3.10]. In addition to the live infection studies, the 
secreted virulence factors produced by SA were also tested for its ability to cause 
HBMvEC interendothelial junctional protein downregulation. Live SA was incubated 
with HBMvEC media for 12 hrs. The SA-conditioned media was then incubated with 
HBMvEC for 36 hrs prior to harvesting total cell protein for VE-cadherin expression 
[Figure 3.11]. VE-cadherin was noticeably downregulated following infection with the 
conditioned media (MOI 10-100).  
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Figure 3.8: Effect of fixed SA infection (dose-dependent) on HBMvEC junctional 
protein expression. (A) Total protein lysates harvested from HBMvEC infected with 
fixed NWT-SA (MOI 0-250, 48 hrs). VE-cadherin (130-140kDa), claudin-5 (23kDa), 
ZO-1 (210-225kDa), occludin (68kDa) and β-actin (42kDa). All gels are representative 
(N=3); (B) Densitometry analysis of Western blot. (*P<0.05 versus MOI 0; δP<0.05). [* 
denotes ANOVA with post-hoc test and δ denotes pairwise comparisons using t-tests. Both statistical tests 
were carried out for all subsequent figures in this chapter]. 
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Figure 3.9: Effect of fixed SA on ZO-1 junctional protein. Fresh stock of HBMvEC 
were seeded onto attachment factor coated coverslips and infected with fixed NWT-SA 
(MOI 0-100, 24 hrs). The cells were stained for the tight junction protein ZO-1 and 
counter stained with rhodamine phalloidin (filamentous actin) and 4’, 6-Diamidino-2-
Phenylindole (DAPI) nuclei stain. Images taken at 60x. 
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Figure 3.10: Effect of live SA infection (dose-dependent) on HBMvEC junctional 
protein expression. (A) Total protein lysates harvested from HBMvEC infected with live 
NWT-SA (MOI 0-100, 3 hrs). All gels are representative (N=3); (B) Densitometry 
analysis of Western blot. (*P<0.05 versus MOI 0; δP<0.05). 
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Figure 3.11: Effect of live SA pre-conditioned media on HBMvEC adherens junction 
protein VE-cadherin. (A) Total protein lysates harvested from HBMvEC treated with 
media pre-conditioned with live NWT-SA for 12 hrs. All gels are representative (N=3); 
(B) Densitometry analysis of Western blots. (*P<0.05 versus MOI 0; δP<0.05). 
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3.1.5 HBMvEC permeabilization 
3.1.5.1 Impact of SA infection on HBMvEC paracellular permeability 
In order to assess the impact of SA infection on paracellular permeability of HBMvEC, a 
transendothelial permeability assay was carried out. Static HBMvEC were allowed to 
grow to confluency in transwell inserts before being infected with fixed SA (MOI 0-250) 
or live SA (MOI 0-100). Post-infection period, FITC-dextran (40 kDa) diffusion across 
the HBMvEC monolayer was used to evaluate the extent of HBMvEC permeabilization. 
Barrier permeability is expressed as percentage transendothelial passage of FITC-dextran 
across the cell monolayer, expressed as % transendothelial exchange (% TEE) [Figure 
3.12]. 
HBMvEC infected with fixed NWT-SA (for 24 hrs) and live NWT-SA (for 3 hrs) were 
monitored for permeability changes. HBMvEC infected with fixed NWT-SA resulted in 
time- and dose-dependent increases in barrier permeability, with a 1.5 fold increase seen 
between MOI 0 and 250 at 180 min time-point [Figure 3.13]. Similarly, time- and dose-
dependent increases in permeability were recorded after live NWT-SA infection with a 
1.65 fold-increase between MOI 0 and MOI 100 [Figure 3.14]. The pro-inflammatory 
cytokine TNF-α (100 ng/ml) was used as a positive control (data not shown). 
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Figure 3.12: HBMvEC permeability – static versus sheared HBMvEC. (A1) Static or 
sheared HBMvEC seeded (4 x105 cells) onto 0.4μm porous transwell membrane and left 
to grow to confluency; (A2) HBMvEC treated with fixed or live SA; (A3) FITC-dextran 
added to apical side of insert (t=0) with sample removal from basolateral (subluminal) 
compartment every 30 mins for 3 hrs and; (A4) FITC-dextran permeates through to the 
subluminal space over time indicative of barrier permeability measured as % TEE FD40 
dextran; (B) Static and sheared (10 dynes/cm2 for 24 hrs) HBMvEC were allowed grow 
to confluency prior to addition of FITC-dextran (40 kDa) for permeability assessment. 
Permeability was monitored every 30 mins over a 3-hr assay period.  
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Figure 3.13: Effect of fixed SA infection (dose-dependent) on HBMvEC 
permeability. (A) Static HBMvEC were seeded onto 0.4 μm transwell inserts (4x105 
cells) and left to grow to confluency prior to infecting with fixed NWT-SA (MOI 0-250, 
24 hrs). Addition of FITC-dextran (40 kDa) post-infection was used to assess barrier 
permeabilization. Permeability was monitored every 30 mins over a 3-hr assay period; 
(B) Permeability expressed as % TEE FD40 dextran specifically at the 180 min time-
point. (N=3)(*P<0.05 versus MOI 0;δ P<0.05). 
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Figure 3.14: Effect of live SA infection (dose-dependent) on HBMvEC permeability. 
(A) Static HBMvEC were seeded onto 0.4 μm transwell inserts (4x105 cells) and left to 
grow to confluency prior to infecting with live NWT-SA (MOI 0-100, 3 hrs). Addition of 
FITC-dextran (40 kDa) post-infection was used to assess barrier permeabilization. 
Permeability was monitored every 30 mins over a 3-hr assay period; (B) Permeability 
expressed as % TEE FD40 dextran specifically at the 180 min time-point. (N=3) (*P<0.05 
versus MOI 0; δP<0.05). 
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3.2 Discussion 
The main objective of this chapter was to develop and characterise an in-vitro co-culture 
infection model using human cerebrovascular endothelial cells (HBMvEC) infected with 
Staphylococcus aureus (SA), to better understand the bacterium’s effect(s) on BBB 
phenotype. In doing so, comparing and contrasting the effects of “formaldehyde-fixed” 
and “live” NWT-SA on HBMvEC cultures. 
SA is a widespread gram-positive bacterium capable of many infections- ranging from 
skin infections to life-threatening sepsis and meningitis. If left untreated, SA sepsis has a 
mortality rate of over 80%. Even though SA is not typically known for causing BBB-
related diseases such as cerebral meningitis in comparison to other gram-positive bacteria 
such as Streptococcus pneumoniae and Streptococcus agalactiae (or Group B 
Streptococcus), it still has a mortality rate ranging from 14-77% (Sheen et al., 2010; Zumo 
et al., 2013; Conrad Stöppler; Shiel, 2015). Other SA-mediated BBB pathologies include: 
cerebritis, a focal inflammation of the brain parenchyma, an event which precedes abscess 
formation; encephalitis, where the brain parenchyma is inflamed; and also bacteraemia. 
It is imperative that new treatment options are found against this pathogen due to its 
capability of avoiding antibacterial treatment, as with MRSA and vancomycin-resistant 
SA (VRSA) (Hiramatsu, 2001). In this respect, it is important to design a robust in-vitro 
bacterial infection model to help delineate SA infection and cellular damage mechanisms 
within the microvascular endothelium. Such a model could prove useful in identifying 
new therapeutic targets relevant to SA-mediated pathologies, and for testing new 
translational drug products designed to kill SA or render it susceptible to antibacterial 
drugs already available. 
In order to design this infection model, it was important to first establish a reproducible 
infection dose range using multiplicity of infection (MOI), and to subsequently identify 
for experimental purposes a dose range that the cells could tolerate. Using phase-contrast 
microscopic imaging and flow cytometry, it was determined that HBMvEC could be 
exposed to “fixed” SA at MOI 250 for up to 48 hrs without causing significant challenge 
to cell morphology and viability. It was noted however that differences in HBMvEC 
source batch (and possibly duration of cell storage in liquid nitrogen following purchase) 
may contribute to variable HBMvEC sensitivity to SA infection, necessitating routine 
optimization of SA dose and infection time between HBMvEC batches. In a related study, 
Matussek et al. (2005) performed similar flow cytometry experiments looking 
specifically at how internalised SA impacts on human umbilical vein endothelial cells 
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(HUVEC) cell viability. The infection method employed differs as the BAEC were 
infected for just 1 hr with stationary phase live SA (clinical isolate from dialysis fluid), 
before the media was changed and the cells left for further incubation with cell harvesting 
at 8, 18 and 42 hrs. The authors did not see any change in cell viability (Strindhall et al., 
2002; Matussek et al., 2005).  
It is important to note that formaldehyde-fixing of SA renders the bacteria metabolically 
inactive, whilst retaining an intact bacterial cell wall and surface protein complement. 
Indeed, Claro et al. (2011) previously demonstrated how the important surface proteins 
are still intact post-fixation as formaldehyde-fixing SA does not affect staphylococcal 
protein A (SpA) expression (Claro et al., 2011). Importantly, extended incubation of 
HBMvEC with fixed bacterial preparations is made possible and practicable due to 
prevention of bacterial growth and media consumption.  
By contrast, incubations with “live” SA could only take place over a short period of time 
(up to 3 hrs) using considerably lower MOI concentrations than previously used for fixed 
SA infection. After testing a range of bacterial doses (up to MOI 100) for various infection 
times (up to 24 hrs), the destructive and impractical nature of using live bacteria over 
fixed became apparent. This became clear when fixed and live SA were incubated with 
supplemented RPMI-1640 media at 37°C for 2 hrs. The live bacteria rapidly utilised the 
media resulting in a colour change and cloudiness, whereas the fixed bacterium did not, 
thereby confirming its inactivity. The media colour change from live SA is likely the 
result of virulence factor production with an increasing bacterial population (generation 
time every 30 mins) and rapid media utilisation (Domingue et al., 1996). An infection 
time of 3 hrs using an MOI concentration up to 100, was decided upon for our live 
experimental conditions, as HBMvEC remained intact on the cell culture dishes without 
succumbing to cell death. 
The first key step in bacterial survival during infection is adherence to the host cell 
surface. In order to explore this concept, HBMvEC were infected with a range of SA 
concentrations (MOI 0-500), fluorescently stained with SYBR Green II. SA bound dose-
dependently up to MOI 300, with higher doses showing no difference in levels of SA 
attachment, suggesting that SA has reached its maximum binding capacity. As such, SA 
dose ranges of <MOI 300 were routinely employed for these studies. In order to examine 
the capabilities of SA binding to other endothelial cell types, two additional endothelial 
cell lines, BAECs and HAECs were used alongside HBMvEC to assess SA adhesion.   
106 
 
Moreover, the effect of hemodynamic cell phenotype (either static or sheared) on SA 
adhesion within these three different cell lines was also tested. Endothelial cells are an 
adherent cell line that grow in a disorganised “cobble-stone” manner in-vitro. However, 
when exposed to chronic fluid shear stress, the natural in-vivo environment of the 
endothelium, cells exhibit a more distinct morphology, aligning tightly together in the 
direction of flow. There are different levels of haemodynamic shear stress across different 
vascular beds. A shear level of 10 dynes/cm2 was used to mimic physiologic shear flow 
consistent with microvascular beds (Dardik et al., 2005; Colgan et al., 2007; Walsh et al., 
2011). Given the known atheroprotective influence of laminar shear stress on endothelial 
cells, we anticipated that sheared cells would be more resistant to SA adherence. 
Unexpectedly, we observed comparable levels of fixed and live bacterial adhesion with 
all three cell lines under both conditions (static and sheared). In similar studies, Reddy & 
Ross (2001) performed two adhesion assays (stopped flow and dynamic flow) using 
BAEC infected with SA. They found that high levels of FITC-stained SA adhered to pre-
sheared BAEC using a stopped-flow assay, which involved the perfusion of the bacterium 
over the BAEC for 5 mins before allowing the bacteria to adhere for a further 30 mins 
under static conditions prior to washing. However, when a dynamic-flow assay was 
performed, where FITC-stained SA was perfused over pre-sheared BAEC for 10 mins 
prior to washing immediately afterwards, they found no SA adhered to the endothelial 
cells (Reddy & Ross, 2001). Interestingly, a more recent study by Claes et al. (2014) 
found that Newman Wild-Type (NWT) SA has a high affinity for both immobilised vWF 
(glass slides coated with vWF) and vWF found on endothelial cells (i.e. HUVEC), under 
both static and sheared conditions, with a noticeable increase in adhesion with increasing 
flow rates (Claes et al., 2014). Unlike Reddy and Ross, the Claes group activated HUVEC 
(using 0.1 mM calcium ionophore, which stimulates nitric oxide production) prior to 
perfusing fluorescently stained SA over the cells, which in turn increased SA adhesion. 
In other studies, Edwards et al. (2012) showed that the Eap protein is involved in bacterial 
attachment and invasion of host cells (Edwards et al., 2012), whilst other research groups 
have discovered other alternative SA surface proteins that enable endothelial adherence. 
Boveri et al. (2006) and Sheen et al. (2010) discovered that lipoteichoic acid (LTA) 
attaches to bovine brain capillary endothelial cells (BBCECs) in-vitro and induces 
permeabilization (Boveri et al., 2006; Sheen et al., 2010). It can be suggested from the 
performed studies, that NWT-SA (both fixed and live strains) have similar adhesive 
properties when tested against three distinct endothelial cell lines, regardless of their 
phenotypic characteristics (static or sheared) or species origin. This observation supports 
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the potential applicability of fixed SA infection models as valid surrogates for live SA 
models in endothelial infection studies. 
Following on from the previous experiments, the ability of the “fixed” and “live” 
infection models to adversely affect the major interendothelial junctional proteins of the 
BBB, and whether or not this leads to barrier dysfunction was tested. In response to fixed 
SA infection for 48 hrs, protein lysate analysis by Western blotting subsequently 
confirmed a 2-fold decrease in VE-cadherin and ZO-1 levels, whilst a 3-fold decrease 
was recorded for claudin-5 levels. However, the opposite was seen for the tight junction 
protein occludin, which dose-dependently increased with MOI concentrations. Some 
pathogenic studies have shown that tight junction proteins are required for internalisation. 
For instance, the Hepatitis C virus and Vibrio cholerae have been shown to require 
occludin for infection (Ploss et al., 2009; Zihni et al., 2014). Seemingly, the reovirus and 
coxsackievirus both require occludin for internalisation (Guttman & Finlay, 2009). One 
could speculate that SA is operating in a similar manner by utilising occludin in the 
paracellular space to initiate SA internalisation and traversal, and thus increasing its 
expression. 
In similar experiments using live SA infection for 3 hrs, it was noted only minimal 
decreases in junctional protein expression following SA infection. The reason for this 
may simply be that 3 hrs was not long enough to induce substantial junctional protein 
disruption or to visualise changes in protein-expression levels by Western blotting.  
ZO-1 is a cytosolic cytoskeletal-associated tight junction protein located at the periphery 
of healthy HBMvEC, which helps to coordinate assembly of adherens and tight junctions 
that create the BBB. However, upon infection of HBMvEC with fixed SA, ZO-1 
immunolocalization, as monitored by fluorescence microscopy, becomes noticeably more 
discontinuous at the endothelial cell-cell border. Some SA virulence factors are known to 
cause actin-cytoskeleton realignment, and in doing so, altering ZO-1 conformation. 
Similar results were seen by Malik et al. (2015) for example, who reported discontinuous 
localization of ZO-1 at the border of epithelial cells after SA infection in-vitro (Malik et 
al., 2015). A paper by Sheen et al. investigated the effects of SA on the cell cytoskeleton. 
The group pre-treated immortalised HBMvEC with cytochalasin D, an actin-cytoskeleton 
disrupting agent, before infecting with SA. This resulted in a decrease in SA invasion in 
comparison to the untreated controls, suggesting that SA can potentially modulate 
cytoskeletal integrity (Sheen et al., 2010).   
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In order to further explore the relevance of SA virulence factors to junctional disruption 
using this infection model, HBMvEC media pre-conditioned by live SA (i.e. to contain 
the various secreted virulence factors that SA possesses) was incubated with HBMvEC 
for 36 hrs prior to harvesting protein to examine junctional protein expression. It was seen 
that the SA-conditioned media resulted in a significant decrease in the expression of 
adherens junction (AJ) VE-cadherin, which typically provides cell-cell anchoring and 
stability to the BBB. Whilst this experiment indicates that components released from SA 
have the potential to cause junctional protein dysregulation, it has previously been 
reported that a direct interaction with the host cell surface is pivotal to initiating and 
establishing SA infection (Vriesema et al., 2000). In conclusion, the data indicates that 
SA can cause downregulation of interendothelial junctional proteins, either via direct cell 
contact or through release of bacterial virulence factors, causing the loosening of 
interendothelial connections. This would undoubtedly contribute to BBB 
permeabilization and may also potentially facilitate SA traversal across the endothelial 
monolayer.  
In order to examine the implications of bacterial infection and junctional protein 
decreases in terms of the cell monolayer, barrier permeability assays were also performed. 
Fixed NWT-SA infection caused a dose-dependent increase in permeabilization of 
HBMvEC monolayers. When the permeability assay was repeated this time using live SA 
for 3 hrs infection, a 4.9% increase in permeability was recorded at the highest bacterial 
concentration used. A potential reason for this may be due to the SA dose range used or 
the length of infection of only 3 hrs, which may not be long enough for SA to release its 
cytolytic toxins to permeabilize the HBMvEC membrane. A paper by Pai et al. (2012) 
carried out similar barrier assays infecting pulmonary microvessel endothelial cells 
(PMEC) with the SA virulence factor, LTA, for 24 hrs. They observed a considerable 
increase in barrier permeability, which they attributed to TLR2 activation (Pai et al., 
2012). In conclusion, the HBMvEC barrier assay confirms that SA has the capabilities of 
inducing increased paracellular permeability after infection with fixed SA and, to a lesser 
extent with live SA. 
From this chapter it has been seen that SA (both fixed and live) is capable of disrupting 
HBMvEC in-vitro. Summary of results shown in Table 3.1 for NWT-SA and B. oleronius 
HBMvEC infections. It is confirmed that formaldehyde-fixed SA can be used as a SA 
infection model, enabling greater control of infection dose and time in contrast to live SA 
infections.   
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NWT-SA 
Experiments Fixed Live 
Infection 
MOI 0-250 
(48 hrs) 
MOI 0-100 
(3 hrs) 
Adhesion assay 
SA-bound to 
Static/Shear HB 
 MOI 0-500 ↑ 
 SA-bound to 
Static/Shear HB 
Interendothelial  
junction proteins 
VE-cadherin  ↓ 
Claudin-5       ↓ 
ZO-1               ↓ 
Occludin        ↑ 
VE-cadherin↓ 
Claudin-5     ↓ 
ZO-1             ↓ 
SA-conditioned 
media 
NP VE-cadherin ↓ 
Barrier 
permeability 
MOI 0-250↑ MOI 0-100 ↑ 
Table 3.1: Summary of Chapter 3 results. 
(Key: ↑ Increase; ↓ Decrease; NC, no change; NP, not performed; HB, HBMvEC). 
 
With evidence of SA adhesion to HBMvEC, along with the downregulation of important 
junctional proteins of the BBB, in conjunction with increased barrier permeabilization, it 
is likely pro-inflammatory cascades are being initiated. Research by Rochfort et al. (2014) 
has shown that pro-inflammatory cytokine treatment of HBMvEC leads to 
downregulation of interendothelial junction proteins and concomitant permeabilization in 
parallel with increased reactive oxygen species (ROS) production (Rochfort et al., 2014). 
Therefore, for the next chapter it was decided to examine the pro-inflammatory 
implications of SA infection in HBMvEC with specific focus on NF-κB activation, 
production of inflammatory cytokines, ROS activation and endothelial microparticle 
(EMP) release.  
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Chapter 4 
Investigation of the pro-
inflammatory effects of 
Staphylococcus aureus infection on 
HBMvEC 
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4.1 Introduction 
The human body is equipped with two host immune responses. The first, called the innate 
immune response, recognises any harmful pathogens present within the host. This 
recognition is achieved by pattern recognition receptors (PRRs) which include toll-like 
receptors (TLRs) and nucleotide-binding oligomerization domains (NODs) (Skaug et al., 
2009; Xie et al., 2012; Napetschnig & Wu, 2013). Pathogen recognition typically triggers 
the activation of the transcription factor nuclear factor kappa B (NF-κB), which 
translocates to the nucleus, activating the production of several cytokines and 
chemokines, whilst also prompting recruitment of leukocytes to the site of infection as a 
means to control and limit the extent of the infection (Gilmore, 2006). However, if this 
initial response fails, the second immune response, called the adaptive or acquired 
immune response, is activated and entails the use of more specialised cells that are capable 
of generating and restoring immunological memory in the form of antibodies (Janeway 
et al., 2001b).  
The objective for this chapter was to investigate and fully characterize the inflammatory 
cascade initiated by SA infection at the BBB, looking at various inflammatory indices. 
HBMvEC routinely used for this study were static (unsheared) cells. Firstly, the activation 
of the transcription factor NF-κB was monitored, which is of key importance in activating 
the inflammatory response. Both dose- and time-dependent studies were examined by 
infecting HBMvEC with fixed SA (MOI 0-250) for up to 48 hrs and live SA (MOI 0-100) 
for up to 3 hrs. Protein lysate samples were harvested post-infection and the activation of 
NF-κB via phosphorylation of its p65 subunit (at serine 536) was monitored. Live SA-
conditioned media studies were also carried out to determine if SA secreted proteins 
and/or toxins could activate an inflammatory response via NF-κB activation. Next, 
enzyme linked immunosorbent assays (ELISA) were used to quantifiably measure the 
production of secreted cytokines with a main emphasis on IL-6, TNF-α and 
thrombomodulin release into the cell culture media during infection. A cytokine array 
panel was also used to monitor a broader range of inflammatory targets activated during 
SA infection, by comparing uninfected media samples versus infected (fixed and live SA) 
from HBMvEC. A key mitigating step of the inflammatory response is the activation of 
reactive oxygen species (ROS) (Alfadda & Sallam, 2012; Rigby & DeLeo, 2012; Mittal 
et al., 2014). Following SA infection of HBMvEC, the presence of ROS was tested using 
a stain for superoxide radical formation called dihydroethidium (DHE), in conjunction 
with flow cytometry. Finally, in recent years, much interest has been shown in the release 
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of “endothelial microparticles” (EMP) by activated or apoptotic endothelial cells (Berezin 
et al., 2015). Using our bacterial infection models, we wanted to examine if EMP were 
released upon SA infection. As with ROS analysis, this was also monitored by flow 
cytometry. 
 
4.1.1 NF-κB activation 
4.1.1.1 Effects of staphylococcal infection on NF-κB activation in HBMvEC 
Phospho-NF-κB (Serine 536) antibody was initially tested with HBMvEC treated with 
100 ng/ml of TNF-α, a known activator (positive control) of the NF-κB pathway. Protein 
lysates were harvested after short term (0-4 hrs) and long-term (24-48 hrs) treatments. 
There was an immediate activation of NF-κB after just 15 mins of TNF-α treatment with 
a mild decrease seen with prolonged treatments. However, even at 48 hrs post-treatment, 
NF-κB activation was still significantly elevated above that of the untreated control 
[Figure 4.1]. 
The effect of “fixed” NWT-SA infection on NF-κB activation was also tested. Both time- 
and dose-dependency studies were conducted. At a single dose of MOI 250, NF-κB 
induction was recorded after just 1 hr infection, which increased time-dependently from 
3 hrs with maximum activation after 48 hrs [Figure 4.2]. When the effect of SA was tested 
over a range of MOI doses (0-250), dose-dependent NF-κB induction was observed after 
48 hrs infection [Figure 4.3A]. In order to determine the lowest MOI at which NF-κB was 
initiated, an MOI low dose range of 0-100 was subsequently employed [Figure 4.3B]. An 
MOI of 10 showed an initial 2 fold-increase over MOI 0, whilst MOI 100 showed a 3 
fold-increase. 
Similar infection assays were applied to examine “live” NWT-SA infection on HBMvEC. 
Using a single dose of MOI 100 live SA, a gradual incline of NF-κB activation with 
maximum expression after 3 hrs [Figure 4.4]. Interestingly, equivalent levels of NF-κB 
activation were observed over the MOI 5-100 live SA dose range during 3 hrs infection 
[Figure 4.5]. HBMvEC media was pre-conditioned with live SA for 12 hrs prior to adding 
to HBMvEC cells for 36 hrs (with the bacterial cells removed). Protein lysates harvested 
recorded NF-κB activation by Western blotting using an MOI dose range of 0-100, with 
maximum expression recorded at MOI 50 [Figure 4.6].  
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Figure 4.1: TNF-α activation of phospho-NF-κB in HBMvEC. (A) Total protein 
lysates harvested from HBMvEC treated with 100 ng/ml TNF-α (0-48 hrs). Blots probed 
for phosphorylation of NF-κB (Serine 536). All gels are representative (N=3); (B) 
Densitometry analysis of Western blot. (*P<0.05 versus 0 mins; δP<0.05). [* denotes 
ANOVA with post-hoc test and δ denotes pairwise comparisons using t-tests. Both statistical tests were 
carried out for all subsequent figures in this chapter]. 
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Figure 4.2: Effect of fixed SA infection (time-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC infected with fixed SA (MOI 250, 0-48 
hrs). Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative 
(N=3); (B) Densitometry analysis of Western blot. (*P<0.05 versus 0 mins; δP<0.05).  
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Figure 4.3: Effect of fixed SA infection (dose-dependent) on NF-κB activation. Total 
protein lysates harvested from HBMvEC infected with fixed SA for 48 hrs; (A) High dose 
(MOI 0-250) (N=4); (B) Low dose (MOI 0-100) (N=3). Blots probed for phosphorylation 
of NF-κB (Serine 536). All gels are representative. Densitometry analysis of Western blot 
(*P<0.05 versus 0 mins; δP<0.05).  
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Figure 4.4: Effect of live SA infection (time-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC treated with live SA (MOI 100, 3 hrs). 
Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative 
(N=4); (B) Densitometry analysis of Western blot (*P<0.05 versus 0 min; δP<0.05). 
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Figure 4.5: Effect of live SA infection (dose-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC treated with live SA (MOI 0-100, 3 hrs). 
Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative 
(N=3); (B) Densitometry analysis of Western blot (δP<0.05). 
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Figure 4.6: Effect of live SA pre-conditioned media on HBMvEC NF-κB activation. 
(A) Total protein lysates harvested after 36 hrs from HBMvEC treated with media pre-
conditioned with live SA for 12 hrs. Protein lysates were probed for phosphorylation of 
NF-κB (Serine 536). All gels are representative (N=3); (B) Densitometry analysis of 
Western blots (δP<0.05). 
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4.1.2 Secreted pro- and anti-inflammatory mediators  
4.1.2.1 Effects of staphylococcal infection on cytokine/chemokine release in HBMvEC 
As with any infection or injury, pro-inflammatory cytokine and chemokine release is an 
important step for host immune protection as they are important facilitators of attracting 
innate and adaptive immune cells to the source of infection, as well as communicating 
with other immune cells to stimulate an inflammatory response (Zhang & An, 2007; 
Ramesh et al., 2013). Enzyme linked immunosorbent assays (ELISA) were used to 
examine the release of pro- and anti-inflammatory cytokines following SA infection with 
HBMvEC. Specifically, the harvested HBMvEC media was used to monitor IL-6, TNF-
α and thrombomodulin (TM) release by ELISA. 
IL-6 is a member of the interleukin family, a class of cytokine with chemotactic activities 
(Zhang & An, 2007). It plays an important role in switching from the innate immune 
response to the acquired immune response, whilst also upregulating cell adhesion 
molecules e.g. ICAM-1 on endothelial cells to increase leukocyte binding and diapedesis 
(Scheller et al., 2011). TNF-α is one of the more well-known inflammatory markers of 
the immune response produced by activated macrophages and T-lymphocytes. Upon 
TNF-α binding to its known receptor (TNFR1 or TNFR2), NF-κB activation may occur. 
TNF-α is required to overcome infectious agents; however, excessive production can be 
dangerous to the host resulting in increased inflammatory mediator production and tissue 
damage (Bradley, 2008). Unlike IL-6 and TNF-α, TM is not a cytokine. However, as a 
membrane-bound glycoprotein present on vascular endothelial cells (including the brain 
microvascular endothelium), it has established itself as an important regulator of vessel 
homeostasis, thus establishing anti-coagulant, anti-fibrinolytic and anti-inflammatory 
properties, which are imperative to endothelial function and integrity (Rochfort & 
Cummins, 2014). Upon endothelial activation via pro-inflammatory cytokines and 
chemokines following an injury or infection, causes a decrease in endothelial TM 
production, in conjunction with elevated soluble TM (sTM) release (Martin et al., 2013 
& 2014). As a result, elevated levels of sTM found in circulation have become a key 
feature of endothelial injury, which is why sTM was included for testing alongside IL-6 
and TNF-α following SA infection of HBMvEC (Martin et al., 2013; Rochfort & 
Cummins, 2014).  
Harvested media from HBMvEC infected for 24-72 hrs with fixed NWT-SA (MOI 0-
250) was used to test for IL-6, TNF-α and TM release. The IL-6 ELISA demonstrated 
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both a time- and dose-dependent increase in IL-6 release in response to SA infection 
[Figure 4.7]. Similarly, harvested media tested for TNF-α demonstrated both a time- and 
dose-dependent increase with maximum release seen at 72 hrs [Figure 4.8]. Likewise, the 
TM ELISA also displayed time- and dose-dependent increases over 24-72 hrs infection 
[Figure 4.9]. Finally, a TNF-α ELISA assay was also carried out using media samples 
harvested from a time-dependent study with live NWT-SA [Figure 4.10]. The results 
showed TNF-α secretion increased even after 15 mins of infection, whilst maintaining 
this elevated secretion for up to 3 hrs.  
 
 
 
Figure 4.7: IL-6 secretion following fixed SA infection. HBMvEC media was harvested 
following infection with fixed NWT-SA (MOI 0-250; 24, 48 and 72 hrs). Media was 
tested for IL-6 secretion using ELISA analysis. (N=3) (*P<0.05 versus MOI 0; δP<0.05).  
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Figure 4.8: TNF-α secretion following fixed SA infection. HBMvEC media was 
harvested following infection with fixed NWT-SA (MOI 0-250; 24, 48 and 72 hrs). Media 
was tested for TNF-α secretion using ELISA analysis. (N=3) (*P<0.05 versus MOI 0; 
δP<0.05). 
 
 
Figure 4.9: TM secretion following fixed SA infection. HBMvEC media was harvested 
following infection with fixed NWT-SA (MOI 0-250; 24, 48 and 72 hrs). Media was 
tested for TM secretion using ELISA analysis. (N=3) (*P<0.05 versus MOI 0; δP<0.05).  
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Figure 4.10: TNF-α secretion following live SA infection. Harvested HBMvEC media 
infected with live NWT-SA (MOI 100, 0-3 hrs) testing for TNF-α secretion using ELISA 
analysis. Results normalised to 100,000 cells. (N=3) (*P<0.05 versus 0 mins; δP<0.05). 
 
In order to gain a more global view of HBMvEC cytokine “secretome” in response to SA 
infection, a human cytokine array panel (Proteome Profiler TM) from R&D Systems was 
purchased. Pre-spotted nitrocellulose membranes with 36 chemokine/cytokines 
antibodies were used. Fresh media samples were harvested from HBMvEC infected for 
48 hrs with fixed NWT-SA at MOI 0 and MOI 250 and from HBMvEC infected with live 
NWT-SA MOI 0 and MOI 100 for 3 and 12 hrs infections. Six upregulated proteins were 
found on the fixed MOI 250 membrane in comparison to the uninfected MOI 0 controls. 
They included regulated upon activation normal T cell expressed and presumably 
secreted (RANTES), interferon gamma-induced protein-10 (IP-10), granulocyte-colony 
stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-
CSF), monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) with trace 
levels of soluble intercellular adhesion molecule-1 (sICAM-1) in the MOI 250 array 
[Figure 4.11]. Refer to Appendix A2 for further details of the cytokine array panel. The 
result from the three independent cytokine arrays are shown in Figures A1-A3. There was 
no major cytokine expressional changes seen between the live SA infection MOI 0 and 
MOI 100 membranes after 3 hrs infection. However, trace levels of IL-13 and IL-23 were 
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noted [Figure 4.12]. It was first thought that the initial 3 hrs infection with live SA was 
not long enough to generate a cytokine and chemokine response. To examine this, the live 
infection study was therefore extended for 12 hrs [Figure 4.13]. As with the live SA 3 hrs 
study, there was no cytokine expressional differences between the infected and uninfected 
membrane even after 12 hrs infection. In the absence of any cytokine release changes 
from the 3 and 12 hrs live SA infections, it was decided to terminate the experiment, due 
to the very high expense of running these arrays. Reference spots (labelled as Ref) are 
included on the cytokine arrays to locate and identify the pre-spotted antibodies using an 
overlay (provided with the array kit). They are also used to validate that the blot has been 
incubated with streptavidin-HRP.  
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Figure 4.11: Cytokine array panel for MOI fixed NWT-SA infection. HBMvEC 
media was harvested following infection with fixed SA (MOI 0 and MOI 250, 48 hrs) 
and analysed for cytokine release. (A) Cytokine array membranes representing each MOI; 
(B) Densitometric analysis of the cytokine array for each MOI for qualitative use only 
(N=3). (Ref, validation for streptavidin-HRP).   
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Figure 4.12: Cytokine array panel for MOI live NWT-SA (3 hrs). HBMvEC media 
was harvested following infection with live SA (MOI 0 and MOI 100, 3 hrs) and analysed 
for cytokine release. (A) Cytokine array membranes representing each MOI; (B) 
Densitometric analysis of the cytokine array for each MOI for qualitative use only (N=1). 
(Ref, validation for streptavidin-HRP).  
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Figure 4.13: Cytokine array panel for MOI live NWT-SA (12 hrs). HBMvEC media 
was harvested following infection with live SA (MOI 0 and MOI 100, 12 hrs) and 
analysed for cytokine release. (A) Cytokine array membranes representing each MOI; (B) 
Densitometric analysis of the cytokine array for each MOI for qualitative use only (N=1). 
(Ref, validation for streptavidin-HRP).  
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4.1.3 ROS production and endothelial microparticle release 
4.1.3.1 ROS production  
Reactive oxygen species (ROS) are used for a wide variety of physiological processes, 
including immune defence strategies, altering vasculature and playing an influential role 
in signal transduction. ROS are normally produced as by-products by the electron 
transport chain (ETC) in mitochondria, whilst also being produced by the endoplasmic 
reticulum (Alfadda & Sallam, 2012). Virtually all cells produce minute levels of ROS 
such as neutrophils, monocytes, eosinophils and endothelial cells via the NADPH oxidase 
(NOX) enzyme as part of normal signalling processes (Alfadda & Sallam, 2012; van 
Sorge et al., 2013; Rochfort et al., 2014). The NOX enzyme is responsible for causing a 
“respiratory burst”, which is a central element of neutrophil killing (van Sorge et al., 
2013). However, increased levels of ROS production is indicative of a homeostatic 
imbalance, as a result of immune defence mechanisms, antibacterial action or signal 
transduction (Alfadda & Sallam, 2012).  
The inflammatory modulator NF-κB was activated using our infection model with 
HBMvEC in-vitro suggesting that the endothelial cells are being challenged by SA; this 
endothelial compromisation is a likely scenario for ROS production. A ROS stain called 
dihydroethidium (DHE) was used to confirm ROS production post-infection with fixed 
NWT-SA using MOI 0-250 for 24 hrs infection. The dye works by converting to ethidium 
in the presence of ROS, allowing it to enter the nucleus and bind to the double-stranded 
DNA, staining it red. Flow cytometry was then used to determine the level of DHE present 
in HBMvEC.  
In order to eliminate the possibility of SA producing ROS, a single sample of fixed SA 
was incubated with the DHE stain, which recorded no change in ROS levels by flow 
cytometry [Figure 4.14A]. However, ROS expression was upregulated in the infected 
HBMvEC samples (MOI 100 and MOI 250), recording an 18 and 26 fold-change 
respectively in comparison to the uninfected control (MOI 0), which recorded negligible 
ROS levels [Figure 4.14 B & C].  
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Figure 4.14: Effect of fixed SA infection (dose-dependent) on HBMvEC ROS 
production. Dihydroethidium (DHE) used to detect ROS production using a PE-Texas 
red detector. (A) SA stained with DHE; (B) HBMvEC infected with fixed SA for 24 hrs, 
MOI 0 (green), MOI 100 (orange) and MOI 250 (red); (C) ROS production shown as 
fold-change (N=3). (*P<0.05 versus MOI 0). 
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4.1.3.2 Endothelial microparticles 
Much recent interest has been shown in the release of endothelial microparticles (EMPs) 
from endothelial cells, as it is believed EMPs could be used as potential biomarkers for 
the early detection of vascular inflammatory conditions (Berezin et al., 2015). EMPs are 
released from activated and apoptotic cells and play an important role in endothelial 
function, inflammation and coagulation (Dignat-George & Boulanger, 2011; Schindler et 
al., 2014). 
Flow cytometry analysis was used to explore the possibility of EMP production during 
SA infection. HBMvEC were infected for 24 hrs with fixed NWT-SA using MOI 0, 100 
and 250. The media was harvested post-infection and spun to generate a microparticle-
containing pellet. The EMP pellets were subsequently stained for FACS analysis using 
two EMP stains VE-cadherin-PE (CD144) and annexin V/FITC. The number of events 
after 60 seconds at a fixed flow rate were recorded [Figure 4.15]. The majority of 
positively-stained EMPs for VE-cadherin and annexinV/FITC were found within the 
infected samples, MOI 100 and MOI 250 recording 9 and 11 fold-increases respectively.  
 
Figure 4.15: Effect of fixed SA infection (dose-dependent) on endothelial 
microparticle release. HBMvEC infected with fixed SA for 24 hrs. Microparticle pellets 
stained with VE-cadherin PE (CD144) and annexin V/FITC. (A) Dot plot representation 
of EMPs found in infected samples; (B) Number of positively-stained microparticles after 
60 seconds (N=3). (*P<0.05 versus MOI 0). 
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4.2 Discussion 
The host immune response quickly tackles and combats any potential molecules that are 
deemed unsafe by removing them safely from circulation (Fournier & Philpott, 2005). 
However, depending on the type of infection/injury sustained, the immune system can 
become compromised enabling the infection to persist for longer, ultimately resulting in 
detrimental effects for the individual. SA is resourceful in its abilities to evade the host 
immune response and ensure its survival through its many virulence factors such as γ-
hemolysin and Panton-Valentine Leukocidin (PVL), which can injure neutrophils and T 
cells (Powers & Bubeck Wardenburg, 2014). Previous studies have highlighted the 
potential of SA to interact with the endothelium (possibly enabling it to traverse the BBB). 
However, its next major challenge in-vivo is to survive, whilst also disguising itself from 
the main immune regulatory cells such as macrophages, neutrophils and dendritic cells 
(Gilmore, 2006). Immune modulation by SA is an important area to understand because 
it has been clearly shown on several occasions that SA can cause severe sepsis due to 
sustaining an inflammatory stimulus as a result of SA virulence secretion (Powers & 
Bubeck Wardenburg, 2014). SA infection may lead to several illnesses, with endocarditis 
and cerebral meningitis proving to be the particularly fatal among the young and 
immunocompromised individuals. In-vivo mouse models infected with SA showed signs 
of hematogenous meningitis 96 hrs post-tail vein injection. Meningeal thickening, 
haemorrhage formation, leukocytic infiltration and abscess formation (with SA 
clustering) were all identified in mouse brains upon sacrifice (Sheen et al., 2010). Because 
of this, it was important to examine the implications of SA infection on BBB endothelial 
cells (HBMvEC) in-vitro, specifically examining the activation of immunoregulatory 
transcription factor NF-κB, as well as cytokine and chemokine release. Both the induction 
of reactive oxygen species (ROS) and endothelial microparticle (EMP) release were also 
examined as both are seen to be induced upon endothelial inflammatory activation.  
NF-κB is a well-known inflammatory mediator, originally residing within the cytoplasm 
bound to IκB (inhibitory κB). The NF-κB pathway can be activated in two ways via the 
canonical (classical) or non-canonical (alternative) pathways. In either case, both 
pathways require NF-κB activation via the removal of an inhibitory protein, thereby 
enabling NF-κB to travel from the cytoplasm to the nucleus, where it may activate specific 
gene targets (Viatour et al., 2005; Gilmore, 2006). In order to monitor NF-κB activation 
following SA infection, protein lysate samples were harvested after both fixed and live 
SA infections using our co-culture infection models with HBMvEC, and subsequently 
131 
 
tested for phosphorylation of NF-κB at the serine-536 residue. Initially, control studies 
were performed treating HBMvEC with 100 ng/ml of TNF-α for up to 48 hrs. It was 
evident that TNF-α treatment could induce immediate NF-κB activation with a 19.5 fold-
increase observed after just 15 mins. This cytokine-induced NF-κB activation was 
sustained for up to 48 hrs, illustrating the long-term stimulation of this transcription 
factor. In response to fixed SA infection, both time- and dose-dependent activation of NF-
κB in HBMvEC. Moreover, when HBMvEC were infected with live SA, time-dependent 
increases were recorded for NF-κB activation, although in parallel dose-response 
experiments, a sustained expression of NF-κB was recorded using MOI 5-100. This may 
be the result of NF-κB inhibition by live SA, whereby other SA virulence factors hamper 
the full induction of the inflammatory response (Foster, 2005; Kim et al., 2012). In 
additional experiments, the potential contribution of the SA “secretome” towards the 
activation of the inflammatory cascade was addressed. When HBMvEC were treated for 
36 hrs with SA-conditioned media (i.e. HBMvEC media containing virulence factors 
released from live SA), a significant increase in NF-κB was recorded in comparison to 
the untreated control. Interestingly, from the NF-κB time-dependent studies, there 
appeared to be temporal increases and decreases of NF-κB activation at certain time 
points. This biphasic response is likely representative of the continuous degradation and 
re-synthesis of IκB due to the continued presence of SA or induced cytokines present in 
the media solution (Gilmore, 2006). The synthesis of NF-κB also induces the activation 
of its inhibitory co-factors (IκB) required to inhibit NF-κB induction in order to limit the 
extent of inflammatory stimulation (Oeckinghaus & Ghosh, 2009). 
Induction of NF-κB was expected in HBMvEC as similar infection studies using 
alternative mammalian cell types have shown this induction. Research by Ning and co-
workers, noted NF-κB activation upon osteoblast infection using live and UV-killed SA 
strains. Ning’s group attributed NF-κB activation through direct SA attachment to human 
osteoblasts and not through secreted SA virulence factors as shown using a transwell 
bicameral chamber (Ning et al., 2010). This result differs to the live experiment using 
only HBMvEC media pre-conditioned with SA-released virulence factors, which still led 
to NF-κB activation. There are several possible reasons for this. Osteoblasts may: (i) be 
more resilient towards SA virulence factors by degrading them; (ii) they might be missing 
the appropriate receptors to allow virulence factor engagement with the cell or; (iii) they 
may possess efflux receptors that can physically reject them. Interestingly, Ning 
suggested that a possible reason for this may be due to the difference between professional 
132 
 
and non-professional phagocytes as murine bone marrow macrophages were seen to 
activate NF-κB via SA-derived exotoxins. Ultimately, osteoblasts require direct cell-
bacterium contact, while endothelial cells may be more sensitive to the secreted virulence 
factors of SA.  
Having seen that NF-κB is activated following infection with either fixed or live SA, 
further experiments were performed to examine what inflammatory mediators may also 
be putatively activated downstream of NF-κB. Media harvested post-infection with fixed 
SA was used to monitor cellular release of IL-6, TNF-α and thrombomodulin (TM) via 
ELISA analysis. Minimal increases were seen for release of IL-6, TNF-α and TM after 
24 hrs infection with fixed SA. However, dose and time-dependent increases were 
observed following 48 and 72 hrs HBMvEC infection with fixed SA. It is important to 
note that the absolute levels of release (pg/ml) were considerably lower for TNF-α (up to 
200 pg/ml), when compared to IL-6 and TM (1000-2000 pg/ml). The ELISA results 
support the notion that the pro-inflammatory cytokine, IL-6, is a potentially stronger 
inducer of the host immune response to SA in comparison to TNF-α. Wang et al. (2000) 
confirmed this by infecting whole human blood with SA peptidoglycan (PGN) and LTA 
fragments (Wang et al., 2000). In this particular study, elevated levels of IL-6 release 
were recorded for up to 24 hrs following infection using PGN and LTA. By contrast, 
maximal expression of TNF-α was seen 6 hrs after PGN infection, whilst LTA did not 
trigger TNF-α release. Based on these observations, some speculative conclusions are 
possible. In this respect, TNF-α communicates with other cells via its TNFR1 and TNFR2 
receptors, which have both been identified on HBMvEC (Bradley, 2008; Rochfort et al., 
2014). As mentioned previously, staphylococcal protein A (SpA) has a high affinity for 
these receptor sites, and indeed, SpA binding to TNFR1, has been shown to also activate 
TNF receptor-associated factor 2 (TRAF2), leading to activation of NF-κB (Gómez et al., 
2006). The binding of SpA to TNFR1 also causes TNFR1 ectodomain shedding via TNF-
α converting enzyme (TACE) or by ADAM 17 (Gómez et al., 2006; Prince et al., 2006; 
Moelants et al., 2013). This may be regarded as an anti-inflammatory event, in that the 
receptor is no longer responsive to any binding partners, thereby limiting the extent of the 
pro-inflammatory response. Moreover, because of TNFR1 shedding, the shed receptor is 
now capable of mopping up any free TNF-α found in circulation/media. This may be a 
potential reason why TNF-α released into media is present at considerably lower levels 
than IL-6 (i.e. SA-induced TNFR1 shedding).   
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TM is an anti-inflammatory protein important for endothelial thromboresistance and is 
known to be released in functional form from the HBMvEC surface (Rochfort & 
Cummins, 2014). Its stimulated release from the endothelial cell surface (e.g. in response 
to pro-inflammatory cytokines) is often considered a marker for endothelial dysfunction 
and stress (Martin et al., 2013; Rochfort & Cummins, 2014). The current thesis 
demonstrates TM release from HBMvEC in response to SA infection, a process that may 
be mediated through the SA-induced upregulation and release of cytokines such as TNF-
α and IL-6 (Rochfort & Cummins, 2014).  
In order to conduct a more extensive screen for secreted inflammatory mediators 
following SA infection on HBMvEC, a human cytokine array panel (Proteome Profiler 
TM) from R&D Systems was subsequently employed. Media was harvested from 
HBMvEC following 48 hrs infection with fixed SA or following 3 and 12 hrs infection 
with live SA. In response to fixed SA infection, six inflammatory markers significantly 
upregulated, which included: (i) regulated upon activation normal T cell expressed and 
secreted (RANTES); (ii) interferon gamma-induced protein 10 (IP-10); (iii) granulocyte-
colony stimulating factor (G-CSF); (iv) granulocyte-macrophage colony-stimulating 
factor (GM-CSF); (v) monocyte chemotactic protein-1 (MCP-1) and; (vi) interleukin-6 
(IL-6). There were also trace levels of sICAM-1 found on the MOI 250 cytokine array. 
An overview of the upregulated cytokine targets are shown in Table 4.1 overleaf. All 
cytokine and chemokines listed on the array are described in Table A2.  
There was no difference in cytokine/chemokine expression after 3 and 12 hrs infection 
with live SA. This may be due to not infecting HBMvEC for long enough (not practical 
with live bacteria) or that the assay was not sensitive enough to record subtle changes in 
released cytokine levels. As live bacteria were used, the bacterial virulence factors may 
have impeded the induction of a substantive inflammatory immune response. 
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Cytokin
e 
Alternativ
e Name Source Function References 
RANTES CCL5 
CD8+T cells 
 Chemoattractant for: 
monocytes & T Helper 
cells. 
 Promotes IFN-γ 
expressing TH1 
lymphocytes. 
 Histamine release. 
(Borish & 
Steinke 
2003) 
IP-10 
CXCL10 
Neutrophils 
EC 
Keratinocytes 
 Chemoattractant for 
activated T cells. 
(Dufour, et 
al., 2002) 
G-CSF 
CSFβ 
CSF-2 
Fibroblasts 
Monocytes 
AGPC 
Neutrophils 
 Granulocyte 
differentiation and 
neutrophil development. 
(Cameron & 
Kelvin, 2000) 
GM-CSF 
CSFα 
CSF-2 
Macrophages 
T cells 
 Stimulates: 
-granulocytes 
-macrophages 
-neutrophils 
-eosinophils 
(Cameron & 
Kelvin, 2000) 
MCP-1 
CCL2 
EC, 
Fibroblasts 
Epithelial 
SMC 
Astrocytes 
Microglial cells 
 Regulates migration and 
infiltration of monocytes 
and macrophages. 
 Inhibits IL-12 production 
from APCs. 
 Enhances IL-4 production 
from activated T cells. 
 (Borish & 
Steinke, 
2003) 
 (Deshmane, 
et al., 2009) 
IL-6 
- 
T & B 
lymphocytes 
EC 
BMC 
 Stimulates B-
lymphocytes to become 
mature plasma cells 
 Mediates T-cell 
activation 
 Stimulates acute phase 
proteins 
(Borish & 
Steinke, 
2003)  
(Akdis et al., 
2011) 
sICAM-1 
CD54 EC 
 Circulating form of ICAM-
1 
 Counter receptor for 
LFA-1 
(Witkowska 
& Borawska, 
2004) 
Table 4.1: Cytokine/chemokine release following fixed NWT-SA infection. 
Upregulated cytokines upon fixed SA infection. (EC, endothelial cells; AGPC, activating 
granulocyte progenitor cells; BMC, bone marrow cells and; SMC, smooth muscle cells).  
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Interestingly, a study by Strindhall et al. (2005) used the same infection procedure to that 
of Matussek et al. (2005) whereby they infected HUVEC for 1 hour with MOI ranging 
from 250-500 live SA before treating with lysostaphin to remove non-adhered bacteria. 
The cells were left to incubate for a further 23 hrs prior to harvesting media for ELISA 
analysis. All eighteen staphylococcal strains tested expressed IL-6, IL-8, GRO-α, GM-
CSF and RANTES, which were all upregulated within our fixed cytokine array 
(Strindhall et al., 2005; Matussek et al., 2005). It is interesting to note that the SA used 
by Strindhall et al. was a live (unfixed) strain, yet the upregulated inflammatory cytokines 
are the same ones seen upregulated from our fixed SA cytokine array. This would suggest 
once again that fixed bacteria experimentation is capable of effectively mimicking live 
SA infection in-vitro, thus confirming the utility of the former (fixed SA) for modeling 
studies on the latter (live SA). As previously mentioned above, there was no difference 
in cytokine/chemokine expression in response to live SA infection, which contrasts with 
Strindhall et al. This may be due to several reasons: (i) the live SA used by Strindhall 
originated from methicillin sensitive Staphylococcus aureus (MSSA) and MRSA clinical 
samples, whilst a NWT strain was used of these experiments; (ii) the use of higher doses 
and longer infection times by Strindhall and; (iii) ELISA analysis used by Strindhall may 
have been sensitive enough to detect subtle changes in cytokine expression, whilst we 
used a semi-quantitative cytokine array (which is based on Western blot and ELISA 
methodology). 
The production of minute quantities of reactive oxygen species (ROS) is a naturally 
occurring event within cells, regulating cell growth, cell-cell adhesion, cell differentiation 
and apoptosis, whilst also playing a protective role in the defence against bacterial and 
viral infections (Mittal et al., 2014). However, excessive production and prolonged 
exposure to ROS is a principal cause in establishing an inflammatory disease (Alfadda & 
Sallam, 2012; Mittal et al., 2014). Other ROS-related studies have shown how other 
bacterial strains are capable of inducing oxidative stress in a variety of infected host cells: 
(i) intestinal/gut epithelia infected with enteric commensal bacteria (Jones et al., 2012); 
(ii) cultured and native gastric epithelial cells infected with Helicobacter pylori (Ding et 
al., 2007); (iii) bovine endothelial cells of the cerebral microvasculature infected with 
Haemophilus somnus, a cause of vasculitis of the cerebrovasculature (Kuckleburg et al., 
2008) and; (iv) rat lung microvascular endothelial cells infected with ultrapure LTA 
(CWA of SA) (Pai et al., 2012), all resulted in the production of ROS and reactive 
nitrogen species (RNS). To the best of one’s knowledge, this is the first study to show 
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ROS induction within primary-derived HBMvEC infected with fixed NWT-SA in-vitro. 
A ROS-sensitive dye, dihydroethidium (DHE), was used to monitor the production of 
ROS in the infected cells. HBMvEC infected with fixed SA showed significant increases 
in ROS production. Previous studies by Rochfort et al. (2014) have proven that treating 
HBMvEC with pro-inflammatory cytokines, TNF-α and IL-6, could induce intracellular 
ROS levels in-vitro (Rochfort et al., 2014). As previously discussed, both IL-6 and TNF-
α were both seen to be upregulated upon SA infection of HBMvEC. This upregulation 
may subsequently contribute to increased ROS levels within HBMvEC during SA 
infection. Another study by Pai et al. (2012) examined the effects of ROS production by 
treating pulomonary microvessel endothelial cells (PMEC) with an SA cell wall-
associated protein, LTA. They found that LTA activated endothelial NOS (eNOS) 
through two phosphorylation sites, which subsequently increased ROS production (Pai et 
al., 2012; Kim et al., 2015b). The increase in oxidant stress was seen to disrupt the tightly 
regulated endothelial monolayer, through the relocalization of the interendothelial 
junctional proteins occludin and VE-cadherin (Pai et al., 2012). This observation may 
correlate to the downregulation of interendothelial junctional proteins expression seen 
previously when HBMvEC were infected with both NWT fixed and live SA. 
Finally, the release of endothelial microparticles (EMP) as a potential outcome of SA 
infection was examined. EMPs are now seen as potential biomarkers for vascular injury 
with noticable differences in EMP complement seen in blood counts of patients with 
lupus, acute coronary syndrome, multiple sclerosis, stroke, cerebral malaria and traumatic 
brain injuries (TBIs) (Simak et al., 2002; Koga et al., 2005; Doeuvre et al., 2009; Fu et 
al., 2015; Ishida et al., 2015). Previous work carried out in our laboratory (by the author 
of this thesis in collaboration with others), examined the release of EMPs from human 
aortic endothelial cells (HAEC) in response to elevated equibiaxal cyclic strain, which is 
a feature of vascular diseases such as hypertension (Martin et al., 2013). Strained HAEC 
recorded significantly higher quantities of EMP release, which were later found to contain 
the glycoprotein TM (Martin/McLoughlin et al., 2014). This observation aroused interest 
in whether or not SA could induce EMP release upon infection of HBMvEC. To 
investigate this, microparticles were isolated from conditioned media harvested from 
HBMvEC infectied with fixed SA. The microparticles were counter-stained with VE-
cadherin-PE (CD144) and annexin V/FITC stain, and subsequently analysed by flow 
cytometry in conjunction with 0.1 μm polystyrene size beads. Only the infected HBMvEC 
(MOI 100 and MOI 250) recorded EMP release, up to 8 and 11 fold-increases 
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respectively, relative to the uninfected control. It has previously been shown that EMP 
are elevated in activated or apoptotic cells in response to interleukins, cytokines and 
chemokines, NF-κB activation, bacterial infection, ROS, and thrombin, any of which may 
reflect a putative mechanism for SA-induced EMP production within our HBMvEC 
infection model (Jimenez et al., 2003; Leroyer et al., 2010; Berezin et al., 2015). Results 
obtained from EMP studies have many discrepancies as different research groups isolate 
EMP from cells in various different manners. Interestingly, a paper by Jimenez et al. 
(2003) used TNF-α for 24 hrs on BMvEC as a stimulant for EMP examination, whilst 
Simak et al. (2002) found that TNF-α did not cause EMP release in HUVEC (Simak et 
al., 2002; Jimenez et al., 2003). This highlights the difficulty in ascertaining such a minute 
population of cells, which were originally referred to as “circulating dust” (Leroyer et al., 
2010). It has been shown that the membrane coat of EMP is dictated by the current state 
of the endothelial cell at the time of microparticle blebbing (Doeuvre et al., 2009; 
Schindler et al., 2014). The more apoptotic the cell becomes, the increased likelihood it 
will express more PS on its outer surface, which will generate EMPs with procoagulant 
activity (Jimenez et al., 2003; Martin et al., 2014). The EMP markers used for this study 
included annexin V, which is a putative marker for phosphatidylserine (PS). The exposure 
of PS on the outer leaflet of EMP can upregulate tissue factor (TF) a known stimulant for 
blood coagulation (Morel et al., 2006). This study is potentially the first to demonstrate 
SA-induced release of EMPs from HBMvEC infected with fixed NWT SA in-vitro. 
In summary, one may conclude that SA is capable of inducing a significant inflammatory 
response with HBMvEC in-vitro. Summary of results is shown in Table 4.2. To this end, 
this chapter has shown, using both fixed and live SA strains, that SA infection of 
HBMvEC induces a broad pro-inflammatory response with the rapid induction of the 
inflammatory transcription factor NF-κB. As expected, the activation of NF-κB induces 
the expression of a variety of pro- and anti-inflammatory cytokines, whose role is to signal 
to adjacent cells to promote the recruitment of leukocytes to the site of the infection. 
Elevated release of cytokines and chemokines from HBMvEC were identified following 
NWT-SA infection, with IL-6 having the higher secretory output in comparison to TNF-
α post-infection. Interestingly, research carried out by Rochfort et al. (2014) has shown 
that treating HBMvEC with either TNF-α or IL-6 causes interendothelial junctional 
protein decreases, in parallel with increased ROS production (Rochfort et al., 2014). 
Similarly, the results obtained from infecting HBMvEC with SA saw both cytokine and 
ROS production, alongside interendothelial junctional protein downregulation, in reponse 
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to increasing concentrations of SA. Moreover, it can be suggested that the activation of 
the inflammatory immune response by SA augments BBB dysfunction as seen in 
conjunction with the Rochfort study. Other case studies have shown EMP release from 
activated or apoptotic cells (Martin et al., 2014). EMPs act as secondary signalling 
molecules activating and stimulating nearby and distal cells with their membrane 
receptors or microparticle contents (i.e. proteins, lipids, miRNA etc) (Schindler et al., 
2014). Therefore, the possibility of EMP production by infecting HBMvEC with NWT-
SA was examined. Elevated EMP production was seen in the infected HBMvEC samples, 
whilst negligible EMPs were retrieved from uninfected cells. All four inflammatory 
mediators investigated in this chapter - from NF-κB activation, cytokine release, ROS 
production and EMP release - are all implicated in the disruption of the HBMvEC. 
NWT-SA 
Experiments Fixed Live 
NF-κB 
1-48 hrs   ↑ 
MOI 0-250↑ 
15 mins-3 hrs ↑ 
MOI 0-100    NC 
ELISA 
IL-6      ↑ 
TNF-α  ↑ 
TM       ↑ 
(MOI 0-250, 
24-72 hrs) 
TNF-α ↑ 
(15 mins-3 hrs) 
Cytokine  
array 
0 v 250 
6↑ cytokines 
0 v 100 
3 hrs/12 hrs  NC 
ROS MOI 0-250 ↑ NP 
Endothelial  
microparticles 
MOI 0-250 ↑ NP 
Table 4.2: Summary of Chapter 4 results. 
(Key: ↑ Increase; ↓Decrease; NC, no change; NP, not performed). 
 
Finally, it has been demonstrated that SA mutants lacking the agr gene (responsible for 
SA quorum sensing) can still invade host cells, but in doing so, it does not trigger an 
inflammatory response and as such remains undetected, possibly representing a 
mechanism through which SA is able to cause serious re-infections resulting in future 
patient relapses (Grundmeier et al., 2010). Studies such as the above employing mutant 
strains of SA, have enabled researchers to delineate the roles of SA-associated virulence 
factors. Therefore, the next result chapter was used explore the influence of the key 
virulence factor, staphylococcal protein A (SpA), with the use of a mutant SpA strain 
(ΔSpA) to infect HBMvEC. SpA is both a cell wall-associated (found on 97% of 
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staphylococcal strains) and secreted (approx. 15-30%) virulence factor of SA, with a 
variety of host cell receptors (Merino et al., 2009; Yung et al., 2011; O’Halloran et al., 
2015). It has been shown to play a crucial role in bacterial adhesion, invasion and evasion 
(Foster et al., 2014). Because SpA plays such an important role for SA, and with the 
ability of binding to TNFR1 receptor to potentially induce NF-κB activation, one can 
hypothesize that it plays a key role in the observed effects of SA on HBMvEC barrier 
dysfunction and inflammatory activation. Both fixed and live ΔSpA strains were therefore 
used to investigate the influence of SpA on interendothelial junctional protein expression, 
barrier dysfunction and pro-inflammatory activation in HBMvEC. 
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Chapter 5 
Staphylococcus aureus protein A 
(SpA) Mutant Studies 
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5.1 Introduction 
Pathogens that are successful in colonising the human host need to be opportunistic, in 
both a hospital and community-based setting. SA is capable on both counts by virtue of 
its large array of virulence factors. One such virulence factor is staphylococcal protein A 
(SpA), a multifunctional protein found on the exterior of SA and also secreted into the 
extracellular medium (O’Halloran et al., 2015). SpA accounts for 7% of the bacterial cell 
wall where it initiates cell adhesion to an array of host cell receptors via von Willebrand 
Factor (vWF), TNFR1, and EGF receptor (EGFR), all of which are located on the surface 
of HBMvEC (Soong et al., 2011; Widaa et al., 2012; Kobayashi & Deleo, 2013; Rochfort 
et al., 2014; Slanina et al., 2014). Along with host cell binding, SpA also targets 
immunoglobulins such as the Fc region of IgG, preventing opsonisation by neutrophils 
and activation of the classical complement pathway. SpA targeting of the Fab heavy 
chains of VH3 region of IgM causes B lymphocytes to become superantigens, ultimately 
resulting in apoptosis and reduced antibody secretion to contend with the ongoing 
infection (Foster, 2005; Claro et al., 2011; Foster et al., 2014). Due to the multiple roles 
played by SpA to ensure host colonisation and survival, it was deemed an appropriate 
protein to target for our mutant studies. In order to examine the participation of a bacterial 
protein or virulence factor within a signalling pathway, the use of mutant studies proves 
invaluable. Therefore, the objective for this chapter was to compare and contrast the initial 
infection results from Newman wild-type (NWT) SA infection to that of mutant SpA 
(ΔSpA) with HBMvEC in-vitro. Site-directed mutagenesis was used to knock out the spa 
gene responsible for SpA transcription. Oligonucleotide probes were designed to target 
NWT SA spa gene and the replicated sequences were then cloned into a temperature-
sensitive E. coli plasmid prior to inserting into SA Newman strain generating spa::Kar; 
DU5971 (Kar, kanamycin resistant) (Ní Eidhin et al., 1998; O’Brien et al., 2002). 
Both fixed and live ΔSpA strains of SA were used to examine interendothelial junctional 
proteins, namely VE-cadherin and claudin-5 using Western blotting. Permeability assays 
were also carried out using ΔSpA SA to assess whether the HBMvEC barrier integrity 
could be dysregulated in the same manner as seen previously using NWT-SA. Because 
SpA is a known ligand of the TNFR1 receptor, experiments were performed to assess if 
its absence from the mutant SA strain had any effect on the activation dynamics of NF-
κB. To examine this, both time- and dose-dependent assays were performed.  
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5.1.1 Fixed ΔSpA infection on HBMvEC 
5.1.1.1 Effects of “fixed” ΔSpA infection on HBMvEC 
Initial infection studies examined the impact of “fixed” ΔSpA on HBMvEC morphology 
[Figure 5.1]. There was clear evidence of HBMvEC cell detachment from the cell culture 
dish with increasing MOI concentrations. A protein A dot blot was performed to ensure 
the ΔSpA strain was not expressing SpA protein. A NWT-SA strain and a Lactococcus 
lactis (L. lactis) with spa gene incorporated into its genome were used as positive 
controls, whilst the WT L. lactis and ΔSpA both proved negative for SpA [Figure 5.2A]. 
Interendothelial junctional protein expression was monitored in HBMvEC post-ΔSpA 
infection using MOI 0-250 [Figure 5.2 B and C]. Both VE-cadherin and claudin-5 were 
downregulated after 48 hrs infection. Consistent with this downregulation, was elevated 
barrier permeabilzation following infection with ΔSpA (MOI 0-250) with up to 3-fold 
increases recorded at the upper dose (MOI 250) [Figure 5.3]. NF-κB activated was also 
tested in response to ΔSpA infection. Both time (0-48 hrs) and dose-dependent (MOI 0-
100) experiments were performed. Time-dependency studies showed NF-κB induction 
after 1 hr infection, which appeared to stabilise from 4 to 24 hrs. However, a significant 
biphasic induction was recorded after 48 hrs infection [Figure 5.4]. When dose-
dependency studies were carried out, a 2-fold increase in NF-κB expression at MOI 100 
and MOI 250 was recorded [Figure 5.5]. However, when the lower concentrations of MOI 
where used (MOI 10-50), NF-κB was induced at MOI 10 and peaked at MOI 25 after 48 
hrs infection [Figure 5.6].   
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Figure 5.1: HBMvEC infected with fixed ΔSpA. Confluent HBMvEC were infected 
with 4.8% formaldehyde-fixed ΔSpA (MOI 0-250, 48 hrs). Images (10x) are 
representative. Comparative HBMvEC infection with fixed NWT-SA included for 
reference (see Figure 3.8).  
∆SpA
MOI 0
MOI 100
MOI 250
HBMvEC infected with “ ixed” SA
NWT
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Figure 5.2: ΔSpA infection. (A) Dot blot for SpA using NWT-SA, ΔSpA, Lactococcus 
lactis WT (-SpA) and Lactococcus lactis (+SpA); (B) Total protein lysates harvested from 
HBMvEC infected with fixed ΔSpA (MOI 0-250, 48 hrs). Blots probed for 
interendothelial junctional proteins. All gels are representative. Bar graphs represent 
densitometric analysis of Western blots (N=3); (C) Comparative HBMvEC infection with 
fixed NWT-SA (see Figure 3.8). [* denotes ANOVA with post-hoc test, while δ denotes pairwise 
comparisons using t-tests. Both statistical tests were carried out for all subsequent figures in this chapter].  
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Figure 5.3: Effect of fixed ΔSpA infection (dose-dependent) on HBMvEC 
permeability. (A) Static HBMvEC were seeded onto 0.4 μm inserts (4x105 cells) and left 
to grow to confluency prior to infecting with fixed ΔSpA (MOI 0-250, 24 hrs). Addition 
of FITC-dextran (40 kDa) post-infection was used to assess barrier permeabilization. 
Permeability was monitored every 30 mins over a 3-hr assay period. Permeability 
expressed as % TEE FD40 dextran at the 180 min time-point. (N=3); (B) Comparative 
HBMvEC infection with fixed NWT-SA (see Figure 3.13). (*P<0.05 versus MOI 0; 
δP<0.05).  
  
 ixed ∆SpA Fixed NWT-SA
A
B
A
B
A B
146 
 
 
Figure 5.4: Effect of fixed ΔSpA infection (time-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC treated with fixed ΔSpA (MOI 100, 0-48 
hrs). Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative. 
Bar graphs represent densitometric analysis of Western blots (N=3); (B) Comparative 
HBMvEC infection with fixed NWT-SA (see Figure 4.2). (*P<0.05 versus 0 mins 
δP<0.05). Statistical significance recorded between the 0 timepoint and 1, 4, 6, 24 and 48 
hr timepoints in Figure 5.4A. 
 
  
 ixed ∆SpA Fixed NWT-SA
NF-κB
β-actin
0         15         1         3          6         24        48
Mins HoursA
B
NF-κB
β-actin
0         15         1         3          6         24        48
Mins HoursA
B
0       15         1          4        6        24        48          
Mins Hours
β-actin
NF-κB
A B
0        15         1          4          6         24         48          
Mins Hours
β-actin
NF-κB
A
B
 
* 
* * 
* 
* 
δ 
147 
 
 
Figure 5.5: Effect of fixed ΔSpA infection (high dose) on NF-κB activation. (A) Total 
protein lysates harvested from HBMvEC treated with fixed ΔSpA (MOI 0-250, 48 hrs). 
Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative. Bar 
graphs represent densitometric analysis of Western blots (N=3); (B) Comparative 
HBMvEC infection with fixed NWT-SA (see Figure 4.3A). (*P<0.05 versus MOI 0; 
δP<0.05).  
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Figure 5.6: Effect of fixed ΔSpA infection (low dose) on NF-κB activation. (A) Total 
protein lysates harvested from HBMvEC treated with fixed ΔSpA (MOI 0-100, 48 hrs). 
Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative. Bar 
graphs represent densitometric analysis of Western blots (N=3); (B) Comparative 
HBMvEC infection with fixed NWT-SA (see Figure 4.3B). (*P<0.05 versus MOI 0; 
δP<0.05). 
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5.1.1.2 Effects of “live” ΔSpA infection on HBMvEC 
Similar experiments were performed to determine the implications of “live” ΔSpA 
infection on HBMvEC. A large proportion of HBMvEC remained attached to the cell 
culture dish after infection with live ΔSpA using MOI 0-100 for 3 hrs. The lower bacterial 
dose showed little-to-no change in the “cobblestone” morphology associated with 
HBMvEC proliferation, whilst the upper bacterial dose showed definite signs of cell 
constriction and challenge. [Figure 5.7]. Interestingly, there were no significant changes 
in the expression of either VE-cadherin or claudin-5 with increasing live ΔSpA up to MOI 
100 [Figure 5.8]. However, NF-κB was activated after 1 hr infection (2.6 fold-increase), 
whilst maximal expression was recorded after 3 hrs (3.2 fold-inxcrease) [Figure 5.9]. 
Interestingly, dose-dependent studies of MOI 0-100 live ΔSpA showed NF-κB activation 
most noticeably at MOI 25, with sustained activation up to MOI 100 [Figure 5.10]. 
 
Figure 5.7: HBMvEC infected with live ΔSpA. Confluent HBMvEC infected with live 
ΔSpA (0-100, 3 hrs). Images (10x) are representative. Comparative HBMvEC infection 
with live NWT-SA included for reference (see Figure 3.5). 
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Figure 5.8: Effect of live ΔSpA infection on HBMvEC junctional protein expression. 
(A) Total protein lysates harvested from HBMvEC infected with live ΔSpA (MOI 0-100, 
3 hrs) and probed for cerebral junctional proteins. All gels are representative. Bar graphs 
represent densitometric analysis of Western blots (N=3); (B) Comparative HBMvEC 
infection with fixed NWT-SA (see Figure 3.10). (*P<0.05 versus MOI 0; δP<0.05). 
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Figure 5.9: Effect of live ΔSpA infection (time-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC treated with live ΔSpA (MOI 100, 0-3 
hrs). Blots probed for phosphorylation of NF-κB (Serine 536). All gels are representative. 
Bar graphs represent densitometric analysis of Western blots (N=3); (B) Comparative 
HBMvEC infection with fixed NWT-SA (see Figure 4.4). (*P<0.05 versus MOI 0; 
δP<0.05).  
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Figure 5.10: Effect of live ΔSpA infection (dose-dependent) on NF-κB activation. (A) 
Total protein lysates harvested from HBMvEC treated with live ΔSpA (MOI 0-100, 3 
hrs); (B) Blots probed for phosphorylation of NF-κB (Serine 536). All gels are 
representative. Bar graphs represent densitometric analysis of Western blots (N=3); (B) 
Comparative HBMvEC infection with fixed NWT-SA (see Figure 4.5). (*P<0.05 versus 
MOI 0; δP<0.05).  
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5.2 Discussion 
Much research has focused on studying the many virulence factors of SA, namely the cell 
wall-associated (CWA) proteins (peptidoglycan, lipoproteins and LTA) and secreted 
enzymes/toxins (coagulase, leukocidin and α-toxin) in order to gain a greater 
understanding of their functional capabilities (Kumar et al., 2007). These virulence 
factors enable hospital-associated MRSA (HA-MRSA) and community-associated 
MRSA (CA-MRSA) to survive in more challenging and competitive environments. 
Approximately 97% of all SA strains produce staphylococcal protein A (SpA), making it 
an ideal marker to distinguish it from other staphylococcal strains (Merino et al., 2009; 
Yung et al., 2011). SpA is normally found on the outer surface of SA acting as a binding 
site to various host cells. However, most SA strains secrete up to 15-30% of their SpA 
complement into the extracellular medium, as seen in tissue and bodily fluids from a 
mouse model infected with MRSA and in patients suffering from MRSA and methicillin 
sensitive Staphylococcus aureus (MSSA) bacterial strains (Merino et al., 2009; Yung et 
al., 2011; O’Halloran et al., 2015). The total SpA content of SA (up to 7% of the cell 
wall) has been shown to have a direct correlation with neutrophil phagocytosis resistance 
(Karlsson et al., 2001; Gao & Stewart, 2004). Because SpA is a relatively well-known 
virulence factor for SA, mediating adhesion and invasion into host cells, the objective of 
this chapter was to examine the implications of using a mutant SpA (ΔSpA) strain to 
infect HBMvEC in-vitro.  
The ΔSpA strain of SA was used to infect HBMvEC in the same manner as discussed 
previously with Newman wild-type SA (NWT-SA). An overview of the experiments 
performed and experimental outcome are displayed in Table 5.1. Initially, HBMvEC were 
infected with “fixed” ΔSpA for 48 hrs to examine interendothelial junctional protein 
expression. Claudin-5, a BBB tight junction protein, recorded the highest expressional 
decrease with increasing MOI concentrations. The mutant bacterium however was 
somewhat attenuated in its ability to lower VE-cadherin expression relative to NWT-SA. 
This could suggest that SpA preferentially influences the expression of VE-cadherin, as 
the fixed NWT strain was seen to reduce VE-cadherin expression to a greater extent (with 
a 2 fold-decrease previously observed). In further studies, fixed ΔSpA was seen to induce 
HBMvEC permeabilization, albeit only at the higher MOI dose employed (MOI 250). 
The lack of permeabilization at the lower MOI 100 dose may again point to a reduced 
potency of the mutant and highlight the importance of SpA in the overall barrier-reducing 
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capabilities of SA. Somewhat consistent with these observations, current research shows 
that ΔSpA strains of SA have significantly reduced virulence in contrast to their WT 
counterparts, as seen using several mouse infection models for septic arthritis, 
septicaemia, skin abscesses, pneumonia and intraperitoneal infections (Karlsson et al., 
2001; Kumar et al., 2007). 
Research by Palmqvist et al. (2002) examined the implications of SA in developing septic 
arthritis in a murine model using NWT and ΔSpA strains. They found that the NWT strain 
caused a severe form of the disease in its ability to cause extensive erosive damage to 
both the cartilage and bone along with increased mortality rates when compared to the 
∆SpA strain. Moreover, increased levels of IL-6 were found in the serum of NWT mice 
following infection. However, it was reported higher levels of TNF-α were found in the 
ΔSpA treated mice. This would suggest that SpA is likely playing an immunoinhibitory 
role in TNF-α function, which may be a plausible reason why low TNF-α levels were 
recorded from the TNF-α ELISA assay following NWT infection [4.8] (Palmqvist et al., 
2002). It has already been demonstrated in this thesis, and by other research groups, that 
SA is an inducer of NF-κB. Work by Gomez et al. (2004) for example has demonstrated 
that SpA can adhere to the TNFR1 receptor on pulmonary epithelial cells and elicit NF-
κB activation leading to cytokine and chemokine release (Gómez et al., 2004; Gómez et 
al., 2006). For this chapter, protein lysates were harvested following infection of 
HBMvEC with fixed ΔSpA prior to probing for phospho-serine 536 residue located on 
NF-κB. Both time- and dose-dependent increases in NF-κB activation were observed in 
response to fixed ΔSpA infection, albeit with different activation dynamics to that seen 
with NWT-SA. NF-κB activation was seen after 1 hr infection (4.6 fold-increase), 
although the highest activation was recorded after 48 hrs (10 fold-increase). The 
equivalent time-dependent NWT-SA experiment showed a steady increase in NF-κB with 
a 3.9 fold-increase after 48 hrs infection, somewhat lower than what was seen in ΔSpA 
experiments. Similar to NWT SA experiments, the lowest fixed ΔSpA concentration used 
(MOI 10) was seen to mildly upregulate NF-κB. This would suggest that the absence of 
SpA does not prevent the induction of NF-κB in HBMvEC. This is understandable as the 
host immune response is equipped with multiple immunoregulatory proteins such as 
TLRs and NOD-like receptors (NLRs) that are able to identify multiple MSCRAMMS 
on the surface of bacteria such as peptidoglycan, cell wall teichoic acids (WTA) and 
lipoteichoic acid (LTA) in the absence of SpA. Interestingly, a paper by Kumar et al. 
(2007) infected human corneal epithelial cells (HCEC) with ΔSpA, where they noted a 
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significant decrease in cytokine production. In contrast to this, the WT strain was seen to 
quickly activate the inflammatory response via NF-κB signalling pathway in the same 
study. This was followed by the subsequent release of pro-inflammatory cytokines and 
chemokines such as TNF-α and IL-8 (Kumar et al., 2007). 
When HBMvEC were infected with “live” ΔSpA, there was no significant change in 
junctional protein expression after 3 hrs infection. However, NWT-SA infection of 
HBMvEC resulted in minor protein expressional decreases in both VE-cadherin and 
claudin-5, which implies that SA lacking SpA displays reduced virulence capabilities in 
the limitation of interendothelial junctional proteins of HBMvEC. Despite not seeing a 
junctional protein decrease with live ΔSpA, NF-κB activation was noted after 1 hr of 
infection, peaking after 3 hrs. Moreover, dose-dependent increases for NF-κB showed 
initial induction at MOI 25 (2 fold-increase). In contrast to this latter result, live NWT-
SA infection showed NF-κB activation from just MOI 5 (1.4 fold-increase). The WT SA 
induced a significant increase in TNF-α production after 2 hrs of infection, whilst the cells 
infected with the mutant strain recorded elevated TNF-α production, albeit at much lower 
levels. Importantly, this suggests that the absence of SpA impedes the activation of NF-
κB by the live bacterium.  
The results obtained from this work are consistent with published data in that ∆SpA is 
reduced in its infective capacity to downregulate the expression of tight/adherens junction 
proteins, to increase barrier permeability at low MOI concentrations and elicit NF-κB 
activation relative to its NWT-SA counterpart. A study by Giai et al. (2013) also recorded 
differences in SA virulence capabilities in TNF-α and TNFR1 shedding when comparing 
WT and ∆SpA strains using a mouse and human macrophage cell line (Giai et al., 2013). 
This may be the result of other SA surface proteins augmenting an inflammatory response 
via peptidoglycan, LTA and δ-toxin (Edwards et al., 2012). Giai and co-workers also 
recorded significant increases in TNFR1 shedding after 30 mins infection with WT SA, 
whilst minimal secretion was recorded after ΔSpA infection. In conclusion, the group 
determined that the TNFR1 shedding occurred well before the release of TNF-α; 
therefore, the shed receptor was able to adhere to free TNF-α in circulation, resulting in 
SA immune evasion. This was further confirmed when the group developed a 
Lactococcus lactis (L. lactis) strain expressing protein A, which showed elevated levels 
of TNF-α and TNFR1 shed receptors. The group backed up their findings by obtaining 
the same results using a mouse infection model (Giai et al., 2013).   
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As mentioned previously, full length SpA is regarded as an MSCRAMM containing four 
key domains; (i) the N-terminal signal sequence, (ii) five IgG binding domains; (iii) the 
variable repeat sequence and; (iv) the C-terminal sequence (containing a LPXTG motif 
including a hydrophobic domain with a charged tail) [Figure 1.8] (Sørum et al., 2013; 
Votintseva et al., 2014). The N-terminal signalling sequence prompts SpA to be exported 
via the export pathway resulting in soluble SpA release, while the C-terminal sequence 
recruits the covalent anchoring of SpA to the cell wall when cleaved by the sortase 
enzyme [Figure 1.9] (Sørum et al., 2013). The mutant strain of SpA used in this study 
was successful at eliminating SpA from both the cell surface and in its secreted form; 
therefore, there were no traces of this virulence factor present in the infection studies, as 
shown using a SpA dot blot [Figure 5.2] (O’Brien et al., 2002). However, it has been 
reported that mutant or truncated SpA strains of SA do exist within the general population, 
with Sørum et al. (2013) discovering seven isolates from patients with bacteraemia and 
from healthy individuals colonised with SA with frameshift mutations located in the spa 
variable repeat region with shortened C-terminal sequences (Sørum et al., 2013). As a 
result, all seven strains identified were unable to localise SpA to the cell surface [Figure 
5.11]. 
 
Figure 5.11: ∆SpA protein found in population. An example of SpA proteins (normal 
and truncated) found in the human population in healthy and colonised individuals. (S) N-
terminal signal sequence, (EDABC) IgG binding domains, (Xr) variable repeat region – one white box 
equivalent to a repeat, (Xc) C-terminal region, black boxes represent frameshift mutations and grey boxes 
represents the translated region before a premature stop codon (Sørum et al., 2013).  
Full-length SpA
157 
 
Despite this, the bacterial strains isolated from blood cultures and a MRSA strain were 
still shown to be virulent and still cause bacteraemia. Even the healthy individual 
colonised with a persistent isolate of deficient SpA showed SpA was not critical for nasal 
carriage (Sørum et al., 2013). Six out of the seven isolates identified showed no presence 
of SpA on the cell surface, yet SpA was found secreted into the extracellular environment 
with its IgG binding domain intact. Biofilm formation is a speciality of SA, rendering the 
bacteria in a semi-active state that allows it to withstand harsh environmental conditions 
through the self-production of an extracellular matrix including extracellular DNA 
(Schwartz et al., 2015). Yet it was found that when SpA was absent from the cell wall, 
the bacteria could still induce biofilm formation via soluble SpA (Merino et al., 2009; 
Yung et al., 2011). Interestingly, when the spa gene that encodes SpA protein was deleted 
it was seen that SA was significantly impaired in colonising medical devices in 
comparison to WT strains (Merino et al., 2009).  
In summary [Table 5.1], one may conclude that HBMvEC infected with ∆SpA are still 
capable of inducing SA pathogenicity via BBB dysfunction at interendothelial junctional 
and immunoregulatory levels, although attenuated responses relative to NWT-SA appear 
to be evident. Using fixed ∆SpA, for example, the bacteria was attenuated in its ability to 
downregulate VE-cadherin protein levels, whilst HBMvEC barrier was still subject to 
barrier permeabilization at only high MOI concentrations. The activation of NF-κB was 
seen using both fixed and live ∆SpA; however, induction of this transcription factor was 
slightly attenuated in comparison to NWT- SA strains, with live ∆SpA activating NF-κB 
at MOI 25, whilst the NWT strain showed immediate activation at MOI 5. 
∆SpA-SA 
Experiments Fixed Live 
Interendothelial  
junctions 
VE-cadherin ↓ 
Claudin-5     ↓ 
VE-cadherin NC 
Claudin-5    NC 
HBMvEC 
 permeability 
MOI 250↑ NP 
NF-κB 
1 hr-48 hrs ↑ 
MOI 10-25 ↑ 
1hr-3 hrs  ↑ 
MOI 25-100↑ 
Table 5.1: Summary of Chapter 5 results. 
(Key: ↑ Increase, ↓ Decrease; NC, no change; NP, not performed).  
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Chapter 6 
Final Summary  
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6.1 Final Summary 
Staphylococcus aureus (SA), is one of many human pathogens responsible for numerous 
illnesses and diseases that can compromise human health, causing skin and soft tissue 
infections, endocarditis, bacteraemia, pneumonia and meningitis (Gao & Stewart, 2004; 
Merino et al., 2009; Sørum et al., 2013). In recent years, it has emerged that SA is no 
longer associated as only being a hospital-based infection, but has gained extra virulence 
properties to survive and spread within the local community. Therefore, the incidence of 
SA is no longer maintained within one environment. The fact that healthy individuals can 
harbour SA and not experience any problematic symptoms associated with it illustrates 
the unusual colonisation strategies of the bacterium, which makes it difficult to contain. 
The ability of this bacterium to constantly evolve and become resistant to antibiotic killing 
makes it increasingly difficult to treat. Vancomycin is currently used to treat patients with 
SA infections namely MRSA. However, resistance to this antibiotic has been detected in 
patients, which ultimately suggests that this antibiotic will become yet another casualty 
of SA evolution (Hiramatsu, 2001). Because more is now known in relation to this 
pathogen, and especially MRSA, hospitals are more equipped to deal with its incidence. 
In Irish hospitals for instance, MRSA accounted for 23% of SA isolates in 2012, 20% in 
2013 and 19% in 2014 (HPSC, 2015). Overall, a 63% decrease was recorded between the 
years 2006-2014, which illustrates that the medical practices being undertaken are having 
a positive impact on maintaining bacterial outbreak. However, the methicillin-sensitive 
Staphylococcus aureus (MSSA) blood stream infection isolates are on the increase with 
900 isolates recovered between 2012-2014, which may be indicative of early stage 
bacterial resistance (HPSC, 2015). 
In order to fully explore the implications of contracting a bacterial infection, well-
characterised infection models are essential. In literature, the majority of in-vitro 
endothelial/epithelial infection studies use immortalised cell lines for example, 
immortalized HBMvEC (Sheen et al., 2010), transformed bronchial epithelial cell line 
(16HBE) (Soong et al., 2011; Cohen & Prince, 2013), immortalized HUVEC (EA hy926) 
(Edwards et al., 2010) and immortalized corneal epithelial cell line (Kumar et al., 2007). 
However, the objective for this project was to explore the implications of SA infection by 
using primary-derived human brain microvascular endothelial cells (HBMvEC) with 
respect to: (i) interendothelial tight/adherens junction (TJ/AJ) protein expression; (ii) 
endothelial permeability and; (iii) pro-inflammatory signalling.  
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Brain microvascular endothelial cells (BMvEC) essentially comprise the frontline BBB 
interface with circulating blood, lacking fenestrations, having low transendothelial 
electrical resistance with minimal paracellular permeability, along with a higher number 
of mitochondria than other peripheral cells to sustain BMvEC high metabolic activity 
(Lawther et al., 2011). However, the key characteristic of BMvEC is the presence of 
adherens and tight junction proteins, located within the intercellular cleft of adjacent cells, 
interlinking with each other to create a controllable barrier to fluids and solutes. The 
research hypothesis was that SA infection causes BBB dysfunction through the 
induction of pro-inflammatory conditions, ultimately leading to dysregulation of 
interendothelial junctional proteins and increased paracellular permeability. To 
investigate this hypothesis, HBMvEC: SA infection models were employed using either 
formaldehyde-fixed or live bacteria.  
In Chapter 3, an in-vitro infection model was designed using Staphylococcus aureus 
(SA) and primary-derived HBMvEC. Initial experiments confirmed the difficulty with 
working with live SA, due to media utilisation and waste production, proving that live 
bacterial experiments could not be conducted for long infection times. By contrast, an 
optimal working time and dose infection range to use with HBMvEC was possible using 
formaldehyde-fixed SA; hence, the majority of the experiments continued to use this 
method. It was found that SA adhered with equal efficacy to different endothelial cells 
(HBMvECs, BAECs, and HAECs) under static or sheared conditions. Moreover, 
infection studies demonstrated the ability of SA to induce disassembly of interendothelial 
junctions in parallel with elevation of HBMvEC permeability.  
With any pathogenic infection, the host inflammatory response is activated through 
pattern recognition receptors (PRRs), namely TLRs, which act as chemoattractants to 
recruit immune cells to the site of infection by eliciting cytokine and chemokine 
induction. Therefore, in Chapter 4, the implications of SA infection on the HBMvEC 
inflammatory response were examined. Firstly, NF-κB activation (via the canonical 
pathway) was monitored. Time- and dose-dependent experiments for NF-κB showed 
immediate activation using fixed SA, whilst only time-dependent increases were recorded 
following live infection studies. The HBMvEC secretome response to SA infection was 
also tested. Initial, cytokine release studies were conducted using ELISAs for IL-6, TNF-
α and TM, with lowest levels of release noted for TNF-α. This may arise due to TNF-α 
receptor (TNFR1) ectodomain shedding into the ECM, as a result of SpA adhesion 
(Kumar et al., 2015). Using a cytokine array panel allowed us to expand the range of 
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released cytokines to be tested, comparing uninfected versus infected samples. 
Interestingly, six upregulated cytokines were identified from the fixed SA infection 
model, whilst there was no change between live infection studies after 3 and 12 hrs 
infection. The latter may be indicative of the live bacterial virulence factors playing a role 
in limiting cytokine release via immune evasion strategies, although cytokine profiler 
assay sensitivity may also be an issue.  
Along with increased cytokine release, ROS generation was dose-dependently increased 
following SA infection, as seen with DHE staining in conjunction with flow cytometry. 
This increase in ROS production may be the outcome of cytokines as according to 
Rochfort et al. (2014) cytokines can contribute in part to the ROS induction (Rochfort et 
al., 2014). Endothelial microparticles (EMPs) have been identified as potential 
biomarkers for vascular dysfunction and disease (Martin et al., 2014; Berezin et al., 
2015). EMPs that were positively-stained for VE-cadherin and annexin V were harvested 
from HBMvEC media in response to SA infection. Because the EMP stained annexin V-
positive, suggests that the HBMvEC were undergoing early apoptosis, with annexin V 
binding to the exposed PS on the outer leaflet of the HBMvEC plasma membrane (and as 
such, the released EMPs). To the best of one’s knowledge, this is the first time that EMP 
induction has been recorded following HBMvEC infection with SA. 
So far, it has been seen that SA activates endothelial cells to induce an inflammatory 
response through NF-κB activation, ROS generation, and cytokine/EMP release. In 
Chapter 5, the main objective was to explore the contribution of one of the principal 
virulence factors, SpA, found both anchored to and secreted from the bacterial cell 
surface. Using a mutant strain of SA lacking SpA (ΔSpA), the differences between mutant 
SA and NWT-SA were examined. Interestingly, the tight junction-associated protein 
claudin-5 was significantly decreased, whilst only a minor decrease was observed for VE-
cadherin, possibly suggesting that the latter adherens junctions are primarily targeted by 
SpA during bacterial adhesion. Similarly, HBMvEC permeabilization was recorded at the 
uppermost concentration of ΔSpA used, once again suggesting a high concentration of 
ΔSpA is required to induce barrier compromisation due to the lack of SpA. The 
transcription factor NF-κB was also activated by ΔSpA but it did show dose-sensitivity 
differences to the NWT-SA strain as seen from the live infection studies with an MOI 5 
versus MOI 25 in NF-κB activation for NWT-SA and ΔSpA respectively. Overall, it can 
be suggested that SpA appears to play a “partial” role in establishing SA infection, and 
impacts on HBMvEC barrier properties (Sørum et al., 2013).   
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A synopsis of the main findings is now shown in Table 6.1. 
There are still many unanswered questions in relation to this project that will require 
further investigation: 
i. The growth rate of SA is an important feature for experimental conditions. SA at 
exponential phase of growth are at their optimum capacity to display surface 
proteins, whilst stationary phase is ideal for secreted proteins (Sørum et al., 2013). 
SA grown to stationary phase was used for all experiments performed in this 
project. Therefore, it would be of benefit to repeat these experiments using SA 
harvested at the exponential phase to assess the differences in infection strategies. 
ii. This project has demonstrated dose-dependent increases in ROS production 
following SA infection of HBMvEC. The source of ROS production is therefore 
of obvious interest. A study by Rochfort et al. (2014, 2015) has shown that 
cytokine treatment of HBMvEC elicits ROS production through the NADPH 
oxidase (NOX) pathway as shown by using selective pharmacological and 
siRNA-based strategies to attenuate NOX subunits (Rochfort et al., 2014, 2015). 
A similar approach could therefore be applied to our infection model to assess 
ROS induction mechanisms by SA.  
iii. A fuller understanding of the different categories of EMPs released from 
HBMvEC in response to SA infection is warranted (i.e. in addition to just annexin 
V/FITC positive EMPs monitored in this study) (Dignat-George & Boulanger, 
2011; Schindler et al., 2014). 
iv. For the mutant studies, the main focus was on one virulence factor SpA, which 
showed that the ∆SpA strain was in fact attenuated in disrupting HBMvEC barrier 
properties in the downregulation of adherens junction proteins, barrier 
compromisation at low concentrations and in the activation of NF-κB. It would 
be worthwhile to investigate a combination of SA knockouts in order to single out 
virulence proteins or gene targets that may be used for therapeutic gain. 
Alternatively, a L. lactis strain positive for SpA could be used to infect HBMvEC 
in order to single out its key role in BBB dysfunction without the assistance of 
other virulence factors. 
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The overall goal of this project was to employ models of HBMvEC: SA infection to 
characterize the influence of pathogenic infection on HBMvEC barrier properties in-vitro. 
The data generated from this project confirms the injurious effects of SA on HBMvEC 
barrier function, with evidence for induction of pro-inflammatory conditions, ROS 
generation, and EMP release [for general diagrammatic overview, see Figure 6.1]. These 
effects were due in part to SpA, a potent virulence factor for SA. These studies reinforce 
the value of “fixed” bacterial infection models for conducting studies of this kind. 
Moreover, these studies will help improve the current overall understanding of 
cerebrovascular injury at the BBB interface in response to bacterial infection. 
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Stationary Phase Staphylococcal Infections 
Experiments 
NWT-SA ∆SpA-SA 
Fixed Live Fixed Live 
Cell viability* 
MOI 0-250 
(48 hrs) 
MOI 0-100 
(3 hrs) 
MOI 0-250 
(48 hrs) 
MOI 0-100 
(3 hrs) 
Adhesion assay 
SA-bound to 
Static/Shear HB 
MOI 0-500 ↑ 
SA-bound to 
Static/Shear HB 
NP NP 
Interendothelial  
junction proteins 
VE-Cadherin↓ 
Claudin-5     ↓ 
ZO-1             ↓ 
Occludin      ↑ 
VE-Cadherin↓ 
Claudin-5     ↓ 
ZO-1         NC 
VE-Cadherin ↓ 
Claudin-5      ↓ 
VE-Cadherin NC 
Claudin-5     NC 
 
SA-conditioned 
media 
NP 
VE-Cadherin ↓ 
NF-κB ↑ 
NP NP 
Barrier 
permeability 
MOI 0-250↑ MOI 0-100 ↑ MOI 250↑ NP 
NF-κB 
1-48 hrs      ↑ 
MOI 0-250  ↑ 
15 mins-3 hrs  ↑ 
MOI 0-100    NC 
1 hr-24 hrs ↑ 
MOI 0-250 ↑ 
1hr-3 hrs     ↑ 
MOI 25-100↑ 
ELISA 
IL-6      ↑ 
TNF-α  ↑ 
TM       ↑ 
(MOI 0-250, 
24-72 hrs) 
TNF-α ↑ 
(15 mins-3 hrs) 
NP NP 
Cytokine array 
0 v 250 
6↑ cytokines 
0 v 100 
3 hrs/12 hrs NC 
NP NP 
ROS MOI 0-250 ↑ NP NP NP 
Endothelial 
Microparticles 
MOI 0-250 ↑ NP NP NP 
Table 6.1: Overview of Staphylococcus aureus infection of HBMvEC. Synopsis of 
results from infection models using HBMvEC infected with either NWT-SA (both 
formaldehyde-fixed and live), and ∆SpA SA strain, and SA-conditioned media 
(containing released virulence factors). Key: ↑ Increase; ↓ Decrease; NC, no change; NP, not 
performed; HB, HBMvEC; *New stock of HBMvEC infection reduced to 24 hrs. 
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Figure 6.1: Overview of potential SA challenges to HBMvEC barrier properties 
upon SA infection. SA gains access to the blood stream and attaches to an endothelial 
surface marker (e.g. TLR, vWF, collagen, TNFR1). [1] SA can disrupt the TJ and AJ 
proteins of the BBB through actin-cytoskeleton rearrangement. [2] NF-κB is activated 
and upregulates the production of inflammatory gene targets (i.e. cytokines and 
chemokines), whilst downregulating interendothelial junction proteins; [3] 
cytokines/chemokines are released from the cell as part of the pro-inflammatory cascade; 
[4] ROS are produced either as a direct consequence of bacterial infection, or through 
release of pro-inflammatory cytokines feeding back onto the cellular NADPH oxidase 
(NOX) system. ROS production is known to elicit downregulation of interendothelial 
junctional proteins; [5] SA infection also elicits endothelial microparticle (EMP) release 
through cell blebbing. 
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A1. Example of MOI calculations 
Viable cell number = 1 x 105 cells 
Want to infect the cells at an MOI 0, 100 and 250. 
Bacteria set to an OD600 nm = 1 using sterile PBS equates to 1x10
8 CFU/ml. 
MOI Cell # x MOI  
SA 
required 
(CFU) 
SA required / 
OD1 
SA (μl) PBS (μl) 
Final 
volume 
(μl) 
0 1x10
5
 x 0 0 0/1x10
8
 0 250 
2000 100 1x10
5 
x 100 1x10
7
 1x10
7
/1x10
8
 100 150 
250 1x10
5
 x 250 2.5x10
7
 2.5x10
7
/1x10
8
 250 0 
Table A1: MOI calculation. 
 
A2. Cytokine array panel 
A human cytokine array panel (Proteome ProfilerTM) from R&D Systems was used to 
identify cytokine/chemokine secretion during staphylococcal infection with HBMvEC. 
Below is a table listing the 36 chemokine and cytokine markers pre-coated on the 
nitrocellulose membrane provided with the kit. 
Cytokine Synonym(s) Role/Function References 
C5/C5a 
Complement 
component 
5/5a 
Potent chemoattractant to facilitate 
phagocytic uptake 
Laarman et 
al., 2010 
CD40 Ligand CD154,  
TRAP T cell-mediated effector functions 
Schönbeck, 
Mach, & 
Libby, 2000 
G-CSF 
(Granulocyte-colony 
stimulating factor) 
CSFβ,  
Colony 
stimulating 
factor-3 
Produced by fibroblasts and monocytes, 
stimulates granulocyte progenitor cells and 
neutrophils, plays a role in granulocyte 
differentiation and neutrophil development. 
Cameron & 
Kelvin, 
2000 
GM-CSF 
(Granulocyte-
macrophage colony-
stimulating factor) 
CSFα,  
CSF-2 
Expressed by macrophages and T cells, 
stimulates macrophages, neutrophils and 
eosinophils. 
Cameron & 
Kelvin, 
2000 
B 
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GROα  
(Growth related 
oncogene-alpha) 
CXCL1,  
MGSA-a+ Neutrophil chemoattractant factor
. abcam, 2009 
I-309 CCL1 
Secreted by activated T cells, attracts 
monocytes, NK cells, B cells and dendritic cells 
via surface receptor CCR8. 
abcam, 
2009 
sICAM-1 
(Soluble intercellular 
adhesion molecule-1) 
CD54 Counter-receptor for the lymphocyte 
function-associated antigen
. 
Witkowska 
& 
Borawska, 
2004 
IFN-γ Type II IFN Secreted by activated T cells and NK cells, 
hallmark of pro-inflammatory Th1 cells. 
Cameron & 
Kelvin, 
2000 
IL-1α 
Hematopoietin-
1, 
 IL-1F1 
Triggers fever and activates lymphocytes. 
Cameron & 
Kelvin, 
2000 
IL-1β IL-1F2, 
 catabolin 
Differentiation of human naive CD4+ T cells 
into Th17 cells, induction of IL-17. 
Akdis et al., 
2011 
IL-1ra 
IL-1 Receptor 
antagonist,  
IL-1F3 
Regulates agonist effects of IL-1 during acute 
phase of infection. 
Cameron & 
Kelvin, 
2000 
IL-2 T cell growth 
factor 
Up regulated on T cells after antigenic or 
mitogenic activation. 
Akdis et al., 
2011 
IL-4 BSF-1 
Produced by TH2 cells, basophils, mast cells, 
and eosinophils. 
Mediates tissue adhesion and inflammation. 
Akdis et al., 
2011 
IL-5 
B-cell 
differentiation 
factor-1 
Produced by activated T cells, aids in the 
growth and differentiation of eosinophils and 
late-developing B cells. 
Akdis et al., 
2011 
IL-6 IFN-β2,  
BSF-2 
Primary inducer of fever, hormones, acute 
phase proteins and T and B cell expansion 
upon injury and infection. 
Akdis et al., 
2011 
IL-8 CXCL8 
Chemoattractant for PMNs, potent 
chemoattractants for neutrophils, stimulates 
neutrophil degranulation and adherence to 
endothelial cells. 
Akdis et al., 
2011 
IL-10 CSIF 
Suppresses the inflammatory responses 
by inhibiting IFN-γ, IL-2, IL-3, TNF-α and GM-
CSF, stimulator of thymocytes, mast cells and 
B cells. 
Borish & 
Steinke, 
2003 
IL-12p70   Induction of Th1 immune responses, 
production in myeloid cells. 
Soong et 
al., 2011 
IL-13 P600 
Expressed by activated T cells, induces IgE 
production by B cells and inhibits 
inflammatory cytokine production. 
Cameron & 
Kelvin, 
2000 
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IL-16 LCF 
T-cell–derived product that is chemotactic for 
CD4+ lymphocytes, eosinophils, and 
monocytes, up regulated by TNF-α, TGF-β, IL-
4, IL-9, and IL-13
. 
Borish & 
Steinke, 
2003 
IL-17 CTLA-8 
Expressed by activated T cells and eosinophils, 
activates macrophages, fibroblasts controlling 
their expression of ICAM-1 and cytokine 
secretion of G-CSF, IL-6, IL-8, IL-11
. 
Borish & 
Steinke, 
2003 
IL-17E IL-25 
Expressed by TH2 cells, mast and epithelial 
cells, eosinophils and basophils, I induction of 
Th2 responses, IgE, IgG1, IL-4, IL-5, IL-13, and 
IL-9 production. 
Akdis et al., 
2011 
IL-23   
Secreted by activated dendritic cells, potent 
inducer of IFN-γ, contribute to Th1-like 
lymphocyte differentiation. 
Borish & 
Steinke, 
2003 
IL-27   Activated DCs, macrophages, epithelial cells. Akdis et al., 
2011 
IL-32α   Splice variant of IL-32, produced by epithelial 
cells. 
Akdis et al., 
2011 
IP-10 
(IFN-γ inducible  
protein-10) 
CXCL10 Chemoattractant for CD4+ T cells. abcam, 
2009 
I-TAC  CXCL11 Attracting eosinophils 
Cameron & 
Kelvin, 
2000 
MCP-1 
(Monocyte chemotactic 
protein) 
CCL2,  
MCAF 
Inhibit IL-12 production from 
APCs and enhance IL-4 production from 
activated T cells. 
Borish & 
Steinke, 
2003 
MIF 
(Macrophage migration 
inhibitory factor) 
GIF,  
DER6 
Stimulates pro-inflammatory mediators to 
counterbalance the anti-inflammatory and 
immunosuppressive effects. 
Roger et al., 
2001 
MIP-1α  
(Macrophage 
inflammatory protein) 
CCL3,  
LD78α 
Promote development of IFN-γ producing TH1 
lymphocytes or indirectly by increasing IL-12 
production from APCs. 
Borish & 
Steinke, 
2003 
MIP-1β  CCL4, LAG-1, 
ACT-2 
RANTES  
(Regulated upon 
activation normally T 
expressed and 
secreted) 
CCL5 
PAI-1 
(Plasminogen activator 
inhibitor-1) 
SerpinE1 Serine protease inhibitor, inhibitor of 
fibrinolysis, causes neutrophil accumulation. 
Park et al., 
2008 
SDF-1  
(Stromal cell-derived 
factor-1) 
CXCL12,  
SDF-1α/β  
Modulator of progenitor cell development in 
the bone marrow. 
Cameron & 
Kelvin, 
2000 
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TNF-α 
(Tumour Necrosis 
Factor-α) 
TNFSF1A 
Pro-inflammatory cytokine, produced by 
activated macrophages, NK cells and T cells, 
role in endothelial activation and lymphocyte 
movement. 
Cameron & 
Kelvin, 
2000 
sTREM-1 
(Soluble triggering 
receptor expressed on 
myeloid cells) 
  
Expressed on the surface of myeloid cells 
neutrophils, monocytes, and macrophages, a 
down regulator of inflammation by binding to 
its ligand
. 
Bucova et 
al., 2012 
Table A2: Cytokines and chemokines on array panel. 
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Figure A1: Cytokine array panel for MOI fixed SA infection (N #1). HBMvEC media 
was harvested following infection with fixed SA (MOI 0 and 250, 48 hrs) and analysed 
for cytokine release. (A) Cytokine array membranes representing each MOI; (B) 
Densitometric analysis of the cytokine array membranes for each MOI. (N #1). (Ref, 
validation for streptavidin-HRP).  
MOI 0 MOI 250
Ref + +
RANTES +
IP-10 +
MIF + +
GROα + +
IL-6 +
SERPINE1 + +
IL-8 + +
Ref + +
MOI 0                  MOI 250
A
B
        
Ref Ref 
Ref Ref 
RANTES 
IP-10 
  MIF GROα   MIF GROα 
SERPINE1 IL-8 
IL-6 
SERPINE1 
IL-8 
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Figure A2: Cytokine array panel for MOI fixed SA infection (N #2). HBMvEC media 
was harvested following infection with fixed SA (MOI 0 and 250, 48 hrs) and analysed 
for cytokine release. (A) Cytokine array membranes representing each MOI; (B) 
Densitometric analysis of the cytokine array membranes for each MOI. (N #2). (Ref, 
validation for streptavidin-HRP).  
MOI 0 MOI 250
Ref + +
RANTES +
IP-10 +
MCP-1 +
MIF + +
GROα + +
IL-6 +
SERPINE1 + +
IL-8 + +
Ref + +
A
B
MOI 0                  MOI 250
             
Ref Ref 
Ref Ref 
RANTES 
IP-10 
  MIF GROα 
  MIF GROα 
MCP-1 
IL-6 
IL-8 
SERPINE1 SERPINE1 
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Figure A3: Cytokine array panel for MOI fixed SA infection (N #3). HBMvEC media 
was harvested following infection with fixed SA (MOI 0 and 250, 48 hrs) and analysed 
for cytokine release. (A) Cytokine array membranes representing each MOI; (B) 
Densitometric analysis of the cytokine array membranes for each MOI. (N #3). (Ref, 
validation for streptavidin-HRP). 
 
